{"head": "Mosunetuzumab", "relation": "is a", "tail": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific antibody"}
{"head": "Mosunetuzumab", "relation": "redirects", "tail": "T cells to eliminate malignant B cells"}
{"head": "YO43555", "relation": "assesses", "tail": "pharmacokinetics of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "YO43555", "relation": "assesses", "tail": "safety of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "YO43555", "relation": "assesses", "tail": "tolerability of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "YO43555", "relation": "assesses", "tail": "efficacy of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "Ethnicity/region", "relation": "impacts", "tail": "pharmacokinetics disposition of mosunetuzumab"}
{"head": "Non-compartmental analysis", "relation": "assesses", "tail": "pharmacokinetics disposition of mosunetuzumab"}
{"head": "Population pharmacokinetics approach", "relation": "assesses", "tail": "pharmacokinetics disposition of mosunetuzumab"}
{"head": "Global popPK model", "relation": "was validated with", "tail": "PK data from study YO43555"}
{"head": "Global popPK model", "relation": "captures", "tail": "individual pharmacokinetics of Chinese population"}
{"head": "Model predicted mosunetuzumab exposure metrics in Chinese patients", "relation": "are similar to", "tail": "those observed in Asian patients in GO29781 R/R FL subpopulation"}
{"head": "Exposure differences between Chinese and Non-Asians", "relation": "are less than", "tail": "20%"}
{"head": "Mosunetuzumab exposure of Chinese patients", "relation": "remains within", "tail": "established bounds for clinical safety and efficacy"}
{"head": "Cytokine biomarkers IL-6 and TNF-\u03b1", "relation": "show", "tail": "similar time-course patterns of release as observed in globally enrolled patients"}
{"head": "Mosunetuzumab pharmacokinetics disposition", "relation": "does not show", "tail": "significant ethnic sensitivity"}
{"head": "Dose adjustment of globally approved mosunetuzumab regimen", "relation": "is not warranted for", "tail": "Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "Noninvasive prognostic evaluation methods", "relation": "are used for", "tail": "hepatocellular carcinoma"}
{"head": "Noninvasive prognostic evaluation methods", "relation": "rely on", "tail": "radiographic imaging features"}
{"head": "Noninvasive prognostic evaluation methods", "relation": "rely on", "tail": "serum biomarkers such as alpha-fetoprotein"}
{"head": "Epigenetic changes in cell-free DNA", "relation": "have shown promise in", "tail": "early cancer diagnosis"}
{"head": "Epigenetic changes in cell-free DNA", "relation": "have shown promise in", "tail": "prognosis"}
{"head": "cfDNA methylation", "relation": "is a predictor for", "tail": "prognostication in patients with active, radiographically viable HCC"}
{"head": "Illumina HumanMethylation450 array data", "relation": "was used to identify", "tail": "158 HCC-related DNA methylation markers associated with overall survival"}
{"head": "158 HCC-related DNA methylation markers", "relation": "are associated with", "tail": "overall survival"}
{"head": "158 HCC-related DNA methylation markers", "relation": "were validated in", "tail": "29 HCC tumor tissue samples"}
{"head": "cfDNA methylation-based risk score (methRisk)", "relation": "was calculated from", "tail": "plasma cfDNA samples of 52 patients"}
{"head": "cfDNA methylation-based risk score (methRisk)", "relation": "predicts", "tail": "overall survival"}
{"head": "cfDNA methylation-based risk score (methRisk)", "relation": "has", "tail": "strong discriminatory power for overall survival prediction"}
{"head": "methRisk", "relation": "improves", "tail": "noninvasive prognostic assessments for overall survival when integrated with Barcelona clinic liver cancer staging"}
{"head": "methRisk", "relation": "is an independent predictor of", "tail": "survival"}
{"head": "cfDNA methylation biomarkers assessed from peripheral blood", "relation": "can stratify", "tail": "HCC patients into clinically meaningful risk groups"}
{"head": "cfDNA methylation", "relation": "is a noninvasive prognostic biomarker for", "tail": "hepatocellular carcinoma"}
{"head": "GLUT2 (SLC2A2)", "relation": "is a", "tail": "glucose transporter in liver, pancreas, and kidney tissues"}
{"head": "GLUT2 (SLC2A2)", "relation": "regulates", "tail": "blood glucose levels"}
{"head": "GLUT2 (SLC2A2)", "relation": "regulates", "tail": "energy metabolism"}
{"head": "SLC2A2", "relation": "contributes to", "tail": "cell differentiation"}
{"head": "SLC2A2", "relation": "contributes to", "tail": "metabolic adaptation during embryogenesis and tissue regeneration"}
{"head": "SLC2A2 expression", "relation": "decreases with", "tail": "HCC progression"}
{"head": "Stemness-associated genes including SOX2 and POU5F1", "relation": "are", "tail": "upregulated with HCC progression"}
{"head": "Zebrafish embryos injected with SLC2A2-targeting morpholino", "relation": "exhibit", "tail": "reduced expression of liver differentiation marker fabp10a"}
{"head": "Zebrafish embryos injected with SLC2A2-targeting morpholino", "relation": "do not significantly alter", "tail": "hepatoblast marker hhex expression"}
{"head": "SLC2A2 knockdown in HepG2 cells", "relation": "increases", "tail": "stemness markers"}
{"head": "SLC2A2 knockdown in HepG2 cells", "relation": "increases", "tail": "IGF1R pathway markers"}
{"head": "SLC2A2", "relation": "supports", "tail": "liver differentiation"}
{"head": "SLC2A2", "relation": "regulates", "tail": "glucose metabolism"}
{"head": "SLC2A2", "relation": "suppresses", "tail": "pathways associated with stemness and malignancy"}
{"head": "Targeting SLC2A2", "relation": "may serve as", "tail": "therapeutic strategy for liver-related diseases including HCC"}
{"head": "Mosunetuzumab", "relation": "redirects", "tail": "T cells to eliminate malignant B cells"}
{"head": "YO43555", "relation": "assesses", "tail": "pharmacokinetics of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "YO43555", "relation": "assesses", "tail": "safety of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "YO43555", "relation": "assesses", "tail": "tolerability of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "YO43555", "relation": "assesses", "tail": "efficacy of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "Ethnicity/region", "relation": "impacts", "tail": "pharmacokinetics disposition of mosunetuzumab"}
{"head": "Global popPK model", "relation": "captures", "tail": "individual pharmacokinetics of the Chinese population"}
{"head": "Model predicted mosunetuzumab exposure metrics in Chinese patients", "relation": "are similar to", "tail": "those observed in Asian patients in GO29781 R/R FL subpopulation with the same dose regimen"}
{"head": "Exposure differences between Chinese and Non-Asians from the global population", "relation": "are less than", "tail": "20%"}
{"head": "Mosunetuzumab exposure of Chinese patients", "relation": "remains within", "tail": "established bounds for clinical safety and efficacy"}
{"head": "Cytokine biomarkers IL-6 and TNF-\u03b1", "relation": "show", "tail": "similar time-course patterns of release as observed in globally enrolled patients"}
{"head": "Mosunetuzumab pharmacokinetics disposition", "relation": "does not show", "tail": "significant ethnic sensitivity that would impact patient outcomes"}
{"head": "Dose adjustment of globally approved mosunetuzumab regimen", "relation": "is not warranted for", "tail": "Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "KRAS mutation", "relation": "is well-established in", "tail": "metastatic colorectal cancer"}
{"head": "BRAF mutation", "relation": "is well-established in", "tail": "metastatic colorectal cancer"}
{"head": "KRAS mutation", "relation": "was identified in", "tail": "29.8% of stage II/III colorectal cancer patients"}
{"head": "NRAS mutation", "relation": "was identified in", "tail": "4.3% of stage II/III colorectal cancer patients"}
{"head": "BRAF mutation", "relation": "was identified in", "tail": "8.5% of stage II/III colorectal cancer patients"}
{"head": "PIK3CA mutation", "relation": "was identified in", "tail": "14.9% of stage II/III colorectal cancer patients"}
{"head": "concurrent mutations in MSS patients", "relation": "are associated with", "tail": "shorter overall survival"}
{"head": "concurrent mutations in MSS patients", "relation": "are associated with", "tail": "shorter disease-free survival"}
{"head": "KRAS mutation", "relation": "is significantly linked to poor overall survival", "tail": "stage II/III colorectal cancer patients"}
{"head": "BRAF mutation", "relation": "is significantly linked to poor overall survival", "tail": "stage II/III colorectal cancer patients"}
{"head": "KRAS mutation", "relation": "is significantly linked to poor disease-free survival", "tail": "stage II/III colorectal cancer patients"}
{"head": "BRAF mutation", "relation": "is significantly linked to poor disease-free survival", "tail": "stage II/III colorectal cancer patients"}
{"head": "BRAF mutation prognostic impact", "relation": "increases with", "tail": "microsatellite instability adjustment"}
{"head": "KRAS mutation in MSS tumors", "relation": "is associated with", "tail": "shorter disease-free survival"}
{"head": "BRAF mutation in MSS tumors", "relation": "is associated with", "tail": "reduced overall survival"}
{"head": "BRAF mutation in MSS tumors", "relation": "is associated with", "tail": "reduced disease-free survival"}
{"head": "no significant survival differences", "relation": "were found between", "tail": "mutant and wildtype patients in MSI-H population"}
{"head": "PIK3CA mutation", "relation": "is nominally associated with", "tail": "overall survival"}
{"head": "KRAS mutation", "relation": "has negative prognostic impact on", "tail": "MSS stage II/III colorectal cancer patients receiving adjuvant therapy"}
{"head": "BRAF mutation", "relation": "has negative prognostic impact on", "tail": "MSS stage II/III colorectal cancer patients receiving adjuvant therapy"}
{"head": "CD8 T cells", "relation": "play role in", "tail": "antitumor immunity"}
{"head": "CD8 T cells", "relation": "become", "tail": "dysfunctional"}
{"head": "CD8 T cells", "relation": "become", "tail": "exhausted"}
{"head": "dysfunctional or exhausted CD8 T cells", "relation": "fail to control", "tail": "tumor growth"}
{"head": "molecular pathways", "relation": "regulate", "tail": "CD8 T cell heterogeneity"}
{"head": "molecular pathways", "relation": "regulate", "tail": "CD8 T cell function"}
{"head": "T cell-intrinsic factors", "relation": "influence", "tail": "CD8 T cell differentiation"}
{"head": "T cell-extrinsic factors", "relation": "influence", "tail": "CD8 T cell differentiation"}
{"head": "T cell-intrinsic factors", "relation": "influence", "tail": "CD8 T cell fate choices"}
{"head": "T cell-extrinsic factors", "relation": "influence", "tail": "CD8 T cell fate choices"}
{"head": "T cell-intrinsic factors", "relation": "influence", "tail": "CD8 T cell functional states"}
{"head": "T cell-extrinsic factors", "relation": "influence", "tail": "CD8 T cell functional states"}
{"head": "T cell-intrinsic and -extrinsic factors", "relation": "dictate", "tail": "CD8 T cell response to therapy"}
{"head": "therapeutic checkpoint blockade", "relation": "is responded to by", "tail": "T cells"}
{"head": "cells that orchestrate long-term antitumor immunity", "relation": "are identified to improve", "tail": "cancer immunotherapy"}
{"head": "mechanisms that govern development and persistence of cells that orchestrate long-term antitumor immunity", "relation": "are critical for", "tail": "improving cancer immunotherapy"}
{"head": "Testicular microcalcifications", "relation": "consist of", "tail": "hydroxyapatite"}
{"head": "Testicular microcalcifications", "relation": "are associated with increased risk of", "tail": "testicular germ cell tumors (TGCTs)"}
{"head": "Loss-of-function variants in phosphate transporter SLC34A2", "relation": "are found in", "tail": "benign testicular microcalcifications"}
{"head": "Fibroblast growth factor 23 (FGF23)", "relation": "regulates", "tail": "phosphate homeostasis"}
{"head": "Fibroblast growth factor 23 (FGF23)", "relation": "is expressed in", "tail": "testicular germ cell neoplasia in situ (GCNIS)"}
{"head": "Fibroblast growth factor 23 (FGF23)", "relation": "is expressed in", "tail": "embryonal carcinoma (EC)"}
{"head": "Fibroblast growth factor 23 (FGF23)", "relation": "is expressed in", "tail": "human embryonic stem cells"}
{"head": "FGF23", "relation": "is not glycosylated in", "tail": "testicular germ cell tumors (TGCTs)"}
{"head": "FGF23", "relation": "is cleaved into", "tail": "C-terminal fragment in TGCTs"}
{"head": "C-terminal fragment of FGF23", "relation": "antagonizes", "tail": "full-length FGF23"}
{"head": "Fgf23 knockout mice", "relation": "present with", "tail": "marked calcifications in epididymis"}
{"head": "Fgf23 knockout mice", "relation": "present with", "tail": "spermatogenic arrest"}
{"head": "Fgf23 knockout mice", "relation": "present with", "tail": "germ cells expressing osteoblast marker Osteocalcin"}
{"head": "Testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins", "relation": "are associated with", "tail": "lower Slc34a2 expression"}
{"head": "Testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins", "relation": "are associated with", "tail": "higher Bglap/Slc34a1 expression"}
{"head": "Human testicular specimens with microcalcifications", "relation": "have", "tail": "lower SLC34A2 expression"}
{"head": "Subpopulation of germ cells in human testicular specimens with microcalcifications", "relation": "express", "tail": "phosphate transporter NPT2a"}
{"head": "Subpopulation of germ cells in human testicular specimens with microcalcifications", "relation": "express", "tail": "Osteocalcin"}
{"head": "Subpopulation of germ cells in human testicular specimens with microcalcifications", "relation": "express", "tail": "RUNX2"}
{"head": "Calcium or phosphate treatment", "relation": "induces", "tail": "deposition of calcium phosphate in spermatogonial cell line"}
{"head": "Pyrophosphate", "relation": "rescues", "tail": "calcium phosphate deposition induced by mineral disturbance in spermatogonial cell line"}
{"head": "Testicular microcalcifications", "relation": "arise secondary to", "tail": "local alterations in mineral homeostasis"}
{"head": "Impaired Sertoli cell function and reduced levels of mineralization inhibitors", "relation": "facilitate", "tail": "osteogenic-like differentiation of testicular cells and deposition of hydroxyapatite in GCNIS and TGCTs"}
{"head": "High alkaline phosphatase activity in GCNIS and TGCTs", "relation": "causes", "tail": "reduced levels of mineralization inhibitors"}
{"head": "cancer-associated fibroblast-related gene signature", "relation": "predicts", "tail": "clinical outcomes in patients with diffuse large B cell lymphoma"}
{"head": "weighted gene co-expression network analysis", "relation": "identifies", "tail": "cancer-associated fibroblast-related module genes"}
{"head": "Least Absolute Shrinkage and Selection Operator Cox regression", "relation": "screens", "tail": "minimal set of genes"}
{"head": "Least Absolute Shrinkage and Selection Operator Cox regression", "relation": "constructs", "tail": "prognostic cancer-associated fibroblast-related gene signature for diffuse large B cell lymphoma"}
{"head": "Kaplan-Meier plots and receiver operating characteristic curves", "relation": "assess", "tail": "prognostic performance of prognostic cancer-associated fibroblast-related genes"}
{"head": "nomogram", "relation": "encompasses", "tail": "clinical information and prognostic scores of patients"}
{"head": "prognostic cancer-associated fibroblast-related gene signature risk model", "relation": "categorizes", "tail": "patients with diffuse large B cell lymphoma into high- and low-risk groups"}
{"head": "prognostic cancer-associated fibroblast-related gene signature risk model", "relation": "predicts", "tail": "survival in diffuse large B cell lymphoma"}
{"head": "nomogram", "relation": "has stronger prognostic ability than", "tail": "clinical factor-based model"}
{"head": "nomogram", "relation": "has stronger prognostic ability than", "tail": "risk score alone"}
{"head": "high- and low-risk groups", "relation": "have significant differences in", "tail": "immune cell profiles"}
{"head": "high- and low-risk groups", "relation": "have significant differences in", "tail": "therapeutic responses"}
{"head": "prognostic cancer-associated fibroblast-related gene-based genetic risk model", "relation": "predicts", "tail": "prognosis of diffuse large B cell lymphoma"}
{"head": "prognostic cancer-associated fibroblast-related gene-based genetic risk model", "relation": "aids in", "tail": "treatment selection for diffuse large B cell lymphoma"}
{"head": "Asian patients", "relation": "have better survival than", "tail": "White patients"}
{"head": "Black patients", "relation": "have worse survival than", "tail": "White patients"}
{"head": "Hispanic patients", "relation": "have no difference in survival compared with", "tail": "White patients"}
{"head": "Black patients in California", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in California"}
{"head": "Black patients in New Jersey", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in New Jersey"}
{"head": "Black patients in Georgia", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in Georgia"}
{"head": "Black patients in Louisiana", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in Louisiana"}
{"head": "Black patients in Connecticut", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in Connecticut"}
{"head": "Black patients in Iowa", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in Iowa"}
{"head": "Hispanic patients in Hawaii", "relation": "have worse survival than", "tail": "White patients in Hawaii"}
{"head": "Hispanic patients in Georgia", "relation": "have worse survival than", "tail": "White patients in Georgia"}
{"head": "Asian patients in California", "relation": "have better survival than", "tail": "White patients in California"}
{"head": "Oral squamous cell carcinoma", "relation": "is most prevalent of", "tail": "oral cancers"}
{"head": "YAP", "relation": "serves as", "tail": "transcriptional regulator in hippo tumor suppressor pathway"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "cellular proliferation"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "alteration"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "migration"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "invasion"}
{"head": "PARK2", "relation": "acts as", "tail": "tumor suppressor"}
{"head": "Immunohistochemical expression of YAP", "relation": "increases from", "tail": "normal oral mucosa to oral squamous cell carcinoma"}
{"head": "Immunohistochemical expression of PARK2", "relation": "decreases from", "tail": "normal oral mucosa to oral squamous cell carcinoma"}
{"head": "YAP expression", "relation": "differs significantly between", "tail": "normal oral mucosa, oral epithelial dysplasia, and oral squamous cell carcinoma"}
{"head": "PARK2 expression", "relation": "differs significantly between", "tail": "normal oral mucosa, oral epithelial dysplasia, and oral squamous cell carcinoma"}
{"head": "YAP and PARK2 expression", "relation": "have inverse moderate correlation in", "tail": "oral squamous cell carcinoma group"}
{"head": "Concomitant immunoexpression of YAP and PARK2", "relation": "could serve as", "tail": "diagnostic and prognostic markers for oral squamous cell carcinoma"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "is a", "tail": "rare malignant neoplasm"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "has propensity for", "tail": "maxilla"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "has male predilection", "tail": "male"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "has approximately sixty-four cases reported", "tail": "cases"}
{"head": "38-year-old male patient", "relation": "has", "tail": "maxillary lesion"}
{"head": "38-year-old male patient", "relation": "was referred to", "tail": "oral and maxillofacial surgery clinic at King Fahad Medical City"}
{"head": "lesion", "relation": "showed", "tail": "ghost cells"}
{"head": "lesion", "relation": "showed", "tail": "dentinoid deposition"}
{"head": "lesion", "relation": "showed", "tail": "ameloblastoma-like epithelial linings"}
{"head": "lesion", "relation": "showed", "tail": "malignant features"}
{"head": "malignant features", "relation": "include", "tail": "nuclear pleomorphism"}
{"head": "malignant features", "relation": "include", "tail": "increased mitosis"}
{"head": "malignant features", "relation": "include", "tail": "necrosis"}
{"head": "malignant features", "relation": "include", "tail": "perivascular invasion"}
{"head": "malignant features", "relation": "include", "tail": "invasion into adjacent bone"}
{"head": "tumor cells", "relation": "were reactive to", "tail": "CAM5.2"}
{"head": "tumor cells", "relation": "were reactive to", "tail": "p63"}
{"head": "tumor cells", "relation": "were reactive to", "tail": "CK5/6"}
{"head": "tumor cells", "relation": "were reactive to", "tail": "CK19"}
{"head": "CK5/6 and CK19", "relation": "were positive in", "tail": "peripheral area in a ring-like pattern in the ghost cell region"}
{"head": "nuclear staining of beta-catenin", "relation": "was detected in", "tail": "tumor cells"}
{"head": "next generation sequencing", "relation": "revealed mutations in", "tail": "CTNNB1 variant c.110 C\u2009>\u2009G p.(Ser37Cys)"}
{"head": "next generation sequencing", "relation": "revealed mutations in", "tail": "ARID1A variant c.4420 C\u2009>\u2009T p. (Gln1474*)"}
{"head": "patient", "relation": "was treated with", "tail": "surgical excision"}
{"head": "patient", "relation": "was treated with", "tail": "bilateral cervical lymph node dissection"}
{"head": "patient", "relation": "was treated with", "tail": "adjuvant radiotherapy"}
{"head": "patient", "relation": "was free of disease after", "tail": "30 months"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "is", "tail": "rare aggressive odontogenic tumor"}
{"head": "CTNNB1", "relation": "is", "tail": "consistent gene mutation in ghost cell odontogenic carcinoma"}
{"head": "ARID1A", "relation": "was reported for the first time in", "tail": "ghost cell odontogenic carcinoma patient"}
{"head": "GWAS", "relation": "identifies", "tail": "three genome-wide significant loci associated with OTSCC"}
{"head": "Locus 5p15.33 (rs27067 near gene LINC01511)", "relation": "is associated with", "tail": "OTSCC"}
{"head": "Locus 10q24 (rs1007771191 near RPS3AP36)", "relation": "is associated with", "tail": "OTSCC"}
{"head": "Locus 20p12.3 (rs1438070080 near PLCB1)", "relation": "is associated with", "tail": "OTSCC"}
{"head": "rs27067", "relation": "is associated with", "tail": "prostate cancer"}
{"head": "rs27067", "relation": "is associated with", "tail": "seborrheic keratosis"}
{"head": "rs27067", "relation": "has co-directional effect with", "tail": "melanoma"}
{"head": "Chondrosarcoma", "relation": "is", "tail": "malignant neoplasm"}
{"head": "Chondrosarcoma", "relation": "characterized by", "tail": "production of a cartilaginous matrix"}
{"head": "58-year-old male patient", "relation": "has symptom", "tail": "swelling in the posterior region of the right maxilla"}
{"head": "58-year-old male patient", "relation": "has history of", "tail": "fibro-osseous lesion in the posterior maxilla region"}
{"head": "Intraoral examination", "relation": "revealed", "tail": "rounded lesion with ulceration in area of teeth 17 and 18"}
{"head": "Panoramic radiograph", "relation": "revealed", "tail": "radiopaque lesion with flocculated pattern in right maxilla"}
{"head": "Computed tomography", "relation": "showed", "tail": "hyperdense lesion containing hypodense areas"}
{"head": "Histopathological analysis", "relation": "revealed", "tail": "presence of immature cartilage with rounded neoplastic cells, nuclei of varied sizes, and intense pleomorphism"}
{"head": "Histopathological analysis", "relation": "led to diagnosis of", "tail": "chondrosarcoma"}
{"head": "Patient", "relation": "underwent", "tail": "surgical resection followed by radiotherapy"}
{"head": "Patient", "relation": "has outcome after one year", "tail": "no signs of recurrence"}
{"head": "Chondrosarcoma", "relation": "should be considered in differential diagnosis of", "tail": "osseous enlargement in gnathic bones"}
{"head": "Loss of heterozygosity", "relation": "is reported in", "tail": "Oral Potentially Malignant Disorders"}
{"head": "Loss of heterozygosity", "relation": "is reported in", "tail": "Oral Squamous Cell Carcinoma"}
{"head": "p53 gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "p16 gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "adenomatous polyposis coli gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "retinoblastoma gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "fragile histidine triad gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "phosphatase and tensin homolog gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "chromosome loci 17p", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "chromosome loci 9p", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "chromosome loci 5q", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "chromosome loci 13q", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "chromosome loci 3p", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "chromosome loci 10q", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "p53", "relation": "interacts with", "tail": "p16"}
{"head": "p53", "relation": "interacts with", "tail": "fragile histidine triad gene"}
{"head": "p53", "relation": "interacts with", "tail": "retinoblastoma gene"}
{"head": "circ_0000517", "relation": "is upregulated in", "tail": "non-small cell lung cancer tissues and cells"}
{"head": "circ_0000517", "relation": "expression is associated with", "tail": "m6A modification"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "proliferation of NSCLC cells"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "colony formation of NSCLC cells"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "migration of NSCLC cells"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "invasion of NSCLC cells"}
{"head": "silenced circ_0000517", "relation": "suppresses", "tail": "EMT-related process"}
{"head": "highly expressed circ_0000517", "relation": "activates", "tail": "CDH6 expression"}
{"head": "highly expressed circ_0000517", "relation": "activates", "tail": "EMT evolution"}
{"head": "highly expressed circ_0000517", "relation": "sponges", "tail": "miR-1233-3p"}
{"head": "miR-1233-3p", "relation": "reverses the promotion effect of", "tail": "circ_0000517 on malignant biological behavior of NSCLC cells"}
{"head": "m6A-modified circ_0000517", "relation": "accelerates malignant evolution of", "tail": "non-small cell lung cancer"}
{"head": "m6A-modified circ_0000517", "relation": "targets", "tail": "miR-1233-3p/CDH6 axis"}
{"head": "MoS2-CuS nanocomposites", "relation": "are synthesized by", "tail": "physically mixing MoS2 suspensions with CuS"}
{"head": "MoS2-AuNR nanocomposites", "relation": "are synthesized by", "tail": "physically mixing MoS2 suspensions with AuNRs"}
{"head": "X-ray diffraction", "relation": "characterizes", "tail": "structural properties of nanocomposites"}
{"head": "transmission electron microscopy", "relation": "characterizes", "tail": "structural properties of nanocomposites"}
{"head": "ultraviolet-visible spectroscopy", "relation": "characterizes", "tail": "optical properties of nanocomposites"}
{"head": "Fourier transform infrared spectroscopy", "relation": "characterizes", "tail": "optical properties of nanocomposites"}
{"head": "MoS2-CuS nanocomposites", "relation": "exhibit", "tail": "enhanced photothermal heating compared to individual components"}
{"head": "MoS2-AuNR nanocomposites", "relation": "exhibit", "tail": "enhanced photothermal heating compared to individual components"}
{"head": "MoS2-AuNR nanocomposites", "relation": "generate", "tail": "higher photothermal heat than MoS2-CuS nanocomposites"}
{"head": "MoS2-CuS nanocomposites", "relation": "have potential as", "tail": "photothermal agents for cancer therapy"}
{"head": "MoS2-AuNR nanocomposites", "relation": "have potential as", "tail": "photothermal agents for cancer therapy"}
{"head": "Melanotic Neuroectodermal Tumor of Infancy", "relation": "is", "tail": "rare locally aggressive tumor"}
{"head": "Melanotic Neuroectodermal Tumor of Infancy", "relation": "commonly occurs in", "tail": "head and neck region"}
{"head": "Melanotic Neuroectodermal Tumor of Infancy", "relation": "consists of", "tail": "biphasic population of small neuroblast-like cells and larger melanin-containing epithelioid cells"}
{"head": "MNTI cases", "relation": "were diagnosed at", "tail": "single institution"}
{"head": "Eleven MNTI cases", "relation": "were identified", "tail": ""}
{"head": "Median patient age", "relation": "was", "tail": "5 months"}
{"head": "Male to Female ratio", "relation": "was", "tail": "1.75 to 1"}
{"head": "Tumor distribution", "relation": "included", "tail": "Maxilla, Mandible, greater wing of Sphenoid, Temporal bone"}
{"head": "All tumors", "relation": "revealed", "tail": "classic biphasic morphology in resection specimens"}
{"head": "Larger epithelioid cells", "relation": "were positive for", "tail": "AE1/AE3 and HMB45"}
{"head": "Smaller neuroblast-like cells", "relation": "were positive for", "tail": "Synaptophysin"}
{"head": "One patient", "relation": "had", "tail": "nested areas composed of mature glial tissue"}
{"head": "One patient with incomplete resection", "relation": "was given", "tail": "adjuvant radiotherapy"}
{"head": "One patient", "relation": "developed", "tail": "solitary ipsilateral lymph nodal metastasis"}
{"head": "Follow-up period", "relation": "ranged from", "tail": "1 to 93 months"}
{"head": "All patients", "relation": "were alive with no evidence of disease at", "tail": "last follow-up"}
{"head": "Lack of consideration of MNTI in differential diagnosis", "relation": "can lead to", "tail": "misdiagnosis and undue exposure to cytotoxic therapies"}
{"head": "Awareness of classic biphasic morphology and distinct immunoprofile of MNTI", "relation": "is essential for", "tail": "correct diagnosis"}
{"head": "CXC chemokines", "relation": "are a class of", "tail": "cytokines"}
{"head": "CXC chemokines", "relation": "exhibit dysregulation in", "tail": "miscellaneous cancer categories"}
{"head": "CXC chemokines", "relation": "are associated with", "tail": "advancement of tumors"}
{"head": "Breast cancer", "relation": "is diagnosed in", "tail": "female population"}
{"head": "Breast cancer", "relation": "is fatal in", "tail": "female population"}
{"head": "Breast cancer pathogenesis and progression", "relation": "involve", "tail": "invasion"}
{"head": "Breast cancer pathogenesis and progression", "relation": "involve", "tail": "metastasis"}
{"head": "Breast cancer pathogenesis and progression", "relation": "involve", "tail": "angiogenesis"}
{"head": "Breast cancer pathogenesis and progression", "relation": "involve", "tail": "inflammation"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "invasion"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "metastasis"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "angiogenesis"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "inflammation"}
{"head": "CXC chemokine receptors (CXCRs) and their related ligands", "relation": "facilitate and control", "tail": "tumor proliferation"}
{"head": "CXCRs", "relation": "are expressed by", "tail": "cancer cells"}
{"head": "CXCRs", "relation": "are expressed by", "tail": "immune cells"}
{"head": "CXCRs", "relation": "regulate", "tail": "tumor microenvironment"}
{"head": "CXCRs", "relation": "regulate", "tail": "immune response"}
{"head": "Psoriasis", "relation": "is", "tail": "chronic systemic autoimmune disease"}
{"head": "Hematopoietic stem cell transplantation", "relation": "is", "tail": "promising therapeutic modality for hematological malignancies"}
{"head": "Hematopoietic stem cell transplantation", "relation": "controls", "tail": "psoriasis in patients with hematological tumor"}
{"head": "Hematopoietic stem cell transplantation", "relation": "prevents", "tail": "recurrence of psoriasis"}
{"head": "Hematopoietic stem cell transplantation", "relation": "has", "tail": "potential immunomodulatory activity"}
{"head": "Hematopoietic stem cell transplantation", "relation": "treats", "tail": "psoriasis"}
{"head": "Hematopoietic stem cell transplantation", "relation": "treats", "tail": "recurrence of psoriasis"}
{"head": "31 of 41 patients", "relation": "did not experience", "tail": "recurrence of psoriasis during follow-up"}
{"head": "10 of 41 patients", "relation": "experienced", "tail": "recurrence of psoriasis during post-transplantation follow-up"}
{"head": "Earliest recurrence of skin lesions", "relation": "occurred at", "tail": "1.4 months after transplantation"}
{"head": "Skin lesions recurrence", "relation": "disappeared at", "tail": "3.5 months after transplantation"}
{"head": "Latest recurrence of psoriasis", "relation": "occurred at", "tail": "60 months post-transplant"}
{"head": "Flare-up of psoriatic arthritis", "relation": "occurred at", "tail": "156 months post-transplant"}
{"head": "Severity and duration of psoriasis and arthritis", "relation": "improved compared to", "tail": "pretransplant"}
{"head": "Nurse cancer survivors", "relation": "face", "tail": "significant challenges in adapting to returning to work"}
{"head": "Nurse cancer survivors", "relation": "require", "tail": "special attention and support"}
{"head": "This interpretive phenomenological study", "relation": "aims to explore", "tail": "NCSs' feelings and experiences after returning to work"}
{"head": "Semi-structured interviews", "relation": "were conducted with", "tail": "15 nurse cancer survivors in China"}
{"head": "The transcripts", "relation": "were analyzed using", "tail": "interpretative phenomenological analysis"}
{"head": "Data", "relation": "was categorized into", "tail": "psychological odyssey"}
{"head": "Data", "relation": "was categorized into", "tail": "accessing social support"}
{"head": "Data", "relation": "was categorized into", "tail": "benefiting from professional background"}
{"head": "Data", "relation": "was categorized into", "tail": "realization of professional values"}
{"head": "Managers", "relation": "should pay attention to", "tail": "psychology of nurse cancer survivors' returning to work"}
{"head": "Managers", "relation": "should enhance", "tail": "support for nurse cancer survivors"}
{"head": "Managers", "relation": "should encourage", "tail": "use of professional strengths by nurse cancer survivors"}
{"head": "Managers", "relation": "should value", "tail": "insights and professional development of nurse cancer survivors"}
{"head": "Oncology patients aged 65 and older", "relation": "visit", "tail": "emergency department"}
{"head": "Infection", "relation": "is a cause of", "tail": "emergency department visits among oncology patients aged 65 and older"}
{"head": "Pain", "relation": "is a cause of", "tail": "emergency department visits among oncology patients aged 65 and older"}
{"head": "Nausea-vomiting", "relation": "is a cause of", "tail": "emergency department visits among oncology patients aged 65 and older"}
{"head": "Dyspnea", "relation": "is a cause of", "tail": "emergency department visits among oncology patients aged 65 and older"}
{"head": "Reason for emergency department visit", "relation": "is associated with", "tail": "knowledge of when to seek medical help"}
{"head": "Recurrent visits of cancer patients to emergency departments", "relation": "suggest", "tail": "inadequacy of comprehensive information for patients and caregivers concerning emergency medical intervention"}
{"head": "gastric venous congestion", "relation": "occurs following", "tail": "total pancreatectomy"}
{"head": "gastric venous drainage reconstruction", "relation": "prevents", "tail": "gastric venous congestion"}
{"head": "total pancreatectomy", "relation": "includes", "tail": "primary one-step total pancreatectomy"}
{"head": "total pancreatectomy", "relation": "includes", "tail": "planned elective completion pancreatectomy"}
{"head": "planned elective completion pancreatectomy", "relation": "follows", "tail": "pancreatoduodenectomy"}
{"head": "planned elective completion pancreatectomy", "relation": "follows", "tail": "distal pancreatectomy"}
{"head": "intraoperative gastric venous congestion", "relation": "necessitates", "tail": "portal vein-right gastroepiploic vein side-to-side anastomosis"}
{"head": "portal vein-right gastroepiploic vein side-to-side anastomosis", "relation": "resolves", "tail": "intraoperative gastric venous congestion"}
{"head": "portal vein-right gastroepiploic vein side-to-side anastomosis", "relation": "prevents", "tail": "postoperative gastric venous congestion"}
{"head": "portal vein-right gastroepiploic vein side-to-side anastomosis", "relation": "has no major complications in", "tail": "patients with intraoperative gastric venous congestion"}
{"head": "acidic urine", "relation": "has pH less than or equal to", "tail": "5.5"}
{"head": "patients with acidic urine", "relation": "have higher", "tail": "fasting plasma glucose levels"}
{"head": "patients with acidic urine", "relation": "have higher", "tail": "serum uric acid level"}
{"head": "patients with acidic urine", "relation": "have lower", "tail": "estimated glomerular filtration rates"}
{"head": "patients with acidic urine", "relation": "have higher rates of", "tail": "abnormal urinary cytology"}
{"head": "acidic urine group", "relation": "has lower", "tail": "recurrence-free survival rate compared to high urine pH group"}
{"head": "acidic urine", "relation": "is associated with", "tail": "disease recurrence after intravesical BCG induction for NMIBC"}
{"head": "intravesical Bacillus Calmette-Gu\u00e9rin induction therapy", "relation": "is used for treatment of", "tail": "nonmuscle-invasive bladder cancer"}
{"head": "patients with nonmuscle-invasive bladder cancer", "relation": "undergo", "tail": "transurethral resection of bladder tumor followed by intravesical Bacillus Calmette-Gu\u00e9rin induction therapy"}
{"head": "images of oral potentially malignant disorders", "relation": "encounter problems related to", "tail": "visual quality and image distortion"}
{"head": "visual quality and image distortion", "relation": "lead to", "tail": "misdiagnosis and missed diagnosis"}
{"head": "multiscale retinex", "relation": "processes", "tail": "original images"}
{"head": "adaptive histogram equalization", "relation": "processes", "tail": "original images"}
{"head": "adaptive contrast enhancement", "relation": "processes", "tail": "original images"}
{"head": "object detection models based on You Only Look Once version 8", "relation": "used for", "tail": "lesion detection"}
{"head": "model performance in the MSR-enhanced image set", "relation": "is superior to", "tail": "model performance in the original image set"}
{"head": "model performance in the MSR-enhanced image set", "relation": "increases", "tail": "total accuracy for all three lesion types"}
{"head": "model performance in the MSR-enhanced image set", "relation": "improves", "tail": "sensitivity of complete correct recognition for complex multi-lesion images"}
{"head": "models trained with adaptive histogram equalization preprocessing", "relation": "show", "tail": "reduced diagnostic performance"}
{"head": "models trained with adaptive contrast enhancement preprocessing", "relation": "show", "tail": "reduced diagnostic performance"}
{"head": "image enhancement algorithms", "relation": "enhance", "tail": "visual quality of OPMDs images"}
{"head": "multiscale retinex algorithm", "relation": "strengthens", "tail": "object detection ability in the computer vision model"}
{"head": "multiscale retinex algorithm", "relation": "reduces", "tail": "misdiagnosis and missed diagnosis of OPMDs lesions in object detection model"}
{"head": "Laparoscopic surgery", "relation": "has shorter operating time than", "tail": "Robotic surgery"}
{"head": "Robotic surgery", "relation": "has lower rate of pancreatic fistula formation than", "tail": "Laparoscopic surgery"}
{"head": "Laparoscopic surgery", "relation": "has higher blood loss than", "tail": "Robotic surgery"}
{"head": "Re-exploration rate", "relation": "is similar in", "tail": "Laparoscopic surgery and Robotic surgery"}
{"head": "Length of hospital stay", "relation": "is similar in", "tail": "Laparoscopic surgery and Robotic surgery"}
{"head": "R0 resection rate", "relation": "is similar in", "tail": "Laparoscopic surgery and Robotic surgery"}
{"head": "Rate of conversion", "relation": "is similar in", "tail": "Laparoscopic surgery and Robotic surgery"}
{"head": "Spleen preservation rate", "relation": "is similar in", "tail": "Laparoscopic surgery and Robotic surgery"}
{"head": "CHD1", "relation": "regulates", "tail": "chromatin dynamics"}
{"head": "CHD1", "relation": "influences", "tail": "gene expression"}
{"head": "CHD1", "relation": "influences", "tail": "DNA repair"}
{"head": "CHD1", "relation": "influences", "tail": "genomic stability"}
{"head": "CHD1", "relation": "acts as", "tail": "tumour suppressor in prostate cancer"}
{"head": "CHD1", "relation": "facilitates", "tail": "neuroendocrine differentiation in prostate cancer"}
{"head": "loss of CHD1", "relation": "linked to", "tail": "aggressive phenotypes in prostate cancer"}
{"head": "loss of CHD1", "relation": "linked to", "tail": "resistance to androgen receptor therapies"}
{"head": "loss of CHD1", "relation": "linked to", "tail": "synthetic lethality with PTEN loss"}
{"head": "CHD1", "relation": "implicated in", "tail": "breast cancer"}
{"head": "CHD1", "relation": "implicated in", "tail": "ovarian cancer"}
{"head": "CHD1", "relation": "implicated in", "tail": "hematological cancers"}
{"head": "CHD1", "relation": "modulates", "tail": "chromatin accessibility in breast, ovarian, and hematological cancers"}
{"head": "CHD1", "relation": "modulates", "tail": "transcription regulation in breast, ovarian, and hematological cancers"}
{"head": "CHD1", "relation": "modulates", "tail": "therapy resistance in breast, ovarian, and hematological cancers"}
{"head": "Immune effector cell-associated neurotoxicity syndrome", "relation": "is a complication of", "tail": "CD19-directed CAR T-cell therapy"}
{"head": "EEG", "relation": "is a predictive biomarker of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Pre-infusion EEG abnormalities", "relation": "are a risk factor for", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Post-infusion qualitative EEG abnormalities", "relation": "are associated with higher risk of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Higher theta energy in post-infusion EEGs", "relation": "is associated with higher risk of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Higher delta + theta/alfa ratio in post-infusion EEGs", "relation": "is associated with higher risk of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Higher beta energy in post-infusion EEGs", "relation": "is protective against", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "EEG", "relation": "identifies patients at risk for", "tail": "Immune effector cell-associated neurotoxicity syndrome before CAR T-cell infusion"}
{"head": "EEG", "relation": "anticipates onset of", "tail": "Immune effector cell-associated neurotoxicity syndrome following infusion"}
{"head": "financial toxicity", "relation": "is prevalent in", "tail": "older Indian patients with cancer"}
{"head": "financial toxicity", "relation": "is assessed by", "tail": "COST-FACIT scale"}
{"head": "financial toxicity", "relation": "is assessed by", "tail": "CFPB Financial Well-Being Scale"}
{"head": "financial toxicity", "relation": "is associated with", "tail": "poor quality of life"}
{"head": "financial toxicity", "relation": "is associated with", "tail": "higher distress"}
{"head": "higher financial toxicity on the COST-FACIT scale", "relation": "is associated with", "tail": "poor financial well-being on the CFPB scale"}
{"head": "history of tobacco chewing", "relation": "is associated with", "tail": "greater financial toxicity"}
{"head": "monthly family income less than \u20b950,000", "relation": "is associated with", "tail": "greater financial toxicity"}
{"head": "lack of health insurance", "relation": "is associated with", "tail": "greater financial toxicity"}
{"head": "illiteracy", "relation": "is associated with", "tail": "greater financial toxicity"}
{"head": "depression", "relation": "is associated with", "tail": "greater financial toxicity"}
{"head": "cognitive impairment", "relation": "is associated with", "tail": "greater financial toxicity"}
{"head": "Testosterone", "relation": "influences", "tail": "development of benign prostatic hyperplasia"}
{"head": "Prostatic inflammation", "relation": "influences", "tail": "development of benign prostatic hyperplasia"}
{"head": "Testicular cancer survivors", "relation": "have incidence of", "tail": "benign prostatic hyperplasia"}
{"head": "Receipt of chemotherapy", "relation": "is not significantly associated with", "tail": "incidence of benign prostatic hyperplasia"}
{"head": "Diagnosis of hypogonadism prior to BPH", "relation": "is not significantly associated with", "tail": "incidence of benign prostatic hyperplasia"}
{"head": "Age at diagnosis", "relation": "is significantly associated with increased incidence of", "tail": "benign prostatic hyperplasia"}
{"head": "Inpatient rehabilitation", "relation": "is provided to", "tail": "patients with brain metastases"}
{"head": "Patients with brain metastasis", "relation": "underwent", "tail": "inpatient rehabilitation"}
{"head": "Median length of inpatient rehabilitation", "relation": "is", "tail": "19.2 days"}
{"head": "33 patients", "relation": "were discharged to", "tail": "home"}
{"head": "1 patient", "relation": "was discharged to", "tail": "long-term care facility"}
{"head": "3 patients", "relation": "were discharged to", "tail": "acute care ward"}
{"head": "2 patients", "relation": "were discharged to", "tail": "palliative care"}
{"head": "Functional Independence Measure", "relation": "was used to assess function after", "tail": "inpatient rehabilitation"}
{"head": "Weighted average total Functional Independence Measure percent gain", "relation": "is", "tail": "14.9%"}
{"head": "Average Functional Independence Measure efficiency", "relation": "is", "tail": "0.61"}
{"head": "Weighted average motor Functional Independence Measure gain", "relation": "is greater than", "tail": "cognitive Functional Independence Measure gain"}
{"head": "Weighted average motor Functional Independence Measure gain", "relation": "is", "tail": "16.5%"}
{"head": "Weighted average cognitive Functional Independence Measure gain", "relation": "is", "tail": "3.6%"}
{"head": "Inpatient rehabilitation", "relation": "enhances", "tail": "functional status in patients with brain metastases"}
{"head": "Inpatient rehabilitation", "relation": "enhances", "tail": "independence in patients with brain metastases"}
{"head": "Resistance training", "relation": "does not significantly impact", "tail": "inflammatory markers in patients with colon cancer undergoing adjuvant chemotherapy"}
{"head": "Patients in the highest tertile of baseline hsCRP", "relation": "are more likely to have received", "tail": "relative dose intensity >70%"}
{"head": "Changes in inflammatory markers", "relation": "are not associated with", "tail": "relative dose intensity"}
{"head": "Patients in the highest tertiles of hsCRP, interleukin-6, and tumor necrosis factor-\u03b1 receptor-II", "relation": "are more likely to have higher", "tail": "baseline body mass index"}
{"head": "Patients in the highest tertiles of hsCRP, interleukin-6, and tumor necrosis factor-\u03b1 receptor-II", "relation": "are more likely to have higher", "tail": "total lean mass"}
{"head": "Patients in the highest tertiles of hsCRP, interleukin-6, and tumor necrosis factor-\u03b1 receptor-II", "relation": "are more likely to have higher", "tail": "total fat mass"}
{"head": "Rectal cancer", "relation": "is a major cause of", "tail": "mortality in the United States"}
{"head": "Locally advanced rectal cancer", "relation": "is defined as", "tail": "up to T3-4 N+"}
{"head": "Standard of care for locally advanced rectal cancer", "relation": "involves", "tail": "total mesorectal excision following neoadjuvant chemoradiotherapy"}
{"head": "Magnetic resonance imaging", "relation": "is the gold standard for", "tail": "local tumor staging"}
{"head": "Magnetic resonance imaging", "relation": "is pivotal in", "tail": "post-treatment restaging"}
{"head": "MRI-based radiomic model", "relation": "identifies", "tail": "characteristic features of peritumoral mesorectal fat"}
{"head": "Patients with locally advanced rectal cancer", "relation": "underwent", "tail": "pre- and post-neoadjuvant chemoradiotherapy MRI scans"}
{"head": "Patients", "relation": "were classified as", "tail": "good responders or poor responders to neoadjuvant therapy based on MRI findings"}
{"head": "MRI findings", "relation": "include", "tail": "tumor volume reduction, signal intensity changes on T2-weighted and diffusion-weighted imaging, alterations in circumferential resection margin and extramural vascular invasion status"}
{"head": "Radiomic model", "relation": "was developed using", "tail": "LASSO algorithm for feature selection and regularization"}
{"head": "LASSO algorithm", "relation": "selected features", "tail": "shape_Sphericity, shape_Maximum2DDiameterSlice, glcm_Imc2"}
{"head": "Radiomic logistic regression model", "relation": "was constructed from", "tail": "selected radiomic features"}
{"head": "Radiomic logistic regression model", "relation": "has an AUC of", "tail": "0.76"}
{"head": "MRI-based radiomic model", "relation": "differentiates and predicts", "tail": "responders and non-responders to neoadjuvant chemoradiotherapy"}
{"head": "MRI-based radiomic model", "relation": "identifies early", "tail": "lesions with high likelihood of requiring surgery"}
{"head": "MRI-based radiomic model", "relation": "identifies early", "tail": "lesions potentially managed with medical treatment alone"}
{"head": "Ultrasound monochromatic Superb Microvascular Index", "relation": "predicts", "tail": "malignancy of solid focal lesions"}
{"head": "Vascular index", "relation": "correlates with", "tail": "bioptic histological results"}
{"head": "Monochromatic Superb Microvascular Index examination", "relation": "visualizes", "tail": "extremely low-velocity flows"}
{"head": "Vascular index", "relation": "is semi-automatically calculated", "tail": "during mSMI examination"}
{"head": "Bioptic procedures", "relation": "are performed under", "tail": "ultrasound guidance"}
{"head": "Malignant lesions", "relation": "have higher vascular index than", "tail": "benign lesions"}
{"head": "Vascular index in malignant lesions", "relation": "is", "tail": "35.45%"}
{"head": "Vascular index in benign lesions", "relation": "is", "tail": "11%"}
{"head": "Threshold vascular index value", "relation": "differentiates", "tail": "malignant lesions"}
{"head": "Vascular index with mSMI", "relation": "has diagnostic accuracy of", "tail": "0.878"}
{"head": "Monochromatic Superb Microvascular Index analysis", "relation": "correlates with", "tail": "histological findings in malignant/benign predictive value"}
{"head": "Monochromatic Superb Microvascular Index analysis", "relation": "reflects", "tail": "histological vascular changes in malignant lesions"}
{"head": "ICRP 103 model", "relation": "estimates lower risk than", "tail": "US EPA model"}
{"head": "ICRP 103 model", "relation": "estimates lower risk than", "tail": "BEIR VII model"}
{"head": "BEIR VII model", "relation": "estimates lifetime attributable risk", "tail": "oncogenic risk related to radiation exposure"}
{"head": "ICRP 103 model", "relation": "estimates lifetime attributable risk", "tail": "oncogenic risk related to radiation exposure"}
{"head": "US EPA model", "relation": "estimates lifetime attributable risk", "tail": "oncogenic risk related to radiation exposure"}
{"head": "different oncogenic risk models", "relation": "estimate different", "tail": "organ, leukemia, and all-cancer risk values"}
{"head": "intraclass correlation coefficient", "relation": "reveals agreement between", "tail": "different risk models"}
{"head": "Friedman test", "relation": "compares risk values between", "tail": "different models"}
{"head": "Ion channels", "relation": "play crucial roles in", "tail": "tumor progression"}
{"head": "Ion channels", "relation": "regulate", "tail": "proliferation"}
{"head": "Ion channels", "relation": "regulate", "tail": "apoptosis"}
{"head": "Ion channels", "relation": "regulate", "tail": "migration"}
{"head": "Ion channels", "relation": "regulate", "tail": "metastasis"}
{"head": "Voltage-gated potassium (Kv) channels", "relation": "have been implicated in", "tail": "oncogenic signaling pathways"}
{"head": "Voltage-gated sodium (Nav) channels", "relation": "have been implicated in", "tail": "oncogenic signaling pathways"}
{"head": "Scorpion venom peptides", "relation": "have", "tail": "selective ion-channel-blocking properties"}
{"head": "Scorpion venom peptides", "relation": "demonstrate", "tail": "antineoplastic activity"}
{"head": "Bioactive fractions derived from Chihuahuanus coahuilae", "relation": "have effects on", "tail": "breast cancer cell lines"}
{"head": "Venom-derived peptides", "relation": "interfere with", "tail": "cancer cell homeostasis"}
{"head": "Venom-derived peptides", "relation": "alter", "tail": "ion fluxes"}
{"head": "Venom-derived peptides", "relation": "promote", "tail": "apoptosis"}
{"head": "Venom-derived peptides", "relation": "inhibit", "tail": "metastatic traits"}
{"head": "Ion-channel-targeting peptides", "relation": "have potential as", "tail": "selective anticancer agents"}
{"head": "Vipera ammodytes venom", "relation": "contains", "tail": "Phospholipases A2"}
{"head": "Vipera ammodytes venom", "relation": "contains", "tail": "C-type lectins"}
{"head": "Vipera ammodytes venom", "relation": "contains", "tail": "metalloproteinases"}
{"head": "Phospholipases A2", "relation": "have", "tail": "cytotoxic properties"}
{"head": "C-type lectins", "relation": "have", "tail": "anti-proliferative properties"}
{"head": "metalloproteinases", "relation": "have", "tail": "tumor-inhibiting properties"}
{"head": "Vipera ammodytes venom", "relation": "is cytotoxic to", "tail": "melanoma cell lines M001, Me501, and A375"}
{"head": "Vipera ammodytes venom", "relation": "has IC50 of", "tail": "approximately 1.1 \u00b5g/mL in melanoma cell lines"}
{"head": "Combined treatment with Vipera ammodytes venom and cisplatin", "relation": "increases", "tail": "cytotoxicity compared to single-agent treatments"}
{"head": "Vipera ammodytes venom", "relation": "enhances sensitivity of", "tail": "cisplatin in resistant melanoma cell lines M001 and Me501"}
{"head": "Vipera ammodytes venom and cisplatin combination", "relation": "increases", "tail": "cell mortality by up to 40% in resistant melanoma cell lines"}
{"head": "A375 cell line", "relation": "is inherently more sensitive to", "tail": "cisplatin"}
{"head": "Vipera ammodytes venom", "relation": "induces", "tail": "morphological changes in melanoma cells"}
{"head": "Vipera ammodytes venom components", "relation": "selectively target", "tail": "melanoma cells in muscle-associated metastases"}
{"head": "Cisplatin", "relation": "has", "tail": "established cytotoxicity"}
{"head": "MyPal project", "relation": "provides", "tail": "palliative care support for patients with cancer"}
{"head": "MyPal project", "relation": "uses", "tail": "electronic patient-reported outcomes eHealth platform"}
{"head": "MyPal for adults", "relation": "is", "tail": "co-designed palliative care mobile app"}
{"head": "MyPal for adults", "relation": "supports", "tail": "adults with cancer"}
{"head": "participants", "relation": "found", "tail": "intervention content useful"}
{"head": "participants", "relation": "reported", "tail": "satisfactory usability"}
{"head": "Post-Study System Usability Questionnaire score", "relation": "is", "tail": "2.458"}
{"head": "System Usability Scale score", "relation": "is", "tail": "68.9"}
{"head": "User Experience Questionnaire aspects", "relation": "surpassed", "tail": "usability quality benchmarks"}
{"head": "qualitative analysis", "relation": "identified", "tail": "43 usability issues"}
{"head": "usability issues", "relation": "related to", "tail": "effectiveness and efficiency as defined in ISO 9241-210"}
{"head": "MyPal for adults app", "relation": "is", "tail": "digital tool designed to enhance the palliative care experience"}
{"head": "study findings", "relation": "reveal", "tail": "user-friendly interface"}
{"head": "study findings", "relation": "reveal", "tail": "positive patient experiences"}
{"head": "Bronchial sleeve lobectomies", "relation": "are", "tail": "technically challenging procedures"}
{"head": "Robotic technique", "relation": "provides", "tail": "advantages for anastomosis"}
{"head": "Uniportal robotic sleeve lower lobectomy", "relation": "is performed for", "tail": "endobronchial tumour of the lower lobe"}
{"head": "Endobronchial tumour of the lower lobe", "relation": "extends to", "tail": "distal end of the intermediate bronchus"}
{"head": "4-cm skin incision", "relation": "is made at", "tail": "sixth intercostal space in the middle axillary line"}
{"head": "30-degree 10-mm camera", "relation": "is placed on", "tail": "posterior edge of the incision"}
{"head": "Right lower sleeve lobectomy", "relation": "includes", "tail": "end-to-end anastomosis between proximal intermediate bronchial stump and middle lobe bronchial stump"}
{"head": "Postoperative endobronchial examination", "relation": "shows", "tail": "well-done anastomosis"}
{"head": "Patient", "relation": "was discharged on", "tail": "postoperative day 5"}
{"head": "Histologic examination", "relation": "confirmed diagnosis of", "tail": "2-cm atypical carcinoid without lymph node involvement"}
{"head": "Glioblastoma", "relation": "is a type of", "tail": "brain cancer"}
{"head": "Glioblastoma", "relation": "has characteristic", "tail": "low survival rate"}
{"head": "Glioblastoma", "relation": "has characteristic", "tail": "frequently invasive"}
{"head": "Epithelial-mesenchymal transition biomarkers", "relation": "are modulated in", "tail": "glioblastoma cells"}
{"head": "Epithelial-mesenchymal transition biomarkers", "relation": "are associated with", "tail": "tumor progression"}
{"head": "Epithelial-mesenchymal transition biomarkers", "relation": "are associated with", "tail": "chemoresistance"}
{"head": "Epithelial-mesenchymal transition biomarkers", "relation": "are associated with", "tail": "relapse after treatment"}
{"head": "Marine eukaryotic microalgae", "relation": "produce", "tail": "secondary metabolites with biological activity"}
{"head": "Dinoflagellates belonging to Amphidinium carterae", "relation": "produce", "tail": "neurotoxins"}
{"head": "Dinoflagellates belonging to Amphidinium carterae", "relation": "produce", "tail": "cytotoxic compounds"}
{"head": "Chemical extracts from Amphidinium carterae", "relation": "modulate", "tail": "EMT markers in T98G human GBM cells"}
{"head": "Chemical extracts from Amphidinium carterae", "relation": "modulate", "tail": "proliferation capability of GBM cells"}
{"head": "Chemical extracts from Amphidinium carterae", "relation": "modulate", "tail": "migration capability of GBM cells"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "inhibit", "tail": "cell viability in A549 and H460 cells"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "reduce", "tail": "cell viability to 38.6% in A549-Ctr cells at 40 \u00b5g/mL after 48 h"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "reduce", "tail": "cell viability to 37.2% in A549-CR cells at 40 \u00b5g/mL after 48 h"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "reduce", "tail": "cell viability to 28.4% in H460-Ctr cells at 40 \u00b5g/mL after 48 h"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "reduce", "tail": "cell viability to 30.4% in H460-CR cells at 40 \u00b5g/mL after 48 h"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "suppress", "tail": "colony formation by over 90% in 2D and soft agar assays"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "show no cytotoxicity", "tail": "normal human keratinocytes up to 80 \u00b5g/mL"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "induce", "tail": "G1 phase arrest in A549-Ctr and A549-CR cells"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "cyclin D1"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "CDK4"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "cyclin E"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "CDK2"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "decrease", "tail": "phosphorylated STAT3"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "decrease", "tail": "c-Myc expression"}
{"head": "STAT3 knockdown", "relation": "phenocopy", "tail": "effects of Allium pseudojaponicum Makino extracts"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "target", "tail": "STAT3 signaling pathway"}
{"head": "lycorine", "relation": "is a major compound of", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "tazettine", "relation": "is a major compound of", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "tricetin", "relation": "is a major compound of", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "alkaloids", "relation": "constitute 71.65% of", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "flavonoids", "relation": "constitute 8.81% of", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "Xanthocillin X dimethyl ether", "relation": "treats", "tail": "triple-negative breast cancer"}
{"head": "Xanthocillin X dimethyl ether", "relation": "binds to", "tail": "hemin"}
{"head": "Hemin", "relation": "is oxidized form of", "tail": "heme"}
{"head": "Xanthocillin X dimethyl ether", "relation": "depletes", "tail": "intracellular regulatory heme"}
{"head": "Xanthocillin X dimethyl ether", "relation": "translocates into", "tail": "mitochondria"}
{"head": "Xanthocillin X dimethyl ether", "relation": "interacts with", "tail": "mitochondrial cytochromes"}
{"head": "Xanthocillin X dimethyl ether", "relation": "disrupts", "tail": "electron transport chain"}
{"head": "Xanthocillin X dimethyl ether", "relation": "inhibits activity of", "tail": "mitochondrial complexes"}
{"head": "Xanthocillin X dimethyl ether", "relation": "inactivates", "tail": "mitochondrial respiration"}
{"head": "Inhibitory activity of Xanthocillin X dimethyl ether on mitochondrial function", "relation": "contributes to", "tail": "anti-triple-negative breast cancer effects"}
{"head": "Resistance to PARP inhibitors", "relation": "is a challenge in", "tail": "ovarian cancer treatment"}
{"head": "Gukulenin A", "relation": "is isolated from", "tail": "marine sponge Phorbas gukhulensis"}
{"head": "Gukulenin A", "relation": "enhances", "tail": "olaparib-induced cytotoxicity in human ovarian cancer cells"}
{"head": "Combination treatment of Gukulenin A and olaparib", "relation": "increases", "tail": "reactive oxygen species levels"}
{"head": "Combination treatment of Gukulenin A and olaparib", "relation": "increases", "tail": "lipid peroxidation"}
{"head": "Combination treatment of Gukulenin A and olaparib", "relation": "induces", "tail": "ferroptotic cell death"}
{"head": "Combination treatment of Gukulenin A and olaparib", "relation": "does not induce", "tail": "apoptotic cell death"}
{"head": "Oxidative stress-related pathways", "relation": "mediate", "tail": "ferroptosis induced by combination treatment"}
{"head": "Inhibition of NADPH oxidase", "relation": "reverses", "tail": "combination-induced cell death"}
{"head": "Ferrostatin-1", "relation": "reduces", "tail": "lipid peroxidation and cytotoxicity induced by combination treatment"}
{"head": "Gukulenin A and olaparib treatment", "relation": "suppresses", "tail": "ERK1/2 activation"}
{"head": "ERK overexpression", "relation": "attenuates", "tail": "combination-induced cell death"}
{"head": "Marine-derived Gukulenin A", "relation": "enhances", "tail": "PARP inhibitor efficacy in ovarian cancer cells"}
{"head": "Gukulenin A", "relation": "induces", "tail": "ferroptosis through oxidative stress and ERK pathway modulation"}
{"head": "Colorectal cancer", "relation": "is", "tail": "third most common malignancy"}
{"head": "Marine-derived quinolone alkaloids", "relation": "exhibit", "tail": "antitumor properties"}
{"head": "Compounds 1-13", "relation": "were semi-synthesized based on", "tail": "4'-desmethoxyyaequinolone J1"}
{"head": "4'-desmethoxyyaequinolone J1", "relation": "is", "tail": "4-phenyl derivative of yaequinolone J1"}
{"head": "Yaequinolone J1", "relation": "was isolated from", "tail": "Penicillium sp. FKI-2140"}
{"head": "CHNQD-02792", "relation": "has sensitivity to", "tail": "HT-29 cells"}
{"head": "CHNQD-02792", "relation": "has IC50", "tail": "4.5 \u03bcM in HT-29 cells"}
{"head": "5-fluorouracil", "relation": "has IC50", "tail": "15.58 \u03bcM in HT-29 cells"}
{"head": "CHNQD-02792", "relation": "inhibits", "tail": "growth of HT-29 cells at 9 \u03bcM"}
{"head": "CHNQD-02792", "relation": "inhibits", "tail": "CDK1 expression in HT-29 cells"}
{"head": "CHNQD-02792", "relation": "triggers", "tail": "G2/M phase arrest in HT-29 cells"}
{"head": "CHNQD-02792", "relation": "induces apoptosis by suppressing", "tail": "Bcl-2"}
{"head": "CHNQD-02792", "relation": "induces apoptosis by upregulating", "tail": "Caspase-3"}
{"head": "CHNQD-02792", "relation": "induces apoptosis by upregulating", "tail": "Bax"}
{"head": "CHNQD-02792", "relation": "inhibits phosphorylation of", "tail": "ERK"}
{"head": "CHNQD-02792", "relation": "inhibits phosphorylation of", "tail": "JNK"}
{"head": "CHNQD-02792", "relation": "regulates", "tail": "MAPK signaling"}
{"head": "CHNQD-02792", "relation": "exerts cytotoxic effects on", "tail": "HT-29 cells"}
{"head": "CHNQD-02792", "relation": "induces", "tail": "G2/M arrest"}
{"head": "CHNQD-02792", "relation": "induces", "tail": "apoptosis"}
{"head": "CHNQD-02792", "relation": "regulates MAPK signaling through", "tail": "ERK/JNK dephosphorylation"}
{"head": "CD4+ T cells", "relation": "activate cytotoxicity of", "tail": "CD8+ T cells"}
{"head": "CD8+ T cells", "relation": "regulate", "tail": "CD4+ T cells"}
{"head": "activated CD4+ and CD8+ T cells", "relation": "are critical for", "tail": "CTT-induced antitumor immunity"}
{"head": "interaction between activated CD4+ and CD8+ T cells", "relation": "is enhanced after", "tail": "cryo-thermal therapy"}
{"head": "reciprocal regulation of activated CD8+ and CD4+ T cells", "relation": "occurs through", "tail": "LFA-1/ICAM-1 interactions"}
{"head": "CD8+ T cells", "relation": "facilitate", "tail": "Notch1-dependent CD4+ Th1-dominant differentiation"}
{"head": "CD8+ T cells", "relation": "promote secretion of", "tail": "IL-2 by CD4+ T cells"}
{"head": "IL-2 derived from CD4+ T cells", "relation": "enhances cytotoxicity of", "tail": "CD8+ T cells"}
{"head": "IL-2", "relation": "increases expression of", "tail": "LFA-1 and ICAM-1 on T cells"}
{"head": "LFA-1/ICAM interactions between CD4+ and CD8+ T cells", "relation": "are correlated with", "tail": "clinical outcomes"}
{"head": "Vasculogenic mimicry", "relation": "nourishes", "tail": "cancer cells"}
{"head": "Tumor cells", "relation": "form", "tail": "three-dimensional channel-like structures"}
{"head": "Three-dimensional channel-like structures", "relation": "transport", "tail": "nutrients and oxygen"}
{"head": "Vasculogenic mimicry", "relation": "occurs in", "tail": "aggressive solid tumors"}
{"head": "Vasculogenic mimicry", "relation": "associated with", "tail": "poor prognosis in oncologic patients"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "protein-encoding genes involved in cancer development and progression"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "cell proliferation"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "apoptosis"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "angiogenesis"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "vasculogenic mimicry"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "therapy response"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "migration"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "invasion"}
{"head": "Long non-coding RNAs", "relation": "regulate", "tail": "metastasis"}
{"head": "miR-146a", "relation": "plays a role in", "tail": "breast cancer"}
{"head": "SNP rs2910164:G>C", "relation": "is located within", "tail": "miR-146a precursor"}
{"head": "SNP rs2910164:G>C", "relation": "is linked to", "tail": "breast cancer risk"}
{"head": "rs2910164:G>C", "relation": "upregulates expression of", "tail": "mature miR-146a sequences 3p and 5p"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "proliferation in luminal A and triple-negative breast cells"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "migration in luminal A and triple-negative breast cells"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "invasion in luminal A and triple-negative breast cells"}
{"head": "pre-miR-146a-C", "relation": "decreases", "tail": "cisplatin-induced apoptosis in luminal A and triple-negative breast cells"}
{"head": "pre-miR-146a C allele", "relation": "decreases", "tail": "cisplatin resistance in MCF-7 cells"}
{"head": "pre-miR-146a C allele", "relation": "increases", "tail": "cisplatin resistance in MDA-MB-231 cells"}
{"head": "rs2910164 C allele", "relation": "promotes", "tail": "miR-146a overexpression"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "proliferation"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "migration"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "invasion"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "apoptosis"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "cisplatin resistance"}
{"head": "Paclitaxel", "relation": "improves", "tail": "overall survival of non-small cell lung cancer patients"}
{"head": "AdipoRon", "relation": "is", "tail": "adiponectin receptor agonist"}
{"head": "AdipoRon", "relation": "is", "tail": "anticancer compound in non-small cell lung cancer"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "inhibits", "tail": "cell growth in non-small cell lung cancer cells"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "inhibits", "tail": "clonogenic potential in non-small cell lung cancer cells"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "induces", "tail": "cell death in non-small cell lung cancer cells"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "causes cleavage of", "tail": "poly-ADP ribose polymerase"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "causes cleavage of", "tail": "caspase-3 apoptotic markers"}
{"head": "AMP-activated protein kinase", "relation": "is critical sensor in", "tail": "efficacy of combination of AdipoRon and Paclitaxel"}
{"head": "Inhibition of AMP-activated protein kinase by Compound-C", "relation": "rescues", "tail": "cell growth in presence of combination of AdipoRon and Paclitaxel"}
{"head": "Combination of AdipoRon and Paclitaxel", "relation": "causes downregulation of", "tail": "extracellular signal-regulated kinase 1/2"}
{"head": "Inhibition of extracellular signal-regulated kinase 1/2 by PD98059", "relation": "counteracts", "tail": "effects of combination of AdipoRon and Paclitaxel"}
{"head": "AdipoRon", "relation": "is candidate in", "tail": "Paclitaxel-based therapy"}
{"head": "Hepatocyte nuclear factor 4\u03b1", "relation": "is a member of", "tail": "nuclear receptor superfamily of transcription factors"}
{"head": "Hepatocyte nuclear factor 4\u03b1", "relation": "is a therapeutic candidate for", "tail": "colorectal adenocarcinoma"}
{"head": "HNF4\u03b1", "relation": "is upregulated during", "tail": "carcinogenesis"}
{"head": "HNF4\u03b1 overexpression", "relation": "promotes", "tail": "CRAC cell migration and invasion"}
{"head": "HNF4\u03b1 inhibition", "relation": "suppresses", "tail": "CRAC cell migration and invasion"}
{"head": "HNF4\u03b1 levels", "relation": "are diminished in", "tail": "metastatic and poorly differentiated CRAC"}
{"head": "Reduced HNF4\u03b1 levels", "relation": "are associated with", "tail": "unfavorable prognostic factors"}
{"head": "HNF4\u03b1 inhibition", "relation": "induces decrease in", "tail": "NF-\u03bab protein levels"}
{"head": "HNF4\u03b1 inhibition", "relation": "induces increase in", "tail": "YAP levels"}
{"head": "HNF4\u03b1 overexpression", "relation": "is linked to", "tail": "early carcinogenesis"}
{"head": "Reduced HNF4\u03b1 expression", "relation": "is associated with", "tail": "progression and metastasis of CRAC"}
{"head": "TIGAR", "relation": "regulates", "tail": "balance between glycolysis and antioxidant defense mechanisms"}
{"head": "Cancer cells", "relation": "exhibit", "tail": "shift towards aerobic glycolysis"}
{"head": "TIGAR", "relation": "inhibits", "tail": "glycolysis"}
{"head": "TIGAR", "relation": "reduces", "tail": "proliferation rate of cancer cells"}
{"head": "Metabolic shift", "relation": "leads to", "tail": "increased levels of reactive oxygen species"}
{"head": "TIGAR", "relation": "promotes", "tail": "pentose phosphate pathway"}
{"head": "Pentose phosphate pathway", "relation": "generates", "tail": "NADPH"}
{"head": "NADPH", "relation": "involved in", "tail": "antioxidant defense"}
{"head": "TIGAR", "relation": "decreases", "tail": "glycolytic flux"}
{"head": "TIGAR", "relation": "increases", "tail": "diversion of glucose-6-phosphate into pentose phosphate pathway"}
{"head": "TIGAR", "relation": "reduces", "tail": "reactive oxygen species levels"}
{"head": "TIGAR", "relation": "supports", "tail": "biosynthesis and cell survival"}
{"head": "TIGAR", "relation": "maintains", "tail": "balance of nucleotides and lipids"}
{"head": "TIGAR", "relation": "is", "tail": "prognostic and potential therapeutic target in different types of cancers"}
{"head": "TIGAR", "relation": "is", "tail": "diagnostic marker and therapeutic target"}
{"head": "Endometrial cancer", "relation": "is a common malignancy in", "tail": "women in developed countries"}
{"head": "Early stages of endometrial cancer", "relation": "show better responses to", "tail": "surgery"}
{"head": "Early stages of endometrial cancer", "relation": "show better responses to", "tail": "adjuvant hormonal therapy"}
{"head": "Early stages of endometrial cancer", "relation": "show better responses to", "tail": "chemotherapy"}
{"head": "Patients with recurrence of endometrial cancer", "relation": "show", "tail": "treatment resistance"}
{"head": "Cancer stem cells", "relation": "are involved in treatment of", "tail": "gynecologic cancer"}
{"head": "Cancer stem cells", "relation": "are involved in treatment of", "tail": "endometrial cancer"}
{"head": "Cancer stem cells", "relation": "have resistance to", "tail": "conventional therapies"}
{"head": "Conventional therapies", "relation": "include", "tail": "chemotherapy"}
{"head": "Conventional therapies", "relation": "include", "tail": "radiotherapy"}
{"head": "Cancer stem cells", "relation": "induce", "tail": "progression of malignancy"}
{"head": "Cancer stem cells", "relation": "induce", "tail": "recurrence of malignancy"}
{"head": "Activation of WNT pathway", "relation": "could be basis of abilities of", "tail": "cancer stem cells"}
{"head": "Activation of PI3K pathway", "relation": "could be basis of abilities of", "tail": "cancer stem cells"}
{"head": "Activation of NF-kB pathway", "relation": "could be basis of abilities of", "tail": "cancer stem cells"}
{"head": "Activation of NOTCH pathway", "relation": "could be basis of abilities of", "tail": "cancer stem cells"}
{"head": "Specific markers and signaling pathways of cancer stem cells", "relation": "could be", "tail": "treatment targets"}
{"head": "Glioma stem cells", "relation": "express", "tail": "immunosuppressive effectors mimicking regulatory T cells"}
{"head": "Immunosuppressive Treg-like GSC state", "relation": "is specific to", "tail": "mesenchymal GSC subset"}
{"head": "Immunosuppressive Treg-like GSC state", "relation": "is driven by", "tail": "TGF\u03b2 type II receptor (TGFBR2)"}
{"head": "Immunosuppressive Treg-like GSC state", "relation": "is not driven by", "tail": "TGFBR1"}
{"head": "Transgenic TGFBR2 expression in patient-derived GBM neurospheres", "relation": "promotes", "tail": "mesenchymal transition"}
{"head": "Transgenic TGFBR2 expression in patient-derived GBM neurospheres", "relation": "induces", "tail": "six-gene ITL signature"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "CD274 (PD-L1)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "NT5E (CD73)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "ENTPD1 (CD39)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "LGALS1 (galectin-1)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "PDCD1LG2 (PD-L2)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "TGFB1"}
{"head": "TGFBR2-driven ITL signature", "relation": "is identified in", "tail": "clinical GBM specimens"}
{"head": "TGFBR2-driven ITL signature", "relation": "is identified in", "tail": "patient-derived GSCs"}
{"head": "TGFBR2-driven ITL signature", "relation": "is identified in", "tail": "systemic mesenchymal malignancies"}
{"head": "TGFBR2high GSCs", "relation": "inhibit", "tail": "CD4+ T cell viability"}
{"head": "TGFBR2high GSCs", "relation": "inhibit", "tail": "CD8+ T cell viability"}
{"head": "TGFBR2high GSCs", "relation": "inhibit", "tail": "capacity of CD4+ and CD8+ T cells to kill GBM cells"}
{"head": "Pharmacologic and shRNA-based TGFBR2 inhibition", "relation": "reverses", "tail": "inhibition of CD4+ and CD8+ T cell viability and function by TGFBR2high GSCs"}
{"head": "Immunosuppressive GSC state", "relation": "is TGFBR2-dependent", "tail": "true"}
{"head": "Immunosuppressive GSC state", "relation": "is susceptible to", "tail": "TGFBR2-targeted therapeutics"}
{"head": "HMGB1", "relation": "is overexpressed in", "tail": "various cancers"}
{"head": "HMGB1", "relation": "is linked to", "tail": "tumor progression"}
{"head": "HMGB1", "relation": "binds to", "tail": "RAGE"}
{"head": "HMGB1/RAGE signaling pathway", "relation": "promotes", "tail": "metastasis"}
{"head": "Metformin", "relation": "interacts with", "tail": "HMGB1"}
{"head": "Metformin", "relation": "inhibits", "tail": "HMGB1 pro-inflammatory functions"}
{"head": "Metformin", "relation": "reduces", "tail": "HMGB1-induced cell migration"}
{"head": "Metformin", "relation": "reduces", "tail": "cell proliferation"}
{"head": "Metformin", "relation": "decreases", "tail": "RAGE stabilization on the cell membrane"}
{"head": "Metformin", "relation": "disrupts", "tail": "NF-\u03baB signaling"}
{"head": "Metformin", "relation": "reverses", "tail": "epithelial-to-mesenchymal transition"}
{"head": "Metformin", "relation": "increases", "tail": "E-cadherin"}
{"head": "Metformin", "relation": "reduces", "tail": "vimentin"}
{"head": "Metformin", "relation": "stabilizes", "tail": "\u03b2-catenin at the cell membrane"}
{"head": "Metformin", "relation": "lowers", "tail": "HMGB1 protein levels"}
{"head": "Metformin", "relation": "lowers", "tail": "RAGE protein levels"}
{"head": "HMGB1/RAGE positive feedback loop", "relation": "promotes", "tail": "cancer aggressiveness"}
{"head": "Metformin", "relation": "inhibits", "tail": "HMGB1/RAGE-driven metastasis"}
{"head": "Metformin", "relation": "has potential as therapeutic agent in", "tail": "triple-negative breast cancer"}
{"head": "Lung cancer", "relation": "has", "tail": "very poor prognosis"}
{"head": "Immunotherapy", "relation": "is", "tail": "mainstay therapy mode"}
{"head": "Immunotherapy", "relation": "is addition to", "tail": "surgery"}
{"head": "Immunotherapy", "relation": "is addition to", "tail": "chemotherapy"}
{"head": "Immunotherapy", "relation": "is addition to", "tail": "radiotherapy"}
{"head": "Immunotherapy", "relation": "is addition to", "tail": "targeted therapies"}
{"head": "Combination therapy", "relation": "enhances", "tail": "efficacy"}
{"head": "Combination therapy", "relation": "overcomes", "tail": "resistance"}
{"head": "Several genetic signatures", "relation": "are associated with", "tail": "therapy resistance"}
{"head": "Several genetic signatures", "relation": "are associated with", "tail": "metastatic potential"}
{"head": "Machine learning techniques", "relation": "enhance", "tail": "predictive potential of genetic signatures"}
{"head": "Artificial intelligence", "relation": "enhance", "tail": "predictive potential of genetic signatures"}
{"head": "Immune checkpoint inhibitors", "relation": "are", "tail": "key aspect of immunotherapy"}
{"head": "PD-L1 expression", "relation": "is", "tail": "molecular biomarker"}
{"head": "Tumour mutation burden", "relation": "is", "tail": "molecular biomarker"}
{"head": "Immunoscore", "relation": "is", "tail": "molecular biomarker"}
{"head": "Neoantigens", "relation": "are", "tail": "molecular biomarkers"}
{"head": "PD-L1 expression", "relation": "is predictive marker for", "tail": "treatment response"}
{"head": "PD-L1 expression", "relation": "is predictive marker for", "tail": "resistance"}
{"head": "Tumour mutation burden", "relation": "is predictive marker for", "tail": "treatment response"}
{"head": "Tumour mutation burden", "relation": "is predictive marker for", "tail": "resistance"}
{"head": "Immunoscore", "relation": "is predictive marker for", "tail": "treatment response"}
{"head": "Immunoscore", "relation": "is predictive marker for", "tail": "resistance"}
{"head": "Neoantigens", "relation": "are predictive markers for", "tail": "treatment response"}
{"head": "Neoantigens", "relation": "are predictive markers for", "tail": "resistance"}
{"head": "Cancer cells", "relation": "need to be softer to migrate and invade", "tail": "tissues"}
{"head": "Cancer cells", "relation": "need to be softer to metastasize in", "tail": "targeted organs"}
{"head": "Softness of cancer cells", "relation": "serves as", "tail": "universal physical marker for malignancy of cancer types"}
{"head": "Stiffer cancer cells", "relation": "are more migratory and invasive", "tail": ""}
{"head": "Stiffer cancer cells", "relation": "lead to", "tail": "more metastases"}
{"head": "Biophysical techniques", "relation": "affect", "tail": "mechanical properties of cancer cells"}
{"head": "Culture and measurement conditions of cancer cells", "relation": "influence", "tail": "mechanical measurements"}
{"head": "Microenvironment", "relation": "affects", "tail": "mechanical characteristics of cancer cells"}
{"head": "Combinatorial approaches", "relation": "determine", "tail": "malignant potential of tumors"}
{"head": "ECM involvement", "relation": "is part of", "tail": "combinatorial approaches"}
{"head": "Cells in homogeneous or heterogeneous association", "relation": "are part of", "tail": "combinatorial approaches"}
{"head": "Biological multi-omics analyses", "relation": "are part of", "tail": "combinatorial approaches"}
{"head": "Dynamic-mechanical analysis of cancer cells", "relation": "is part of", "tail": "combinatorial approaches"}
{"head": "Malignant pleural mesothelioma", "relation": "is a type of", "tail": "aggressive cancer of the pleural lining"}
{"head": "Malignant pleural mesothelioma", "relation": "is associated with", "tail": "asbestos exposure"}
{"head": "Epithelial-mesenchymal transition", "relation": "drives", "tail": "MPM pathogenesis"}
{"head": "Epithelial-mesenchymal transition", "relation": "drives", "tail": "MPM metastasis"}
{"head": "Epithelial-mesenchymal transition", "relation": "drives", "tail": "MPM resistance to therapy"}
{"head": "TGF-\u03b2 signaling pathway", "relation": "is involved in", "tail": "EMT in MPM"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "is involved in", "tail": "EMT in MPM"}
{"head": "PI3K/Akt signaling pathway", "relation": "is involved in", "tail": "EMT in MPM"}
{"head": "EMT-related biomarkers", "relation": "have", "tail": "diagnostic significance in MPM"}
{"head": "EMT-related biomarkers", "relation": "have", "tail": "prognostic significance in MPM"}
{"head": "Targeted therapies", "relation": "aim at", "tail": "reversing EMT"}
{"head": "Targeted therapies", "relation": "exploit", "tail": "EMT-induced vulnerabilities"}
{"head": "MARS 2 trial", "relation": "is a", "tail": "clinical trial related to MPM treatment"}
{"head": "Bone morphogenetic proteins", "relation": "regulate", "tail": "developmental processes such as limb, kidney and lung formation, cell fate determination, cell proliferation, and apoptosis"}
{"head": "Cancer stem cells", "relation": "are", "tail": "a subpopulation of self-renewing cells within tumors that possess stemness properties and a tumor cell-forming capability"}
{"head": "Cancer stem cells", "relation": "are linked to", "tail": "growth, metastasis, treatment resistance and cancer recurrence"}
{"head": "Tumor microenvironment", "relation": "plays role in", "tail": "onset, progression and treatment resistance in many cancers"}
{"head": "Bone morphogenetic proteins and growth differentiation factors", "relation": "counterbalance", "tail": "transforming growth factor-beta in maintenance of CSC pluripotency and cancer cell differentiation"}
{"head": "BMP signaling", "relation": "functions as", "tail": "tumor suppressor in various cancers"}
{"head": "BMP signaling", "relation": "induces", "tail": "CSC differentiation"}
{"head": "BMP signaling", "relation": "suppresses", "tail": "stemness characteristics"}
{"head": "Differentiation process", "relation": "curtails", "tail": "self-renewal capacity of CSCs"}
{"head": "Self-renewal capacity", "relation": "characterizes", "tail": "Cancer stem cells"}
{"head": "GREMLIN1", "relation": "is", "tail": "a secreted antagonist of BMPs"}
{"head": "GREMLIN1", "relation": "is overexpressed in", "tail": "human cancers such as gastric, colorectal, glioblastoma, and breast cancer"}
{"head": "GREMLIN1 overexpression", "relation": "inhibits", "tail": "BMP signaling"}
{"head": "Inhibition of BMP signaling by GREMLIN1", "relation": "facilitates", "tail": "maintenance of pluripotency in CSCs"}
{"head": "Maintenance of pluripotency in CSCs", "relation": "promotes", "tail": "tumorigenesis"}
{"head": "GREMLIN1 overexpression", "relation": "contributes to", "tail": "CSC immune evasion"}
{"head": "GREMLIN1", "relation": "is target of", "tail": "fibroblast growth factor to Sonic hedgehog signaling"}
{"head": "GREMLIN1", "relation": "is target of", "tail": "Wnt/Frizzled pathway"}
{"head": "Fibroblast growth factor to Sonic hedgehog signaling and Wnt/Frizzled pathway", "relation": "contribute to", "tail": "maintenance of CSC stemness"}
{"head": "Inhibiting GREMLIN1", "relation": "may reduce", "tail": "CSC burden in cancers"}
{"head": "Inhibiting GREMLIN1", "relation": "may improve", "tail": "patient outcomes"}
{"head": "Colorectal cancer", "relation": "is", "tail": "malignant pathology"}
{"head": "Drug resistance", "relation": "contributes to", "tail": "poor prognosis of neoplastic diseases"}
{"head": "Drug resistance", "relation": "reduces", "tail": "utility of therapeutic protocols"}
{"head": "Autophagy", "relation": "maintains", "tail": "nutrient recycling"}
{"head": "Autophagy", "relation": "maintains", "tail": "metabolic adaptation"}
{"head": "Autophagy", "relation": "is related to", "tail": "carcinogenesis"}
{"head": "Autophagy inhibition", "relation": "limits", "tail": "tumor growth"}
{"head": "Autophagy inhibition", "relation": "improves", "tail": "response to cancer therapeutics"}
{"head": "Lysosomes", "relation": "are key players in", "tail": "autophagy"}
{"head": "Lysosomes", "relation": "are targets for", "tail": "anticancer treatment"}
{"head": "Lysosome-associated membrane glycoproteins (LAMPs)", "relation": "are related to", "tail": "autophagy"}
{"head": "Lysosome-associated membrane glycoproteins (LAMPs)", "relation": "are involved in", "tail": "autophagy"}
{"head": "Lysosome-associated membrane glycoproteins (LAMPs)", "relation": "are involved in", "tail": "cancer development"}
{"head": "LAMPs", "relation": "drive", "tail": "drug resistance in colorectal cancer"}
{"head": "Allogeneic hematopoietic stem cell transplantation", "relation": "treats", "tail": "acute myeloid leukemia"}
{"head": "Risk stratification", "relation": "includes", "tail": "molecular profiling"}
{"head": "Risk stratification", "relation": "includes", "tail": "measurable residual disease assessment"}
{"head": "Post-transplant cyclophosphamide", "relation": "is used for", "tail": "graft-versus-host disease prophylaxis"}
{"head": "Advances in risk stratification", "relation": "improve", "tail": "outcomes"}
{"head": "Advances in conditioning regimens", "relation": "improve", "tail": "outcomes"}
{"head": "Advances in graft-versus-host disease prophylaxis", "relation": "improve", "tail": "outcomes"}
{"head": "Advances in risk stratification", "relation": "expand", "tail": "donor selection"}
{"head": "Advances in conditioning regimens", "relation": "expand", "tail": "donor selection"}
{"head": "Advances in graft-versus-host disease prophylaxis", "relation": "expand", "tail": "donor selection"}
{"head": "Advances in risk stratification", "relation": "expand", "tail": "transplant eligibility"}
{"head": "Advances in conditioning regimens", "relation": "expand", "tail": "transplant eligibility"}
{"head": "Advances in graft-versus-host disease prophylaxis", "relation": "expand", "tail": "transplant eligibility"}
{"head": "Chemotherapy", "relation": "is a component of", "tail": "leukemia treatment"}
{"head": "Targeted therapy", "relation": "is a component of", "tail": "leukemia treatment"}
{"head": "Post-transplant maintenance therapy", "relation": "is a component of", "tail": "leukemia treatment"}
{"head": "Artesunate", "relation": "inhibits", "tail": "metastatic potential in cisplatin-resistant bladder cancer cells"}
{"head": "Artesunate", "relation": "inhibits", "tail": "growth in cisplatin-sensitive bladder cancer cells"}
{"head": "Artesunate", "relation": "inhibits", "tail": "growth in cisplatin-resistant bladder cancer cells"}
{"head": "Artesunate", "relation": "reduces", "tail": "tumor cell adhesion to vascular endothelium in parental bladder cancer cells"}
{"head": "Artesunate", "relation": "reduces", "tail": "tumor cell adhesion to vascular endothelium in cisplatin-resistant bladder cancer cells"}
{"head": "Artesunate", "relation": "reduces", "tail": "tumor cell adhesion to immobilized collagen in parental bladder cancer cells"}
{"head": "Artesunate", "relation": "reduces", "tail": "tumor cell adhesion to immobilized collagen in cisplatin-resistant bladder cancer cells"}
{"head": "Artesunate", "relation": "suppresses", "tail": "tumor cell motility in bladder cancer cells"}
{"head": "Artesunate", "relation": "diminishes", "tail": "integrin expression in bladder cancer cells"}
{"head": "Functional blocking of integrins altered by Artesunate", "relation": "reduces", "tail": "cell adhesion in bladder cancer cells"}
{"head": "Functional blocking of integrins altered by Artesunate", "relation": "reduces", "tail": "invasion of bladder cancer cells"}
{"head": "Systemic lupus erythematosus", "relation": "increases", "tail": "radiosensitivity"}
{"head": "Chromosomal aberrations", "relation": "are biomarkers of", "tail": "radiosensitivity"}
{"head": "SLE patients", "relation": "have higher background rates of", "tail": "chromosomal aberrations than healthy individuals"}
{"head": "SLE patients", "relation": "have lower rates of", "tail": "chromosomal aberrations than cancer patients"}
{"head": "Non-oncologic SLE patients", "relation": "show similar rates of", "tail": "chromosomal aberrations as healthy individuals"}
{"head": "Patients with SLE and cancer", "relation": "have higher chromosome aberration rates than", "tail": "healthy individuals"}
{"head": "Patients with SLE and cancer", "relation": "have higher chromosome aberration rates than", "tail": "patients with isolated cancer"}
{"head": "Patients with SLE and cancer", "relation": "have higher chromosome aberration rates than", "tail": "patients with isolated SLE"}
{"head": "45% of patients in oncologic SLE cohort", "relation": "show", "tail": "increased radiosensitivity"}
{"head": "Anti-Ro-52 autoantibodies", "relation": "have weak association with", "tail": "radiosensitivity"}
{"head": "Radiation dose reduction", "relation": "was recommended in", "tail": "11 oncological SLE patients"}
{"head": "Radiation dose reduction", "relation": "was achieved in", "tail": "5 oncological SLE patients"}
{"head": "Radiation dose reduction", "relation": "reduced dose by", "tail": "up to 21% per fraction"}
{"head": "Inflammatory bowel disease", "relation": "comprises", "tail": "ulcerative colitis"}
{"head": "Inflammatory bowel disease", "relation": "comprises", "tail": "Crohn's disease"}
{"head": "Inflammatory bowel disease", "relation": "is marked by", "tail": "persistent intestinal inflammation"}
{"head": "Disease onset", "relation": "involves", "tail": "genetic predisposition"}
{"head": "Disease onset", "relation": "involves", "tail": "environmental factors"}
{"head": "Genetic predisposition and environmental factors", "relation": "disrupt", "tail": "intestinal immune homeostasis"}
{"head": "Intestinal microbiome and immune response", "relation": "play pivotal roles in", "tail": "disease progression"}
{"head": "Advances in molecular therapies and early interventions", "relation": "have reduced", "tail": "surgery rates"}
{"head": "Colorectal cancer", "relation": "remains", "tail": "significant concern"}
{"head": "Colorectal cancer", "relation": "is driven by", "tail": "chronic inflammation"}
{"head": "Risk of UC-associated neoplasia", "relation": "increases with", "tail": "disease duration"}
{"head": "Crohn's disease patients", "relation": "face elevated risks of", "tail": "small intestine cancer"}
{"head": "Crohn's disease patients", "relation": "face elevated risks of", "tail": "anal fistula cancer"}
{"head": "Crohn's disease patients", "relation": "face elevated risks of", "tail": "anal canal cancer"}
{"head": "Endoscopic surveillance", "relation": "is advised for", "tail": "UC-associated neoplasia"}
{"head": "UC-associated neoplasia morphology", "relation": "complicates", "tail": "detection"}
{"head": "UC-associated neoplasia morphology", "relation": "differs pathologically from", "tail": "sporadic colorectal cancer"}
{"head": "UC-associated neoplasia", "relation": "is frequently surrounded by", "tail": "dysplasia"}
{"head": "p53 mutations", "relation": "are evident at", "tail": "dysplasia stage"}
{"head": "IBD-associated gastrointestinal cancers", "relation": "exemplify", "tail": "inflammation-driven carcinogenesis"}
{"head": "IBD-associated gastrointestinal cancers", "relation": "have distinct molecular mechanisms from", "tail": "adenoma-carcinoma sequence"}
{"head": "Chemotherapies", "relation": "cause", "tail": "side effects"}
{"head": "Chemotherapies", "relation": "cause", "tail": "adverse health implications"}
{"head": "Cardiac and microvascular defects", "relation": "pose", "tail": "greatest health risk"}
{"head": "Cardiac and microvascular defects", "relation": "are", "tail": "leading cause of death amongst cancer survivors who do not succumb to relapse"}
{"head": "Cardiovascular risk of morbidity", "relation": "outweighs", "tail": "risk of recurrence in many low-grade cancers"}
{"head": "Polyphenols", "relation": "are", "tail": "naturally occurring metabolites"}
{"head": "Polyphenols", "relation": "have", "tail": "vasoprotective effects"}
{"head": "Polyphenols", "relation": "possess", "tail": "antioxidant activities"}
{"head": "Polyphenols", "relation": "possess", "tail": "anti-inflammatory activities"}
{"head": "Polyphenols", "relation": "modulate", "tail": "vascular signalling pathways"}
{"head": "Polyphenols", "relation": "modulate", "tail": "gene expression"}
{"head": "Polyphenols", "relation": "counteract", "tail": "vascular toxicity induced by chemotherapy"}
{"head": "Cancer risk", "relation": "increases in", "tail": "dysmetabolic obese or overweight people with overt type 2 diabetes"}
{"head": "Cancer risk", "relation": "increases in", "tail": "individuals with intermediate hyperglycemia (pre-diabetes)"}
{"head": "Cancer risk", "relation": "increases by", "tail": "25 to 250%"}
{"head": "Cancer risk", "relation": "is especially pronounced for", "tail": "pancreatic cancer"}
{"head": "Cancer risk", "relation": "is especially pronounced for", "tail": "hepatocellular cancer"}
{"head": "Cancer risk", "relation": "is especially pronounced for", "tail": "obesity-related cancers"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "colorectal cancer"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "kidney cancer"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "bladder cancer in men"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "endometrial cancer in women"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "breast cancer in women"}
{"head": "Cancer", "relation": "may be present before or upon diagnosis of", "tail": "diabetes"}
{"head": "Insulin resistance", "relation": "is a common pathogenetic background for developing", "tail": "diabetes"}
{"head": "Insulin resistance", "relation": "is a common pathogenetic background for developing", "tail": "cardiorenal disease"}
{"head": "Insulin resistance", "relation": "is a common pathogenetic background for developing", "tail": "cancer"}
{"head": "Hyperinsulinemia", "relation": "is a potential carcinogenic priming event for", "tail": "cancer"}
{"head": "Ectopic visceral, hepatic, pancreatic, or renal fat accumulation", "relation": "fuels", "tail": "inflammation and lipo-oncogenic signals"}
{"head": "Inflammation and lipo-oncogenic signals", "relation": "cause", "tail": "mitochondrial oxidative stress and deregulation"}
{"head": "Hyperinsulinemia", "relation": "may foster", "tail": "mitogenic MAP kinase-related signaling"}
{"head": "Mitogenic MAP kinase-related signaling", "relation": "can occur via", "tail": "IGF1 receptors"}
{"head": "Increased free IGF1 levels in obesity", "relation": "cause", "tail": "mitogenic MAP kinase-related signaling via IGF1 receptors"}
{"head": "Weight reduction of 10% or more in obese people with diabetes or pre-diabetes", "relation": "is associated with", "tail": "significantly lower incidence of diabesity-associated cancers"}
{"head": "Intensive lifestyle intervention", "relation": "causes", "tail": "weight reduction of 10% or more in obese people with diabetes or pre-diabetes"}
{"head": "Bariatric (metabolic) surgery", "relation": "causes", "tail": "weight reduction of 10% or more in obese people with diabetes or pre-diabetes"}
{"head": "Treatment with GLP-1 receptor agonists", "relation": "causes", "tail": "weight reduction of 10% or more in obese people with diabetes or pre-diabetes"}
{"head": "Treatment with metformin", "relation": "causes", "tail": "weight reduction of 10% or more in obese people with diabetes or pre-diabetes"}
{"head": "Cardio-Renal-Metabolic-Cancer Syndrome approach", "relation": "includes", "tail": "looking for cancer at the time of diabetes diagnosis"}
{"head": "Cardio-Renal-Metabolic-Cancer Syndrome approach", "relation": "includes", "tail": "proactively screening for undiagnosed dysglycemia"}
{"head": "Glioblastoma", "relation": "is", "tail": "primary brain tumor"}
{"head": "Glioblastoma", "relation": "has property", "tail": "rapid growth"}
{"head": "Glioblastoma", "relation": "has property", "tail": "extensive infiltration"}
{"head": "Glioblastoma", "relation": "has property", "tail": "resistance to standard therapies"}
{"head": "Glioblastoma stem cells", "relation": "possess", "tail": "self-renewal capacity"}
{"head": "Glioblastoma stem cells", "relation": "possess", "tail": "multipotency"}
{"head": "Glioblastoma stem cells", "relation": "have ability", "tail": "regenerate tumor heterogeneity"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "glioblastoma progression"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "resistance to chemotherapy"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "resistance to radiotherapy"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "tumor recurrence"}
{"head": "Glioblastoma stem cells", "relation": "exhibit", "tail": "distinct molecular signatures"}
{"head": "Glioblastoma stem cells", "relation": "exhibit", "tail": "enhanced DNA repair"}
{"head": "Glioblastoma stem cells", "relation": "exhibit", "tail": "metabolic adaptations"}
{"head": "Metabolic adaptations", "relation": "protect", "tail": "glioblastoma stem cells against conventional treatments"}
{"head": "Glioblastoma stem cells", "relation": "reside within", "tail": "specialized niches"}
{"head": "Specialized niches", "relation": "include", "tail": "perivascular microenvironments"}
{"head": "Specialized niches", "relation": "include", "tail": "hypoxic microenvironments"}
{"head": "Specialized niches", "relation": "sustain", "tail": "stemness"}
{"head": "Specialized niches", "relation": "promote", "tail": "immunosuppression"}
{"head": "Specialized niches", "relation": "facilitate", "tail": "angiogenesis"}
{"head": "Notch signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "Hedgehog signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "STAT3-PARN signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "TFPI2", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "HML-2", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "Notch signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "Hedgehog signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "STAT3-PARN signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "TFPI2", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "HML-2", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "Notch signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "Hedgehog signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "STAT3-PARN signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "TFPI2", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "HML-2", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "Emerging therapeutic strategies", "relation": "target", "tail": "glioblastoma stem cells"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "surface markers"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "immunotherapeutics"}
{"head": "Immunotherapeutics", "relation": "include", "tail": "CAR T cells"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "metabolic vulnerabilities"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "combination regimens"}
{"head": "Patient-derived organoids", "relation": "enable", "tail": "accurate representation of tumor ecosystem"}
{"head": "Single-cell omics", "relation": "enable", "tail": "accurate representation of tumor ecosystem"}
{"head": "3D co-culture models", "relation": "enable", "tail": "accurate representation of tumor ecosystem"}
{"head": "Improved understanding of glioblastoma stem cell-specific targets and tumor microenvironment", "relation": "promises", "tail": "more effective interventions"}
{"head": "More effective interventions", "relation": "pave way to", "tail": "better clinical outcomes for glioblastoma patients"}
{"head": "Glioblastoma in patients affected by NF1 germline mutation", "relation": "represents", "tail": "a unique heterogeneous clinical and pathological entity"}
{"head": "NF1-associated GBM", "relation": "has better response to", "tail": "standard therapy"}
{"head": "NF1-associated GBM", "relation": "has better overall survival than", "tail": "GBM in the non-NF1 population"}
{"head": "Case 1", "relation": "is", "tail": "38-year-old woman with cerebellar GBM"}
{"head": "Case 1", "relation": "underwent", "tail": "surgical asportation and the Stupp protocol many times"}
{"head": "Case 1", "relation": "has overall survival of", "tail": "117 months"}
{"head": "Case 2", "relation": "is", "tail": "47-year-old woman with GBM in the eloquent area of the right frontal lobe"}
{"head": "Case 2", "relation": "underwent", "tail": "surgical asportation and the Stupp protocol"}
{"head": "Case 2", "relation": "has overall survival of", "tail": "25 months"}
{"head": "NF1-associated GBM patients", "relation": "could be considered", "tail": "long-term survivors"}
{"head": "Androgen receptor pathway inhibitors (ARPI)", "relation": "treat", "tail": "advanced prostate cancer (PCa)"}
{"head": "Patients with metastatic castration-sensitive PCa (mCSPC)", "relation": "progress to", "tail": "metastatic castration-resistant PCa (mCRPC)"}
{"head": "Patients with nonmetastatic castration-sensitive PCa (nmCSPC)", "relation": "progress to", "tail": "metastatic castration-resistant PCa (mCRPC)"}
{"head": "Early use of ARPIs", "relation": "is most cost-effective in", "tail": "advanced prostate cancer (PCa) at CAD 100K per QALY threshold"}
{"head": "Early use of ARPIs", "relation": "is most cost-effective in", "tail": "mCSPC-starting patients at CAD 50K per QALY threshold"}
{"head": "Early use of ARPIs", "relation": "is not most cost-effective in", "tail": "nmCSPC-starting patients at CAD 50K per QALY threshold"}
{"head": "Abiraterone", "relation": "is most cost-effective ARPI at", "tail": "current Canadian prices"}
{"head": "Abiraterone", "relation": "has", "tail": "lower price level"}
{"head": "Two million people", "relation": "are diagnosed with", "tail": "lung cancer each year"}
{"head": "85% of lung cancer patients", "relation": "have", "tail": "non-small cell lung cancer (NSCLC)"}
{"head": "Targeted therapies", "relation": "treat", "tail": "advanced/metastatic NSCLC"}
{"head": "Study population", "relation": "included", "tail": "4841 Stage IB-IIIA NSCLC patients"}
{"head": "Mean age", "relation": "was", "tail": "70.9 \u00b1 8.6 years"}
{"head": "69.9% of patients", "relation": "received", "tail": "definitive treatment"}
{"head": "Definitive treatment", "relation": "includes", "tail": "surgery"}
{"head": "Definitive treatment", "relation": "includes", "tail": "definitive radiation"}
{"head": "Definitive treatment", "relation": "includes", "tail": "definitive chemoradiation"}
{"head": "30.1% of patients", "relation": "did not receive", "tail": "definitive treatment"}
{"head": "52.6% of surgery patients", "relation": "received", "tail": "perioperative systemic therapy"}
{"head": "52.2% of radiation patients", "relation": "received", "tail": "perioperative systemic therapy"}
{"head": "75.5% of chemoradiation patients", "relation": "received", "tail": "perioperative systemic therapy"}
{"head": "Neoadjuvant use", "relation": "was limited in", "tail": "surgery patients"}
{"head": "Neoadjuvant use", "relation": "was limited in", "tail": "radiation patients"}
{"head": "Neoadjuvant use", "relation": "was limited in", "tail": "chemoradiation patients"}
{"head": "54.6% of patients", "relation": "received", "tail": "adjuvant therapy"}
{"head": "Immune checkpoint inhibitors", "relation": "were the most common adjuvant therapy for", "tail": "definitive radiation patients"}
{"head": "Immune checkpoint inhibitors", "relation": "were the most common adjuvant therapy for", "tail": "chemoradiation patients"}
{"head": "Surgical patients", "relation": "predominantly received", "tail": "platinum-doublet therapy"}
{"head": "Surgical patient outcomes", "relation": "were similar across", "tail": "all groups"}
{"head": "Definitive chemoradiation or radiation patients without systemic therapy", "relation": "had", "tail": "lower survival rates"}
{"head": "Bispecific T-cell engager (TCE)", "relation": "treats", "tail": "relapsed or refractory multiple myeloma"}
{"head": "T-cell engagers", "relation": "associated with", "tail": "sustained efficacy in patients with heavily treated myeloma"}
{"head": "T-cell engagers", "relation": "associated with", "tail": "progression-free survival benefits in patients with heavily treated myeloma"}
{"head": "Bispecific T-cell engager (TCE) therapy", "relation": "complicated by", "tail": "cytokine release syndrome (CRS)"}
{"head": "Bispecific T-cell engager (TCE) therapy", "relation": "complicated by", "tail": "immune effector cell-associated neurotoxicity syndrome (ICANS)"}
{"head": "Bispecific T-cell engager (TCE) therapy", "relation": "complicated by", "tail": "infections"}
{"head": "annual per-beneficiary spending", "relation": "increased by", "tail": "32.8%"}
{"head": "annual per-beneficiary spending", "relation": "increased from", "tail": "CAD 4422 in 2017/18 to CAD 6579 in 2020/21"}
{"head": "small-molecule targeted therapy and immunotherapy drug classes", "relation": "accounted for", "tail": "three-quarters of total public payer spending on take-home cancer medications in 2020/21"}
{"head": "small-molecule targeted therapy and immunotherapy drug classes", "relation": "dispensed to", "tail": "less than 8% of beneficiaries"}
{"head": "SARS-CoV-2 emergency declaration", "relation": "caused", "tail": "short-term decline in per-beneficiary spending between March and June 2020"}
{"head": "per-beneficiary spending", "relation": "declined by", "tail": "CAD 179 per month between March and June 2020"}
{"head": "number of beneficiaries receiving low-cost take-home cancer medications within the cytotoxic chemotherapy and hormonal therapy drug class", "relation": "increased by", "tail": "5582 per month between March and June 2020"}
{"head": "increase in number of beneficiaries receiving low-cost take-home cancer medications within the cytotoxic chemotherapy and hormonal therapy drug class", "relation": "occurred without", "tail": "corresponding rise in public payer spending"}
{"head": "Crizotinib", "relation": "inhibits", "tail": "viability of bladder cancer cells"}
{"head": "Crizotinib", "relation": "inhibits", "tail": "migration of bladder cancer cells"}
{"head": "Crizotinib", "relation": "inhibits", "tail": "invasion of bladder cancer cells"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "phosphorylated c-Met"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "phosphorylated Akt"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "c-Met/PI3K/Akt pathway"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "cell proliferation in T24 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "cell proliferation in T24R2 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "migration in T24 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "migration in T24R2 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "invasion in T24 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "invasion in T24R2 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "increases expression of", "tail": "apoptosis-related genes"}
{"head": "Crizotinib", "relation": "reduces expression of", "tail": "E-cadherin"}
{"head": "Crizotinib", "relation": "enhances expression of", "tail": "vimentin"}
{"head": "c-Met", "relation": "induces", "tail": "PI3K/Akt pathway"}
{"head": "Physical activity interventions", "relation": "are safe and feasible for", "tail": "children and adolescents with cancer undergoing treatment"}
{"head": "Physical activity interventions", "relation": "improve", "tail": "physical fitness in children and adolescents with cancer undergoing treatment"}
{"head": "Physical activity interventions", "relation": "improve", "tail": "strength in children and adolescents with cancer undergoing treatment"}
{"head": "Physical activity interventions", "relation": "improve", "tail": "quality of life in children and adolescents with cancer undergoing treatment"}
{"head": "Physical activity interventions", "relation": "reduce", "tail": "fatigue in children and adolescents with cancer undergoing treatment"}
{"head": "Physical activity", "relation": "is disrupted by", "tail": "cancer diagnosis and treatment in children and adolescents"}
{"head": "Physical activity interventions", "relation": "are adjunct to", "tail": "cancer treatment in children and adolescents"}
{"head": "Late radiation-associated dysphagia", "relation": "occurs in", "tail": "head and neck cancer survivorship"}
{"head": "Fiberoptic Endoscopic Evaluation of Swallowing", "relation": "is preferred diagnostic approach for", "tail": "oropharyngeal dysphagia assessment in head and neck cancer population"}
{"head": "Swallowing safety", "relation": "is quantified using", "tail": "Penetration-Aspiration Scale"}
{"head": "Swallowing efficacy", "relation": "is measured via", "tail": "Yale Pharyngeal Residue Severity Rating Scale"}
{"head": "Six distinct dysphagia phenotypes", "relation": "are characterized in", "tail": "head and neck cancer patients with late radiation-associated dysphagia"}
{"head": "Propulsion deficit", "relation": "is predominant phenotype in", "tail": "head and neck cancer patients with late radiation-associated dysphagia"}
{"head": "Propulsion deficit", "relation": "occurs in", "tail": "92% of patients"}
{"head": "Delayed pharyngeal phase", "relation": "occurs in", "tail": "37.5% of patients"}
{"head": "Protective deficit", "relation": "occurs in", "tail": "25% of patients"}
{"head": "Multiple phenotypes", "relation": "occur in", "tail": "46% of patients"}
{"head": "Unsafe swallowing", "relation": "occurs most frequently with", "tail": "liquid consistency"}
{"head": "Unsafe swallowing with liquid consistency", "relation": "occurs in", "tail": "62.5% of patients"}
{"head": "Residue with semisolid consistency", "relation": "is most prevalent in", "tail": "valleculae (82.6%)"}
{"head": "Residue with semisolid consistency", "relation": "is most prevalent in", "tail": "pyriform sinuses (52.2%)"}
{"head": "Residue with solid consistency", "relation": "is most prevalent in", "tail": "valleculae (92.3%)"}
{"head": "Residue with solid consistency", "relation": "is most prevalent in", "tail": "pyriform sinuses (53.8%)"}
{"head": "Penetration-aspiration scores", "relation": "correlate with", "tail": "pharyngeal residue scores across consistencies"}
{"head": "FEES examination", "relation": "reveals distinct phenotypes in", "tail": "late radiation-associated dysphagia"}
{"head": "Propulsion deficit", "relation": "is predominant phenotype revealed by", "tail": "FEES examination"}
{"head": "Safety parameters", "relation": "are interdependent with", "tail": "efficacy parameters in late radiation-associated dysphagia"}
{"head": "Salivary gland carcinomas", "relation": "account for", "tail": "3-6% of all head and neck cancers"}
{"head": "Surgical resection", "relation": "remains standard for", "tail": "locoregional control of salivary gland carcinomas"}
{"head": "Radiotherapy", "relation": "remains standard for", "tail": "locoregional control of salivary gland carcinomas"}
{"head": "Systemic treatment", "relation": "is indicated for", "tail": "recurrent or metastatic salivary gland carcinomas"}
{"head": "Molecular profiling", "relation": "has identified", "tail": "actionable targets in salivary gland carcinomas"}
{"head": "Actionable targets", "relation": "include", "tail": "NTRK gene fusions"}
{"head": "Actionable targets", "relation": "include", "tail": "HER2"}
{"head": "Actionable targets", "relation": "include", "tail": "immune checkpoint regulators"}
{"head": "Actionable targets", "relation": "include", "tail": "androgen receptors"}
{"head": "Actionable targets", "relation": "include", "tail": "RET receptors"}
{"head": "Targeted therapies", "relation": "include", "tail": "TRK inhibitors"}
{"head": "Targeted therapies", "relation": "include", "tail": "HER2-directed agents"}
{"head": "Targeted therapies", "relation": "include", "tail": "androgen receptor modulators"}
{"head": "Targeted therapies", "relation": "include", "tail": "combinations of immunotherapy and chemotherapy"}
{"head": "Breast reconstruction after mastectomy", "relation": "improves", "tail": "quality of life for many patients with breast cancer"}
{"head": "Nipple-sparing mastectomy", "relation": "is oncologically safe", "tail": "provided there is no clinical, radiological, or pathological indication of nipple-areolar complex involvement"}
{"head": "Surgical factors including incision location", "relation": "may affect", "tail": "rates of complications such as necrosis"}
{"head": "Immediate reconstruction", "relation": "may result in", "tail": "better short to medium-term quality of life"}
{"head": "Immediate and delayed reconstruction", "relation": "have", "tail": "similar long-term outcomes"}
{"head": "Studies", "relation": "delayed reconstruction after radiotherapy by", "tail": "at least 3 months and more commonly at least 6 months"}
{"head": "Radiation after immediate reconstruction", "relation": "is", "tail": "a reasonable option"}
{"head": "Surgical complications", "relation": "are similar between", "tail": "prepectoral and dual-plane or subpectoral reconstruction"}
{"head": "Prepectoral placement", "relation": "may give", "tail": "better quality of life due to lower rates of long-term complications such as pain and animation deformity"}
{"head": "Autologous fat grafting", "relation": "was found to be", "tail": "oncologically safe"}
{"head": "Use of autologous fat grafting", "relation": "may improve", "tail": "quality of life and aesthetic results"}
{"head": "Combination of immunotherapy and radiotherapy", "relation": "has", "tail": "synergistic potential"}
{"head": "Immune checkpoint inhibitors", "relation": "are administered in combination with", "tail": "radiotherapy"}
{"head": "CTLA-4 inhibitors", "relation": "have been assessed in", "tail": "clinical and preclinical studies"}
{"head": "PD-L1 inhibitors", "relation": "have been assessed in", "tail": "clinical and preclinical studies"}
{"head": "PD-1 inhibitors", "relation": "have been assessed in", "tail": "clinical and preclinical studies"}
{"head": "Radiotherapy", "relation": "activates", "tail": "immunomodulatory mechanisms"}
{"head": "Immunomodulatory mechanisms", "relation": "produce", "tail": "in situ vaccination effect"}
{"head": "Immunomodulatory mechanisms", "relation": "produce", "tail": "abscopal distant response of lesions outside irradiation field"}
{"head": "TIGIT", "relation": "is a", "tail": "new therapeutic target"}
{"head": "LAG-3", "relation": "is a", "tail": "new therapeutic target"}
{"head": "TIM-3", "relation": "is a", "tail": "new therapeutic target"}
{"head": "New therapeutic targets TIGIT, LAG-3, TIM-3", "relation": "are associated with", "tail": "traditional ICIs and radiotherapy"}
{"head": "Dynamic evaluation of T lymphocyte expression", "relation": "could have", "tail": "biomarker value in assessing response to combination therapy"}
{"head": "Combination therapy with traditional and new ICIs and irradiation", "relation": "is being explored in", "tail": "clinical trials in various tumor pathologies"}
{"head": "patients with metastatic non-small-cell lung cancer", "relation": "had", "tail": "5-year overall survival rate of up to 10%"}
{"head": "pembrolizumab", "relation": "was approved for", "tail": "patients with metastatic NSCLC and PD-L1 \u2265 50%"}
{"head": "pembrolizumab", "relation": "is used in", "tail": "first-line setting"}
{"head": "patients with locally advanced and metastatic NSCLC", "relation": "had", "tail": "PD-L1 \u2265 50%"}
{"head": "progression-free survival", "relation": "was", "tail": "9 months"}
{"head": "overall survival", "relation": "was", "tail": "14 months"}
{"head": "five-year overall survival rate", "relation": "was", "tail": "20%"}
{"head": "six-year overall survival rate", "relation": "was", "tail": "17.2%"}
{"head": "immunotherapy", "relation": "is a revolution in treatment of", "tail": "NSCLC"}
{"head": "Medical care structures", "relation": "differ between", "tail": "urban and rural areas"}
{"head": "Brandenburg-Berlin Clinical-Epidemiological Cancer Registry", "relation": "documents", "tail": "5805 cases of gastric carcinoma"}
{"head": "Preoperative therapy for cT3/cT4N0 tumors", "relation": "is more common in", "tail": "Berlin"}
{"head": "Preoperative therapy for cT3/cT4N0 tumors", "relation": "is more common in", "tail": "Berlin than in Brandenburg"}
{"head": "Perioperative therapy", "relation": "is associated with", "tail": "survival benefit for stages T3-/T4N+"}
{"head": "Perioperative therapy", "relation": "is not associated with", "tail": "survival benefit for stages T1N+ or T2"}
{"head": "Survival data", "relation": "show", "tail": "no significant differences between Berlin and Brandenburg"}
{"head": "Gastric cancer treatment outcomes", "relation": "are comparable between", "tail": "rural region of Brandenburg and urban center of Berlin"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "white blood cell count"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "neutrophil count"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "platelet count"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "C-reactive protein levels"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "preoperative carcinoembryonic antigen levels"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "lymphovascular invasion"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "perineural invasion"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "tumor budding"}
{"head": "Age", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "ASA score", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "C-reactive protein", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Preoperative carcinoembryonic antigen", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Preoperative carbohydrate antigen 19-9", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Lymphovascular invasion", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Perineural invasion", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Tumor budding", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Age", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "ASA score", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "C-reactive protein", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Preoperative carcinoembryonic antigen", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Preoperative carbohydrate antigen 19-9", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Lymphovascular invasion", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Perineural invasion", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Tumor budding", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "T stage", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Tumor size", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Pancreatic cancer", "relation": "is", "tail": "one of the deadliest types of cancer globally"}
{"head": "Early detection", "relation": "helps avert", "tail": "adverse outcomes"}
{"head": "Screening", "relation": "is recommended for", "tail": "individuals at high risk"}
{"head": "High risk individuals", "relation": "include", "tail": "those with familial and/or genetic predispositions"}
{"head": "One-time screening for pancreatic cancer among high-risk individuals", "relation": "is", "tail": "cost-effective compared with no screening"}
{"head": "Annual screening for pancreatic cancer among high-risk individuals", "relation": "is", "tail": "cost-effective"}
{"head": "High risk", "relation": "is defined as", "tail": ">5% lifetime risk of pancreatic cancer"}
{"head": "High risk individuals", "relation": "include", "tail": "individuals with familial pancreatic cancer"}
{"head": "High risk individuals", "relation": "include", "tail": "individuals with genetic susceptibility syndromes"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "Peutz-Jeghers Syndrome"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "hereditary pancreatitis"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "hereditary non-polypoid colorectal cancer syndrome"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "familial adenomatous polyposis"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "BRCA2 mutations"}
{"head": "Individuals with new-onset diabetes", "relation": "are considered", "tail": "high-risk"}
{"head": "Screening using mainly endoscopic ultrasound", "relation": "is cost-effective among", "tail": "familial pancreatic cancer individuals"}
{"head": "Screening using mainly endoscopic ultrasound", "relation": "is cost-effective among", "tail": "individuals with genetic syndromes"}
{"head": "Risk-based screening", "relation": "is cost-effective among", "tail": "patients with new-onset diabetes"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "epidemiological factors"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "cost"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "diagnostic performance of screening tools"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "overall design of studies"}
{"head": "Bone metastases", "relation": "are a major concern in", "tail": "cancer management"}
{"head": "Bone metastases", "relation": "contribute to", "tail": "morbidity and mortality"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "breast cancer"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "prostate cancer"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "lung cancer"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "kidney cancer"}
{"head": "Metastatic lesions", "relation": "affect", "tail": "approximately 25% of cancer patients"}
{"head": "Metastatic lesions", "relation": "lead to", "tail": "pain"}
{"head": "Metastatic lesions", "relation": "lead to", "tail": "fractures"}
{"head": "Metastatic lesions", "relation": "lead to", "tail": "neurological deficits"}
{"head": "Oligometastases", "relation": "are defined by", "tail": "limited metastatic spread (1-5 lesions)"}
{"head": "Oligometastases", "relation": "offer", "tail": "a potential window for curative treatment"}
{"head": "Curative treatment", "relation": "includes", "tail": "stereotactic ablative radiotherapy"}
{"head": "Curative treatment", "relation": "includes", "tail": "resection surgery"}
{"head": "Tumor boards", "relation": "integrate", "tail": "systemic therapies with local interventions"}
{"head": "Tumor boards", "relation": "are crucial to optimize", "tail": "treatment"}
{"head": "Folliculin (FLCN)", "relation": "is a tumor suppressor gene in", "tail": "thyroid tumors"}
{"head": "FLCN", "relation": "has pathogenic alterations in", "tail": "thyroid tumors"}
{"head": "Patient 1", "relation": "has germline FLCN mutation and history of", "tail": "Birt-Hogg-Dub\u00e9 (BHD) syndrome"}
{"head": "Patient 1", "relation": "presented with", "tail": "oncocytic adenoma"}
{"head": "Patient 1", "relation": "has biallelic FLCN inactivation", "tail": "thyroid tumor"}
{"head": "Patient 1", "relation": "remained disease-free after", "tail": "thyroidectomy"}
{"head": "Patient 2", "relation": "harbored somatic FLCN mutation in", "tail": "oncocytic poorly differentiated thyroid carcinoma"}
{"head": "Oncocytic poorly differentiated thyroid carcinoma", "relation": "exhibited", "tail": "extensive angioinvasion"}
{"head": "Oncocytic poorly differentiated thyroid carcinoma", "relation": "exhibited", "tail": "high proliferative activity"}
{"head": "Oncocytic poorly differentiated thyroid carcinoma", "relation": "harbored concurrent mutations in", "tail": "TP53 and RB1"}
{"head": "Oncocytic poorly differentiated thyroid carcinoma", "relation": "progressed with", "tail": "metastatic disease despite multimodal treatment"}
{"head": "Thyroid carcinomas", "relation": "show FLCN alterations in", "tail": "1.1% of cases"}
{"head": "Pathogenic FLCN mutations", "relation": "are associated with", "tail": "oncocytic morphology"}
{"head": "Homozygous FLCN deletions", "relation": "occur more frequently in", "tail": "genomically unstable tumors including anaplastic thyroid carcinoma"}
{"head": "FLCN mutations", "relation": "may act as early oncogenic drivers in", "tail": "oncocytic thyroid neoplasms"}
{"head": "FLCN deletions", "relation": "represent secondary events in", "tail": "aggressive tumor evolution"}
{"head": "Lack of FLCN coverage in standard thyroid molecular panels", "relation": "underestimates", "tail": "clinical relevance of FLCN"}
{"head": "Including FLCN in genetic testing", "relation": "could improve", "tail": "tumor detection and characterization"}
{"head": "BHD patients", "relation": "may benefit from", "tail": "routine thyroid screening"}
{"head": "Computed tomography-based radiomic nomogram", "relation": "predicts", "tail": "occult pleural metastasis in lung cancer"}
{"head": "carcinoembryonic antigen", "relation": "is a predictor of", "tail": "occult pleural metastasis"}
{"head": "neutrophil-to-lymphocyte ratio", "relation": "is a predictor of", "tail": "occult pleural metastasis"}
{"head": "clinical T stage", "relation": "is a predictor of", "tail": "occult pleural metastasis"}
{"head": "tumor-pleural relationship", "relation": "is a predictor of", "tail": "occult pleural metastasis"}
{"head": "clinical model", "relation": "achieves", "tail": "area under the curve of 0.761"}
{"head": "integrated model combining radiomic scores, carcinoembryonic antigen, and neutrophil-to-lymphocyte ratio", "relation": "achieves", "tail": "area under the curve of 0.890 in training cohort"}
{"head": "integrated model combining radiomic scores, carcinoembryonic antigen, and neutrophil-to-lymphocyte ratio", "relation": "achieves", "tail": "area under the curve of 0.855 in validation cohort"}
{"head": "radiomic features derived from CT scans", "relation": "identify", "tail": "patients with lung cancer at risk of occult pleural metastasis"}
{"head": "nomogram integrating carcinoembryonic antigen, neutrophil-to-lymphocyte ratio, and radiomic tumor area scores", "relation": "enhances", "tail": "precision of preoperative occult pleural metastasis prediction"}
{"head": "Childhood Cancer Registry of Campania", "relation": "is", "tail": "Italian largest population-based registry specializing in children 0-19 years old"}
{"head": "Childhood Cancer Registry of Campania", "relation": "has target population", "tail": "approximately 1.1 million inhabitants"}
{"head": "study cohort", "relation": "included", "tail": "219 adolescents with newly diagnosed central nervous system tumors"}
{"head": "annual average incidence rate", "relation": "is", "tail": "48.9 cases per million/year"}
{"head": "5-year observed survival rate after diagnosis of CNS tumor", "relation": "is", "tail": "84.8%"}
{"head": "most common tumor site", "relation": "is", "tail": "pituitary gland and craniopharyngeal duct"}
{"head": "pituitary gland and craniopharyngeal duct", "relation": "represents", "tail": "22.4% of all tumors"}
{"head": "most frequently occurring malignant primary CNS tumor", "relation": "is", "tail": "germinoma"}
{"head": "most common non-malignant tumor", "relation": "is", "tail": "pituitary adenoma"}
{"head": "most patients", "relation": "were referred to", "tail": "adult services"}
{"head": "nearly half of patients", "relation": "migrated outside the region to receive", "tail": "cancer care"}
{"head": "care of adolescents with CNS tumors", "relation": "is fragmented across", "tail": "institutions"}
{"head": "significant variations in practice", "relation": "exist between", "tail": "adult and pediatric practitioners"}
{"head": "Head-and-neck cancer patients with dysphagia", "relation": "have", "tail": "lower health-related quality of life"}
{"head": "Head-and-neck cancer patients with dysphagia", "relation": "have", "tail": "lower physical functioning"}
{"head": "Head-and-neck cancer patients with dysphagia", "relation": "have", "tail": "lower social functioning"}
{"head": "Head-and-neck cancer patients with dysphagia", "relation": "have", "tail": "lower emotional functioning"}
{"head": "Head-and-neck cancer patients with dysphagia", "relation": "report", "tail": "more severe general symptoms including fatigue, pain, sleep disturbances, nausea/vomiting, diarrhea, and financial worries"}
{"head": "Control-2 patients", "relation": "have", "tail": "worse emotional functioning than Control-1 patients"}
{"head": "Control-2 patients", "relation": "have", "tail": "worse social functioning than Control-1 patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "social functioning in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "emotional functioning in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "role functioning in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "fatigue in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "nausea/vomiting in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "insomnia in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "appetite loss in head-and-neck cancer patients"}
{"head": "Improvements in health-related quality of life", "relation": "are most noticeable in", "tail": "dysphagia patients"}
{"head": "Psychooncological counseling", "relation": "reduces", "tail": "depression in dysphagia patients"}
{"head": "Psychooncological counseling", "relation": "reduces", "tail": "depression in Control-2 patients"}
{"head": "Depression levels after psychooncological counseling in dysphagia and Control-2 patients", "relation": "are comparable to", "tail": "levels in the general population"}
{"head": "Pseudomyogenic haemangioendotheliomas", "relation": "occur mostly in", "tail": "soft tissue"}
{"head": "Malignant cases of pseudomyogenic haemangioendotheliomas", "relation": "are", "tail": "uncommon"}
{"head": "28-year-old male patient", "relation": "was initially suspected of having", "tail": "fibroblastic osteosarcoma of the right femur"}
{"head": "28-year-old male patient", "relation": "was diagnosed with", "tail": "primary pseudomyogenic hemangioendothelioma of the bone"}
{"head": "Primary pseudomyogenic hemangioendothelioma of the bone", "relation": "has", "tail": "synchronous metastases to other skeletal segments"}
{"head": "Molecular analysis through targeted RNA sequencing", "relation": "confirmed", "tail": "correct diagnosis of primary pseudomyogenic hemangioendothelioma"}
{"head": "Molecular analysis", "relation": "revealed", "tail": "fusion transcript ACTB::FOSB"}
{"head": "Patient", "relation": "suffered from", "tail": "multiple pathological fractures"}
{"head": "This case", "relation": "showed", "tail": "rapid skeletal progression"}
{"head": "This case", "relation": "showed", "tail": "onset of distant metastases"}
{"head": "Typical clinical course of pseudomyogenic haemangioendothelioma", "relation": "is", "tail": "indolent"}
{"head": "breast cancer", "relation": "is associated with", "tail": "non-Hodgkin lymphoma of the spleen"}
{"head": "39-year-old woman", "relation": "developed", "tail": "invasive lobular carcinoma"}
{"head": "invasive lobular carcinoma", "relation": "occurred in", "tail": "right breast"}
{"head": "invasive lobular carcinoma", "relation": "was treated with", "tail": "mastectomy"}
{"head": "invasive lobular carcinoma", "relation": "was treated with", "tail": "hormonal therapy"}
{"head": "right axillary mass", "relation": "was confirmed by", "tail": "fine-needle aspiration biopsy"}
{"head": "patient", "relation": "received", "tail": "neoadjuvant chemotherapy"}
{"head": "patient", "relation": "underwent", "tail": "axillary lymph node dissection"}
{"head": "patient", "relation": "underwent", "tail": "bilateral adnexectomy"}
{"head": "CT and PET scans", "relation": "showed", "tail": "suspicious splenic lesions"}
{"head": "suspicious splenic lesions", "relation": "are suggestive of", "tail": "metastases"}
{"head": "laparoscopic splenectomy", "relation": "was performed on", "tail": "patient"}
{"head": "histological examination", "relation": "revealed", "tail": "follicular B-cell non-Hodgkin lymphoma"}
{"head": "patient", "relation": "is on", "tail": "biannual follow-up"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "is defined as", "tail": "a type of non-mucinous tumor"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has tumor size", "tail": "\u2264 3 cm"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "exhibits lepidic growth", "tail": "\u2265 15%"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "lacks non-predominant high-grade patterns", "tail": "\u226510% cribriform, \u22655% micropapillary, \u22655% solid"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has absence of", "tail": "angiolymphatic invasion"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has absence of", "tail": "visceral pleural invasion"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has absence of", "tail": "spread through air spaces (STAS)"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has absence of", "tail": "necrosis"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has absence of", "tail": ">1 mitosis per 2 mm2"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has tumor size", "tail": "\u2264 3 cm"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has invasive size", "tail": "\u2265 0.5 cm"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has lepidic growth", "tail": "\u2265 15%"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has absence of", "tail": "mitosis (>1 per 2 mm2)"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has absence of", "tail": "mucinous subtype"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has absence of", "tail": "angiolymphatic invasion"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has absence of", "tail": "visceral pleural invasion"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has absence of", "tail": "spread through air spaces (STAS)"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has absence of", "tail": "tumor necrosis"}
{"head": "Patients with low-malignant-potential adenocarcinoma", "relation": "have cancer-specific survival", "tail": "100% 10-year CSS"}
{"head": "Patients without low-malignant-potential adenocarcinoma", "relation": "have cancer-specific survival", "tail": "77.4% 10-year CSS"}
{"head": "Low-malignant-potential adenocarcinoma", "relation": "has better prognosis than", "tail": "other solid adenocarcinomas at IA stage"}
{"head": "Low-malignant-potential adenocarcinoma features", "relation": "have prognostic role", "tail": "low risk of recurrence"}
{"head": "Low-malignant-potential adenocarcinoma features", "relation": "have prognostic role", "tail": "good cancer-specific survival"}
{"head": "Low-malignant-potential adenocarcinoma features", "relation": "have prognostic role", "tail": "good disease-free survival"}
{"head": "Lymph node status", "relation": "is", "tail": "the most critical prognostic factor in vulvar cancer"}
{"head": "Inguinofemoral lymphadenectomy", "relation": "is associated with", "tail": "significant morbidity"}
{"head": "Sentinel lymph node biopsy", "relation": "is", "tail": "a less invasive alternative to inguinofemoral lymphadenectomy"}
{"head": "Sentinel lymph node biopsy", "relation": "has", "tail": "favorable oncologic outcomes in selected cases of vulvar cancer"}
{"head": "Sentinel lymph node biopsy", "relation": "is recommended for", "tail": "unifocal vulvar tumors less than 4 cm with stromal invasion greater than 1 mm and clinically negative nodes"}
{"head": "GROINSS-V-I and GOG-173 trials", "relation": "confirmed", "tail": "accuracy and lower morbidity of sentinel lymph node biopsy compared to lymphadenectomy"}
{"head": "Sentinel lymph node biopsy utilization", "relation": "has increased since", "tail": "its inclusion in guidelines"}
{"head": "Lymphadenectomy rates", "relation": "have declined concurrently with", "tail": "increased sentinel lymph node biopsy utilization"}
{"head": "Combined detection techniques", "relation": "are", "tail": "mandatory for sentinel lymph node biopsy"}
{"head": "Indocyanine green", "relation": "is", "tail": "an emerging option for sentinel lymph node biopsy detection"}
{"head": "Sentinel lymph node biopsy", "relation": "is", "tail": "a validated, minimally invasive staging approach in early-stage vulvar cancer"}
{"head": "Soft tissue sarcoma", "relation": "has incidence in", "tail": "adolescent and young adult population"}
{"head": "Soft tissue sarcoma tumors", "relation": "are", "tail": "aggressive"}
{"head": "Soft tissue sarcoma tumors", "relation": "require", "tail": "multimodal management"}
{"head": "Multimodal management", "relation": "includes", "tail": "surgery"}
{"head": "Multimodal management", "relation": "includes", "tail": "radiation"}
{"head": "Multimodal management", "relation": "includes", "tail": "chemotherapy"}
{"head": "Surgical and radiation-related morbidity", "relation": "are", "tail": "lasting side effects of therapy"}
{"head": "Chemotherapy toxicity", "relation": "is", "tail": "a lasting side effect of therapy"}
{"head": "Secondary effects on other organ systems", "relation": "include", "tail": "cardiac dysfunction"}
{"head": "Secondary effects on other organ systems", "relation": "include", "tail": "endocrine dysfunction"}
{"head": "Secondary effects on other organ systems", "relation": "include", "tail": "development of secondary cancers"}
{"head": "Sarcoma diagnosis", "relation": "has long-term impacts on", "tail": "fertility"}
{"head": "Sarcoma diagnosis", "relation": "has long-term impacts on", "tail": "mental health"}
{"head": "Sarcoma diagnosis", "relation": "has long-term impacts on", "tail": "relationship"}
{"head": "Sarcoma diagnosis", "relation": "has long-term impacts on", "tail": "education"}
{"head": "Sarcoma diagnosis", "relation": "has long-term impacts on", "tail": "career"}
{"head": "Azacitidine and venetoclax", "relation": "are part of", "tail": "new standard of care for elderly patients with Acute Myeloid Leukemia"}
{"head": "patients with AML at our centre", "relation": "were routinely admitted during initiation of", "tail": "Azacitidine and venetoclax for close monitoring for tumour lysis syndrome"}
{"head": "incidence of tumour lysis syndrome", "relation": "was", "tail": "25% using Cairo-Bishop diagnostic criteria"}
{"head": "tumour lysis syndrome incidence", "relation": "was", "tail": "2% using Howard diagnostic criteria"}
{"head": "patients who developed Cairo-Bishop tumour lysis syndrome", "relation": "had", "tail": "significantly higher baseline white blood count"}
{"head": "patients with white blood count less than 30 \u00d7 10^9/L", "relation": "completed", "tail": "outpatient initiation of Azacitidine and venetoclax"}
{"head": "one patient with white blood count less than 30 \u00d7 10^9/L", "relation": "developed", "tail": "mild, transient tumour lysis syndrome by Cairo-Bishop criteria but not by Howard criteria"}
{"head": "significant portion of patients", "relation": "could safely initiate", "tail": "Azacitidine and venetoclax in outpatient facility"}
{"head": "hospitalization", "relation": "impacts", "tail": "patient experience"}
{"head": "hospitalization", "relation": "is", "tail": "significant resource burden"}
{"head": "Intensity-modulated radiotherapy", "relation": "treats", "tail": "localized prostate cancer"}
{"head": "Intensity-modulated proton therapy", "relation": "treats", "tail": "localized prostate cancer"}
{"head": "Intensity-modulated radiotherapy", "relation": "causes", "tail": "clinically meaningful decline in bowel function mean score at 24 months post-radiotherapy"}
{"head": "Intensity-modulated proton therapy", "relation": "does not cause", "tail": "clinically meaningful decline in bowel function mean score at 24 months post-radiotherapy"}
{"head": "Intensity-modulated radiotherapy", "relation": "causes", "tail": "higher proportion of clinically relevant reduction in bowel function compared to intensity-modulated proton therapy"}
{"head": "Intensity-modulated radiotherapy", "relation": "does not cause", "tail": "statistically significant or clinically relevant changes in urinary incontinence scores"}
{"head": "Intensity-modulated radiotherapy", "relation": "does not cause", "tail": "statistically significant or clinically relevant changes in urinary irritative/obstructive symptoms scores"}
{"head": "Intensity-modulated proton therapy", "relation": "does not cause", "tail": "statistically significant or clinically relevant changes in urinary incontinence scores"}
{"head": "Intensity-modulated proton therapy", "relation": "does not cause", "tail": "statistically significant or clinically relevant changes in urinary irritative/obstructive symptoms scores"}
{"head": "Intensity-modulated proton therapy", "relation": "leads to", "tail": "smaller decrease in bowel function than intensity-modulated radiotherapy at 24 months post-radiotherapy"}
{"head": "Merkel cell carcinomas", "relation": "spread to", "tail": "lymph nodes"}
{"head": "Merkel cell carcinomas", "relation": "spread to", "tail": "distant metastases"}
{"head": "patients", "relation": "presented with", "tail": "lymph node metastases"}
{"head": "patients", "relation": "presented with", "tail": "distant metastases"}
{"head": "patients", "relation": "developed", "tail": "lifetime distant metastases"}
{"head": "patients with lifetime distant metastases", "relation": "also developed", "tail": "lymph node metastases"}
{"head": "patients", "relation": "developed lymph node metastases before", "tail": "distant metastases"}
{"head": "time from initial diagnosis to lymph node metastases", "relation": "is shorter than", "tail": "time from initial diagnosis to distant metastases"}
{"head": "patients with primary tumors \u22641 cm", "relation": "developed", "tail": "lifetime distant metastases"}
{"head": "prior lymph node metastases", "relation": "give rise to", "tail": "subsequent distant metastases"}
{"head": "patients with nodal metastases", "relation": "should be considered for", "tail": "adjuvant systemic therapy studies"}
{"head": "Fear of cancer recurrence", "relation": "affects", "tail": "family caregivers"}
{"head": "Fear of cancer recurrence in cancer patients", "relation": "has been documented", "tail": "well"}
{"head": "Focus group and semi-structured interviews", "relation": "were conducted with", "tail": "family caregivers of cancer survivors"}
{"head": "Family caregivers", "relation": "described experience of", "tail": "fear of cancer recurrence"}
{"head": "Fear of cancer recurrence in family caregivers", "relation": "is", "tail": "all-consuming"}
{"head": "Fear of cancer recurrence in family caregivers", "relation": "is", "tail": "constant"}
{"head": "Fear of cancer recurrence in family caregivers", "relation": "is marked by", "tail": "sense of helplessness"}
{"head": "Relational aspects of fear of cancer recurrence in family caregivers", "relation": "include", "tail": "patient-centric hypervigilance"}
{"head": "Relational aspects of fear of cancer recurrence in family caregivers", "relation": "include", "tail": "self-silencing"}
{"head": "Relational aspects of fear of cancer recurrence in family caregivers", "relation": "include", "tail": "fear of cancer recurrence as isolating"}
{"head": "Relational aspects of fear of cancer recurrence in family caregivers", "relation": "include", "tail": "finding support"}
{"head": "Relational factors", "relation": "shape", "tail": "how family caregivers experience and manage fear of cancer recurrence"}
{"head": "High-quality survivorship care", "relation": "should include", "tail": "fear of cancer recurrence interventions tailored to family caregivers"}
{"head": "Oral squamous cell carcinoma", "relation": "has high recurrence rates", "tail": "recurrence rates"}
{"head": "Tongue", "relation": "is most affected site in", "tail": "oral squamous cell carcinoma"}
{"head": "Tongue", "relation": "has highest recurrence rate", "tail": "oral squamous cell carcinoma"}
{"head": "Floor of the mouth", "relation": "has second highest recurrence rate", "tail": "oral squamous cell carcinoma"}
{"head": "24.3% of patients", "relation": "experienced", "tail": "recurrence"}
{"head": "Most recurrence cases", "relation": "occurred within", "tail": "first year"}
{"head": "T2 tumors", "relation": "had highest recurrence rates", "tail": "oral squamous cell carcinoma"}
{"head": "Recurrence rates", "relation": "were comparable between", "tail": "patients with and without adjuvant therapy"}
{"head": "Positive surgical margins", "relation": "were more common in", "tail": "recurrence cases"}
{"head": "No significant correlation", "relation": "was found between", "tail": "margin status and recurrence in patients without adjuvant therapy"}
{"head": "Recurrence-free survival in oral squamous cell carcinoma", "relation": "does not solely depend on", "tail": "surgical technique"}
{"head": "Recurrence-free survival in oral squamous cell carcinoma", "relation": "does not solely depend on", "tail": "adjuvant therapy"}
{"head": "Tumors of the tongue and floor of the mouth", "relation": "exhibited high recurrence rates regardless of", "tail": "disease stage"}
{"head": "Ectopic adrenocorticotropic hormone syndrome", "relation": "occurs when", "tail": "a tumor develops neuroendocrine differentiation with the secretion of ACTH"}
{"head": "Secretion of ACTH", "relation": "results in", "tail": "hypercortisolism"}
{"head": "Secretion of ACTH", "relation": "results in", "tail": "Cushing's syndrome"}
{"head": "5-10% of Cushing's syndrome cases", "relation": "are attributed to", "tail": "Ectopic adrenocorticotropic hormone syndrome"}
{"head": "Breast tumors", "relation": "comprise less than", "tail": "1% of Ectopic adrenocorticotropic hormone syndrome cases"}
{"head": "Breast neuroendocrine tumors", "relation": "include", "tail": "neuroendocrine-differentiated carcinoma"}
{"head": "Breast neuroendocrine tumors", "relation": "include", "tail": "ductal carcinoma with neuroendocrine features"}
{"head": "Biopsy", "relation": "demonstrated", "tail": "invasive poorly differentiated breast carcinoma with high-grade neuroendocrine features and necrosis"}
{"head": "Staging at diagnosis", "relation": "confirmed", "tail": "metastatic disease of the liver and bone"}
{"head": "First-line chemotherapy (Cisplatin/Etoposide/Durvalumab)", "relation": "was initiated for", "tail": "disease progression after four cycles"}
{"head": "Simple mastectomy", "relation": "was performed for", "tail": "local control and complete pathologic analysis"}
{"head": "Pathologic analysis", "relation": "demonstrated", "tail": "high-grade neuroendocrine carcinoma with large-cell features"}
{"head": "Second-line therapy (Adriamycin/Cyclophosphamide)", "relation": "was initiated for", "tail": "three cycles"}
{"head": "Workup", "relation": "confirmed", "tail": "elevated ACTH consistent with paraneoplastic Ectopic adrenocorticotropic hormone syndrome"}
{"head": "Workup", "relation": "confirmed", "tail": "evidence of disease progression"}
{"head": "Third-line therapy (Nab-Paclitaxel)", "relation": "was initiated", "tail": ""}
{"head": "Genetic testing", "relation": "confirmed", "tail": "PIK3 mutation"}
{"head": "Access to Alpelisib therapy", "relation": "was requested for", "tail": "PIK3 mutation"}
{"head": "Patient", "relation": "underwent", "tail": "urgent bilateral laparoscopic adrenalectomy"}
{"head": "Laparoscopic bilateral adrenalectomy", "relation": "is", "tail": "an accepted, definitive treatment option for Ectopic adrenocorticotropic hormone syndrome resulting in Cushing's syndrome secondary to breast neuroendocrine carcinoma"}
{"head": "Biological sex and gender factors", "relation": "influence", "tail": "pathogenesis in hematologic malignancies"}
{"head": "Biological sex and gender factors", "relation": "influence", "tail": "progression in hematologic malignancies"}
{"head": "Biological sex and gender factors", "relation": "influence", "tail": "treatment response in hematologic malignancies"}
{"head": "Male patients", "relation": "have higher disease incidence", "tail": "multiple myeloma"}
{"head": "Male patients", "relation": "have higher disease incidence", "tail": "acute myeloid leukemia hospitalizations for ages 18-39"}
{"head": "Male patients", "relation": "have inferior outcomes", "tail": "hematologic malignancies"}
{"head": "Male patients with acute myeloid leukemia", "relation": "have 5-year relative survival rate of", "tail": "48.8%"}
{"head": "Female patients with acute myeloid leukemia", "relation": "have 5-year relative survival rate of", "tail": "60.4%"}
{"head": "Female patients", "relation": "exhibit superior survival", "tail": "hematologic malignancies"}
{"head": "Female patients", "relation": "experience greater treatment-related toxicities", "tail": "hematologic malignancies"}
{"head": "Sex-specific patterns", "relation": "include", "tail": "distinct mutational profiles"}
{"head": "Sex-specific patterns", "relation": "include", "tail": "differences in immune system function"}
{"head": "Sex-specific patterns", "relation": "include", "tail": "sex-based pharmacokinetic variations"}
{"head": "Females", "relation": "demonstrate favorable prognostic mutations", "tail": "leukemias"}
{"head": "Females", "relation": "have higher rates of chromosomal abnormalities", "tail": "multiple myeloma"}
{"head": "Neuropilin-1", "relation": "is a", "tail": "neuronal guidance protein"}
{"head": "Neuropilin-1", "relation": "regulates", "tail": "cancer biology"}
{"head": "Neuropilin-1", "relation": "influences", "tail": "tumor cell proliferation"}
{"head": "Neuropilin-1", "relation": "influences", "tail": "tumor cell migration"}
{"head": "Neuropilin-1", "relation": "influences", "tail": "tumor cell invasion"}
{"head": "Neuropilin-1", "relation": "influences", "tail": "tumor cell metastasis"}
{"head": "Neuropilin-1", "relation": "interacts with", "tail": "vascular endothelial growth factor"}
{"head": "Neuropilin-1", "relation": "interacts with", "tail": "semaphorins"}
{"head": "Neuropilin-1", "relation": "interacts with", "tail": "transforming growth factor-beta"}
{"head": "Neuropilin-1", "relation": "modulates", "tail": "tumor microenvironment"}
{"head": "Neuropilin-1", "relation": "promotes", "tail": "angiogenesis"}
{"head": "Neuropilin-1 expression", "relation": "correlates with", "tail": "poor prognosis in various malignancies"}
{"head": "targeting Neuropilin-1", "relation": "inhibits", "tail": "tumor growth"}
{"head": "targeting Neuropilin-1", "relation": "enhances", "tail": "efficacy of chemotherapy"}
{"head": "targeting Neuropilin-1", "relation": "enhances", "tail": "efficacy of radiotherapy"}
{"head": "NRP1-targeted therapies", "relation": "include", "tail": "monoclonal antibodies"}
{"head": "NRP1-targeted therapies", "relation": "include", "tail": "small molecule inhibitors"}
{"head": "NRP1-targeted therapies", "relation": "include", "tail": "gene silencing techniques"}
{"head": "noninvasive prognostic evaluation methods", "relation": "are used for", "tail": "hepatocellular carcinoma"}
{"head": "noninvasive prognostic evaluation methods", "relation": "rely on", "tail": "radiographic imaging features"}
{"head": "noninvasive prognostic evaluation methods", "relation": "rely on", "tail": "serum biomarkers"}
{"head": "serum biomarkers", "relation": "include", "tail": "alpha-fetoprotein"}
{"head": "epigenetic changes in cell-free DNA", "relation": "have shown promise in", "tail": "early cancer diagnosis"}
{"head": "epigenetic changes in cell-free DNA", "relation": "have shown promise in", "tail": "prognosis"}
{"head": "cfDNA methylation", "relation": "is a predictor for", "tail": "prognostication in patients with active, radiographically viable HCC"}
{"head": "Illumina HumanMethylation450 array data", "relation": "was used to identify", "tail": "158 HCC-related DNA methylation markers"}
{"head": "158 HCC-related DNA methylation markers", "relation": "are associated with", "tail": "overall survival"}
{"head": "158 HCC-related DNA methylation markers", "relation": "were validated in", "tail": "29 HCC tumor tissue samples"}
{"head": "cfDNA methylation-based risk score (methRisk)", "relation": "was calculated from", "tail": "plasma cfDNA samples"}
{"head": "cfDNA methylation-based risk score (methRisk)", "relation": "predicts", "tail": "overall survival"}
{"head": "methRisk", "relation": "has discriminatory power for", "tail": "overall survival"}
{"head": "methRisk", "relation": "improves prognostic assessments when integrated with", "tail": "Barcelona clinic liver cancer staging"}
{"head": "methRisk", "relation": "is an independent predictor of", "tail": "survival"}
{"head": "cfDNA methylation biomarkers", "relation": "can stratify", "tail": "HCC patients into clinically meaningful risk groups"}
{"head": "cfDNA methylation", "relation": "is a noninvasive prognostic biomarker for", "tail": "hepatocellular carcinoma"}
{"head": "GLUT2 (SLC2A2)", "relation": "is a", "tail": "glucose transporter in liver, pancreas, and kidney tissues"}
{"head": "GLUT2 (SLC2A2)", "relation": "regulates", "tail": "blood glucose levels"}
{"head": "GLUT2 (SLC2A2)", "relation": "regulates", "tail": "energy metabolism"}
{"head": "SLC2A2", "relation": "contributes to", "tail": "cell differentiation"}
{"head": "SLC2A2", "relation": "contributes to", "tail": "metabolic adaptation during embryogenesis and tissue regeneration"}
{"head": "SLC2A2 expression", "relation": "decreases with", "tail": "HCC progression"}
{"head": "Stemness-associated genes", "relation": "include", "tail": "SOX2"}
{"head": "Stemness-associated genes", "relation": "include", "tail": "POU5F1"}
{"head": "Zebrafish embryos injected with SLC2A2-targeting morpholino", "relation": "exhibit", "tail": "reduced expression of liver differentiation marker fabp10a"}
{"head": "Zebrafish embryos injected with SLC2A2-targeting morpholino", "relation": "do not significantly alter", "tail": "hepatoblast marker hhex expression"}
{"head": "SLC2A2 knockdown in HepG2 cells", "relation": "increases", "tail": "stemness markers"}
{"head": "SLC2A2 knockdown in HepG2 cells", "relation": "increases", "tail": "IGF1R pathway markers"}
{"head": "SLC2A2 knockdown in HepG2 cells", "relation": "induces", "tail": "shift toward less differentiated states"}
{"head": "SLC2A2", "relation": "supports", "tail": "liver differentiation"}
{"head": "SLC2A2", "relation": "regulates", "tail": "glucose metabolism"}
{"head": "SLC2A2", "relation": "suppresses", "tail": "pathways associated with stemness and malignancy"}
{"head": "Targeting SLC2A2", "relation": "may serve as", "tail": "therapeutic strategy for liver-related diseases"}
{"head": "Targeting SLC2A2", "relation": "may serve as", "tail": "therapeutic strategy for hepatocellular carcinoma"}
{"head": "Mosunetuzumab", "relation": "is a", "tail": "CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific antibody"}
{"head": "Mosunetuzumab", "relation": "redirects", "tail": "T cells to eliminate malignant B cells"}
{"head": "YO43555", "relation": "assesses", "tail": "pharmacokinetics of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "YO43555", "relation": "assesses", "tail": "safety of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "YO43555", "relation": "assesses", "tail": "tolerability of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "YO43555", "relation": "assesses", "tail": "efficacy of mosunetuzumab in Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "Global popPK model", "relation": "adequately captures", "tail": "individual pharmacokinetics of mosunetuzumab in Chinese population"}
{"head": "Global popPK model", "relation": "predicts", "tail": "mosunetuzumab exposure metrics in Chinese patients similar to Asian patients in GO29781 R/R FL subpopulation"}
{"head": "Exposure differences between Chinese and Non-Asians", "relation": "are", "tail": "less than 20%"}
{"head": "Mosunetuzumab exposure in Chinese patients", "relation": "remains within", "tail": "established bounds for clinical safety and efficacy"}
{"head": "Cytokine biomarkers IL-6 and TNF-\u03b1", "relation": "show", "tail": "similar time-course patterns of release as in globally enrolled patients"}
{"head": "Mosunetuzumab pharmacokinetics disposition", "relation": "does not show", "tail": "significant ethnic sensitivity impacting patient outcomes"}
{"head": "Dose adjustment of globally approved mosunetuzumab regimen", "relation": "is not warranted for", "tail": "Chinese patients with relapsed/refractory follicular lymphoma"}
{"head": "KRAS mutation", "relation": "is associated with", "tail": "poor overall survival in colorectal cancer"}
{"head": "BRAF mutation", "relation": "is associated with", "tail": "poor overall survival in colorectal cancer"}
{"head": "KRAS mutation", "relation": "is associated with", "tail": "poor disease-free survival in colorectal cancer"}
{"head": "BRAF mutation", "relation": "is associated with", "tail": "poor disease-free survival in colorectal cancer"}
{"head": "KRAS mutation", "relation": "is associated with", "tail": "shorter disease-free survival in microsatellite-stable tumors"}
{"head": "BRAF mutation", "relation": "is associated with", "tail": "reduced overall survival in microsatellite-stable tumors"}
{"head": "BRAF mutation", "relation": "is associated with", "tail": "reduced disease-free survival in microsatellite-stable tumors"}
{"head": "Concurrent mutations in KRAS, NRAS, BRAF, and PIK3CA", "relation": "are associated with", "tail": "shorter overall survival and disease-free survival in microsatellite-stable patients"}
{"head": "PIK3CA mutation", "relation": "is nominally associated with", "tail": "overall survival"}
{"head": "KRAS and BRAF mutations", "relation": "have", "tail": "negative prognostic impact on microsatellite-stable stage II/III colorectal cancer patients receiving adjuvant therapy following curative resection"}
{"head": "CD8 T cells", "relation": "play role in", "tail": "antitumor immunity"}
{"head": "CD8 T cells", "relation": "become", "tail": "dysfunctional"}
{"head": "CD8 T cells", "relation": "become", "tail": "exhausted"}
{"head": "dysfunctional or exhausted CD8 T cells", "relation": "fail to control", "tail": "tumor growth"}
{"head": "molecular pathways", "relation": "regulate", "tail": "CD8 T cell heterogeneity"}
{"head": "molecular pathways", "relation": "regulate", "tail": "CD8 T cell function"}
{"head": "T cell-intrinsic factors", "relation": "influence", "tail": "CD8 T cell differentiation"}
{"head": "T cell-extrinsic factors", "relation": "influence", "tail": "CD8 T cell differentiation"}
{"head": "T cell-intrinsic factors", "relation": "influence", "tail": "CD8 T cell fate choices"}
{"head": "T cell-extrinsic factors", "relation": "influence", "tail": "CD8 T cell fate choices"}
{"head": "T cell-intrinsic factors", "relation": "influence", "tail": "CD8 T cell functional states"}
{"head": "T cell-extrinsic factors", "relation": "influence", "tail": "CD8 T cell functional states"}
{"head": "T cell-intrinsic and -extrinsic factors", "relation": "dictate", "tail": "CD8 T cell response to therapy"}
{"head": "therapeutic checkpoint blockade", "relation": "is responded to by", "tail": "T cells"}
{"head": "cells that orchestrate long-term antitumor immunity", "relation": "are critical for", "tail": "improving cancer immunotherapy"}
{"head": "Testicular microcalcifications", "relation": "consist of", "tail": "hydroxyapatite"}
{"head": "Testicular microcalcifications", "relation": "are associated with increased risk of", "tail": "testicular germ cell tumors"}
{"head": "Loss-of-function variants in SLC34A2", "relation": "are found in", "tail": "benign cases with testicular microcalcifications"}
{"head": "Fibroblast growth factor 23", "relation": "regulates", "tail": "phosphate homeostasis"}
{"head": "Fibroblast growth factor 23", "relation": "is expressed in", "tail": "testicular germ cell neoplasia in situ"}
{"head": "Fibroblast growth factor 23", "relation": "is expressed in", "tail": "embryonal carcinoma"}
{"head": "Fibroblast growth factor 23", "relation": "is expressed in", "tail": "human embryonic stem cells"}
{"head": "Fibroblast growth factor 23 in testicular germ cell tumors", "relation": "is not glycosylated", "tail": ""}
{"head": "Fibroblast growth factor 23 in testicular germ cell tumors", "relation": "is cleaved into", "tail": "C-terminal fragment"}
{"head": "C-terminal fragment of fibroblast growth factor 23", "relation": "antagonizes", "tail": "full-length fibroblast growth factor 23"}
{"head": "Fgf23 knockout mice", "relation": "present with", "tail": "marked calcifications in the epididymis"}
{"head": "Fgf23 knockout mice", "relation": "present with", "tail": "spermatogenic arrest"}
{"head": "Germ cells in Fgf23 knockout mice", "relation": "express", "tail": "osteoblast marker Osteocalcin"}
{"head": "Testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins", "relation": "are associated with", "tail": "lower Slc34a2 expression"}
{"head": "Testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins", "relation": "are associated with", "tail": "higher Bglap/Slc34a1 expression"}
{"head": "Human testicular specimens with microcalcifications", "relation": "have", "tail": "lower SLC34A2 expression"}
{"head": "A subpopulation of germ cells in human testicular specimens with microcalcifications", "relation": "express", "tail": "phosphate transporter NPT2a"}
{"head": "A subpopulation of germ cells in human testicular specimens with microcalcifications", "relation": "express", "tail": "Osteocalcin"}
{"head": "A subpopulation of germ cells in human testicular specimens with microcalcifications", "relation": "express", "tail": "RUNX2"}
{"head": "Calcium or phosphate treatment in vitro", "relation": "induces", "tail": "deposition of calcium phosphate in spermatogonial cell line"}
{"head": "Pyrophosphate", "relation": "rescues", "tail": "calcium phosphate deposition induced by mineral disturbance in spermatogonial cell line"}
{"head": "Testicular microcalcifications", "relation": "arise secondary to", "tail": "local alterations in mineral homeostasis"}
{"head": "Impaired Sertoli cell function and reduced levels of mineralization inhibitors", "relation": "facilitate", "tail": "osteogenic-like differentiation of testicular cells"}
{"head": "High alkaline phosphatase activity in GCNIS and TGCTs", "relation": "facilitates", "tail": "osteogenic-like differentiation of testicular cells"}
{"head": "Osteogenic-like differentiation of testicular cells", "relation": "facilitates", "tail": "deposition of hydroxyapatite"}
{"head": "cancer-associated fibroblast-related gene signature", "relation": "predicts", "tail": "clinical outcomes in patients with diffuse large B cell lymphoma"}
{"head": "weighted gene co-expression network analysis", "relation": "identifies", "tail": "cancer-associated fibroblast-related module genes"}
{"head": "Least Absolute Shrinkage and Selection Operator Cox regression", "relation": "screens", "tail": "minimal set of genes"}
{"head": "Least Absolute Shrinkage and Selection Operator Cox regression", "relation": "constructs", "tail": "prognostic cancer-associated fibroblast-related gene signature for diffuse large B cell lymphoma"}
{"head": "Kaplan-Meier plots and receiver operating characteristic curves", "relation": "assess", "tail": "prognostic performance of prognostic cancer-associated fibroblast-related genes"}
{"head": "nomogram", "relation": "encompasses", "tail": "clinical information and prognostic scores of patients"}
{"head": "prognostic cancer-associated fibroblast-related gene signature risk model", "relation": "categorizes", "tail": "patients with diffuse large B cell lymphoma into high- and low-risk groups"}
{"head": "nomogram", "relation": "shows", "tail": "stronger prognostic ability than clinical factor-based model or risk score alone"}
{"head": "high- and low-risk groups", "relation": "have", "tail": "significant differences in immune cell profiles and therapeutic responses"}
{"head": "prognostic cancer-associated fibroblast-related gene-based genetic risk model", "relation": "predicts", "tail": "prognosis of diffuse large B cell lymphoma"}
{"head": "Asian patients", "relation": "have better survival than", "tail": "White patients"}
{"head": "Black patients", "relation": "have worse survival than", "tail": "White patients"}
{"head": "Hispanic patients", "relation": "have no difference in survival compared with", "tail": "White patients"}
{"head": "Black patients in California", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in California"}
{"head": "Black patients in New Jersey", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in New Jersey"}
{"head": "Black patients in Georgia", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in Georgia"}
{"head": "Black patients in Louisiana", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in Louisiana"}
{"head": "Black patients in Connecticut", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in Connecticut"}
{"head": "Black patients in Iowa", "relation": "have worse uterine cancer-specific survival than", "tail": "White patients in Iowa"}
{"head": "Hispanic patients in Hawaii", "relation": "have worse survival than", "tail": "White patients in Hawaii"}
{"head": "Hispanic patients in Georgia", "relation": "have worse survival than", "tail": "White patients in Georgia"}
{"head": "Asian patients in California", "relation": "have better survival than", "tail": "White patients in California"}
{"head": "Oral squamous cell carcinoma", "relation": "is most prevalent of", "tail": "oral cancers"}
{"head": "YAP", "relation": "serves as", "tail": "transcriptional regulator in hippo tumor suppressor pathway"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "cellular proliferation"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "alteration"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "migration"}
{"head": "YAP", "relation": "activates transcription of genes involved in", "tail": "invasion"}
{"head": "PARK2", "relation": "acts as", "tail": "tumor suppressor"}
{"head": "Immunohistochemical expression of YAP", "relation": "increases from", "tail": "normal oral mucosa to oral squamous cell carcinoma"}
{"head": "Immunohistochemical expression of PARK2", "relation": "decreases from", "tail": "normal oral mucosa to oral squamous cell carcinoma"}
{"head": "YAP expression", "relation": "differs significantly between", "tail": "normal oral mucosa, oral epithelial dysplasia, and oral squamous cell carcinoma groups"}
{"head": "PARK2 expression", "relation": "differs significantly between", "tail": "normal oral mucosa, oral epithelial dysplasia, and oral squamous cell carcinoma groups"}
{"head": "YAP expression", "relation": "is inversely correlated with", "tail": "PARK2 expression in oral squamous cell carcinoma group"}
{"head": "Concomitant immunoexpression of YAP and PARK2", "relation": "could serve as", "tail": "diagnostic and prognostic markers for oral squamous cell carcinoma"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "is a", "tail": "rare malignant neoplasm"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "has propensity for", "tail": "maxilla"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "has male predilection", "tail": "male"}
{"head": "38-year-old male patient", "relation": "has", "tail": "maxillary lesion"}
{"head": "Lesion", "relation": "shows", "tail": "ghost cells"}
{"head": "Lesion", "relation": "shows", "tail": "dentinoid deposition"}
{"head": "Lesion", "relation": "has", "tail": "ameloblastoma-like epithelial linings"}
{"head": "Lesion", "relation": "has malignant features", "tail": "nuclear pleomorphism"}
{"head": "Lesion", "relation": "has malignant features", "tail": "increased mitosis"}
{"head": "Lesion", "relation": "has malignant features", "tail": "necrosis"}
{"head": "Lesion", "relation": "has malignant features", "tail": "perivascular invasion"}
{"head": "Lesion", "relation": "has malignant features", "tail": "invasion into adjacent bone"}
{"head": "Tumor cells", "relation": "are reactive to", "tail": "CAM5.2"}
{"head": "Tumor cells", "relation": "are reactive to", "tail": "p63"}
{"head": "Tumor cells", "relation": "are reactive to", "tail": "CK5/6"}
{"head": "Tumor cells", "relation": "are reactive to", "tail": "CK19"}
{"head": "CK5/6 and CK19", "relation": "are positive in", "tail": "peripheral area in a ring-like pattern in the ghost cell region"}
{"head": "Tumor cells", "relation": "have nuclear staining of", "tail": "beta-catenin"}
{"head": "Next generation sequencing", "relation": "revealed mutation in", "tail": "CTNNB1 variant c.110 C\u2009>\u2009G p.(Ser37Cys)"}
{"head": "Next generation sequencing", "relation": "revealed mutation in", "tail": "ARID1A variant c.4420 C\u2009>\u2009T p. (Gln1474*)"}
{"head": "Patient", "relation": "was treated with", "tail": "surgical excision"}
{"head": "Patient", "relation": "was treated with", "tail": "bilateral cervical lymph node dissection"}
{"head": "Patient", "relation": "was treated with", "tail": "adjuvant radiotherapy"}
{"head": "Patient", "relation": "was free of disease after", "tail": "30 months"}
{"head": "Ghost cell odontogenic carcinoma", "relation": "is", "tail": "rare aggressive odontogenic tumor"}
{"head": "CTNNB1", "relation": "is", "tail": "consistent gene mutation in ghost cell odontogenic carcinoma"}
{"head": "ARID1A", "relation": "was reported for the first time in", "tail": "ghost cell odontogenic carcinoma"}
{"head": "Osteosarcoma", "relation": "is", "tail": "primary bone cancer in children and adolescents"}
{"head": "35-45% of osteosarcoma patients", "relation": "do not respond to", "tail": "standard chemotherapeutic treatments"}
{"head": "non-response to standard chemotherapeutic treatments", "relation": "results in", "tail": "5-20% 5-year survival rate"}
{"head": "ATG4B", "relation": "is", "tail": "cysteine protease for autophagosome formation"}
{"head": "ATG4B", "relation": "is overexpressed in", "tail": "various cancers"}
{"head": "ATG4B overexpression", "relation": "correlates with", "tail": "poor prognosis in various cancers"}
{"head": "ATG4B expression", "relation": "correlates with", "tail": "tumor size in osteosarcoma"}
{"head": "ATG4B expression", "relation": "correlates with", "tail": "tumor stage in osteosarcoma"}
{"head": "ATG4B expression", "relation": "correlates with", "tail": "histological response to neoadjuvant chemotherapy in osteosarcoma"}
{"head": "VEGF expression", "relation": "correlates with", "tail": "tumor size in osteosarcoma"}
{"head": "VEGF expression", "relation": "correlates with", "tail": "tumor stage in osteosarcoma"}
{"head": "VEGF expression", "relation": "correlates with", "tail": "presence of distant metastasis at diagnosis in osteosarcoma"}
{"head": "ATG4B expression", "relation": "positively correlates with", "tail": "VEGF expression in osteosarcoma"}
{"head": "High ATG4B overexpression", "relation": "is associated with", "tail": "worse overall survival in osteosarcoma"}
{"head": "High VEGF overexpression", "relation": "is associated with", "tail": "worse overall survival in osteosarcoma"}
{"head": "ATG4B", "relation": "acts as", "tail": "tumor promoter in osteosarcoma"}
{"head": "ATG4B", "relation": "is potential therapeutic target to", "tail": "inhibit tumor growth in osteosarcoma"}
{"head": "Elevated ATG4B levels", "relation": "serve as", "tail": "marker for poor prognosis in osteosarcoma"}
{"head": "VEGF overexpression", "relation": "is linked to", "tail": "greater likelihood of pulmonary metastasis in osteosarcoma"}
{"head": "VEGF overexpression", "relation": "is linked to", "tail": "worse overall prognosis in osteosarcoma"}
{"head": "Absence of ATG4B and VEGF", "relation": "indicates", "tail": "better chemotherapy response in osteosarcoma"}
{"head": "GWAS analysis", "relation": "identified", "tail": "three genome-wide significant loci associated with OTSCC"}
{"head": "loci at 5p15.33 (rs27067 near gene LINC01511)", "relation": "associated with", "tail": "OTSCC"}
{"head": "loci at 10q24 (rs1007771191 near RPS3AP36)", "relation": "associated with", "tail": "OTSCC"}
{"head": "loci at 20p12.3 (rs1438070080 near PLCB1)", "relation": "associated with", "tail": "OTSCC"}
{"head": "rs27067", "relation": "associated with", "tail": "prostate cancer"}
{"head": "rs27067", "relation": "associated with", "tail": "seborrheic keratosis"}
{"head": "rs27067", "relation": "has co-directional effect with", "tail": "melanoma"}
{"head": "Chondrosarcoma", "relation": "is", "tail": "malignant neoplasm"}
{"head": "Chondrosarcoma", "relation": "characterized by", "tail": "production of a cartilaginous matrix"}
{"head": "Patient", "relation": "has swelling in", "tail": "posterior region of right maxilla"}
{"head": "Intraoral examination", "relation": "revealed", "tail": "rounded lesion with ulceration in area of teeth 17 and 18"}
{"head": "Panoramic radiograph", "relation": "revealed", "tail": "radiopaque lesion with flocculated pattern in right maxilla"}
{"head": "Computed tomography", "relation": "showed", "tail": "hyperdense lesion containing hypodense areas"}
{"head": "Histopathological analysis", "relation": "revealed", "tail": "presence of immature cartilage with rounded neoplastic cells, nuclei of varied sizes, and intense pleomorphism"}
{"head": "Histopathological analysis", "relation": "led to diagnosis of", "tail": "chondrosarcoma"}
{"head": "Patient", "relation": "underwent", "tail": "surgical resection followed by radiotherapy"}
{"head": "Patient", "relation": "has shown no signs of recurrence after", "tail": "one year of follow-up"}
{"head": "Chondrosarcoma", "relation": "should be considered in differential diagnosis of", "tail": "osseous enlargement in gnathic bones"}
{"head": "Loss of heterozygosity", "relation": "is reported in", "tail": "Oral Potentially Malignant Disorders"}
{"head": "Loss of heterozygosity", "relation": "is reported in", "tail": "Oral Squamous Cell Carcinoma"}
{"head": "p53 gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "p16 gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "adenomatous polyposis coli gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "retinoblastoma gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "fragile histidine triad gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "phosphatase and tensin homolog gene", "relation": "is associated with", "tail": "Loss of heterozygosity in Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "Chromosome loci 17p", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "Chromosome loci 9p", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "Chromosome loci 5q", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "Chromosome loci 13q", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "Chromosome loci 3p", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "Chromosome loci 10q", "relation": "is frequently reported in", "tail": "Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma"}
{"head": "p53", "relation": "interacts with", "tail": "p16"}
{"head": "p53", "relation": "interacts with", "tail": "fragile histidine triad gene"}
{"head": "p53", "relation": "interacts with", "tail": "retinoblastoma gene"}
{"head": "Loss of heterozygosity patterns", "relation": "are seen in", "tail": "Oral Potentially Malignant Disorders"}
{"head": "Loss of heterozygosity patterns", "relation": "are seen in", "tail": "Oral Squamous Cell Carcinoma"}
{"head": "circ_0000517", "relation": "is upregulated in", "tail": "non-small cell lung cancer tissues and cells"}
{"head": "circ_0000517", "relation": "expression is associated with", "tail": "m6A modification"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "proliferation of NSCLC cells"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "colony formation of NSCLC cells"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "migration of NSCLC cells"}
{"head": "silenced circ_0000517", "relation": "hinders", "tail": "invasion of NSCLC cells"}
{"head": "silenced circ_0000517", "relation": "suppresses", "tail": "EMT-related process"}
{"head": "highly expressed circ_0000517", "relation": "activates", "tail": "CDH6 expression"}
{"head": "highly expressed circ_0000517", "relation": "activates", "tail": "EMT evolution"}
{"head": "highly expressed circ_0000517", "relation": "sponges", "tail": "miR-1233-3p"}
{"head": "miR-1233-3p", "relation": "reverses the promotion effect of", "tail": "circ_0000517 on malignant biological behavior of NSCLC cells"}
{"head": "m6A-modified circ_0000517", "relation": "accelerates malignant evolution of", "tail": "non-small cell lung cancer"}
{"head": "m6A-modified circ_0000517", "relation": "targets", "tail": "miR-1233-3p/CDH6 axis"}
{"head": "MoS2-CuS nanocomposites", "relation": "are synthesized by", "tail": "physically mixing MoS2 suspensions with CuS"}
{"head": "MoS2-AuNR nanocomposites", "relation": "are synthesized by", "tail": "physically mixing MoS2 suspensions with AuNRs"}
{"head": "X-ray diffraction", "relation": "characterizes", "tail": "structural properties of nanocomposites"}
{"head": "transmission electron microscopy", "relation": "characterizes", "tail": "structural properties of nanocomposites"}
{"head": "ultraviolet-visible spectroscopy", "relation": "characterizes", "tail": "optical properties of nanocomposites"}
{"head": "Fourier transform infrared spectroscopy", "relation": "characterizes", "tail": "optical properties of nanocomposites"}
{"head": "MoS2-CuS nanocomposites", "relation": "exhibit", "tail": "enhanced photothermal heating compared to individual components"}
{"head": "MoS2-AuNR nanocomposites", "relation": "exhibit", "tail": "enhanced photothermal heating compared to individual components"}
{"head": "MoS2-AuNR nanocomposites", "relation": "generate", "tail": "higher photothermal heat than MoS2-CuS nanocomposites"}
{"head": "MoS2-CuS nanocomposites", "relation": "have potential as", "tail": "photothermal agents for cancer therapy"}
{"head": "MoS2-AuNR nanocomposites", "relation": "have potential as", "tail": "photothermal agents for cancer therapy"}
{"head": "Melanotic Neuroectodermal Tumor of Infancy", "relation": "is", "tail": "rare tumor"}
{"head": "Melanotic Neuroectodermal Tumor of Infancy", "relation": "is", "tail": "locally aggressive tumor"}
{"head": "Melanotic Neuroectodermal Tumor of Infancy", "relation": "commonly occurs in", "tail": "head and neck region"}
{"head": "Melanotic Neuroectodermal Tumor of Infancy", "relation": "consists of", "tail": "biphasic population of small neuroblast-like cells and larger melanin-containing epithelioid cells"}
{"head": "Tumor distribution", "relation": "includes", "tail": "Maxilla"}
{"head": "Tumor distribution", "relation": "includes", "tail": "Mandible"}
{"head": "Tumor distribution", "relation": "includes", "tail": "greater wing of Sphenoid"}
{"head": "Tumor distribution", "relation": "includes", "tail": "Temporal bone"}
{"head": "All tumors", "relation": "revealed", "tail": "classic biphasic morphology"}
{"head": "Larger epithelioid cells", "relation": "are positive for", "tail": "AE1/AE3"}
{"head": "Larger epithelioid cells", "relation": "are positive for", "tail": "HMB45"}
{"head": "Smaller neuroblast-like cells", "relation": "are positive for", "tail": "Synaptophysin"}
{"head": "One patient", "relation": "had", "tail": "nested areas composed of mature glial tissue"}
{"head": "One patient", "relation": "was given", "tail": "adjuvant radiotherapy"}
{"head": "One patient", "relation": "developed", "tail": "solitary ipsilateral lymph nodal metastasis"}
{"head": "All patients", "relation": "were alive with no evidence of disease at", "tail": "last follow-up"}
{"head": "CXC chemokines", "relation": "exhibit dysregulation in", "tail": "miscellaneous cancer categories"}
{"head": "CXC chemokines", "relation": "are associated with", "tail": "advancement of tumors"}
{"head": "Breast cancer pathogenesis and progression", "relation": "involve", "tail": "invasion"}
{"head": "Breast cancer pathogenesis and progression", "relation": "involve", "tail": "metastasis"}
{"head": "Breast cancer pathogenesis and progression", "relation": "involve", "tail": "angiogenesis"}
{"head": "Breast cancer pathogenesis and progression", "relation": "involve", "tail": "inflammation"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "invasion"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "metastasis"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "angiogenesis"}
{"head": "Chemokines and their receptors", "relation": "are involved in", "tail": "inflammation"}
{"head": "CXC chemokine receptors (CXCRs) and their related ligands", "relation": "facilitate and control", "tail": "tumor proliferation"}
{"head": "CXCRs", "relation": "are expressed by", "tail": "cancer cells"}
{"head": "CXCRs", "relation": "are expressed by", "tail": "immune cells"}
{"head": "CXCRs", "relation": "regulate", "tail": "tumor microenvironment"}
{"head": "CXCRs", "relation": "regulate", "tail": "immune response"}
{"head": "Psoriasis", "relation": "is", "tail": "chronic systemic autoimmune disease"}
{"head": "Psoriasis", "relation": "has", "tail": "high rate of progression and relapse"}
{"head": "Hematopoietic stem cell transplantation", "relation": "is", "tail": "promising therapeutic modality for hematological malignancies"}
{"head": "Hematopoietic stem cell transplantation", "relation": "controls", "tail": "psoriasis in patients with hematological tumor"}
{"head": "Hematopoietic stem cell transplantation", "relation": "prevents", "tail": "recurrence of psoriasis"}
{"head": "Hematopoietic stem cell transplantation", "relation": "has", "tail": "immunomodulatory activity"}
{"head": "Hematopoietic stem cell transplantation", "relation": "treats", "tail": "psoriasis"}
{"head": "31 of 41 patients", "relation": "did not experience", "tail": "recurrence of psoriasis during follow-up"}
{"head": "10 of 41 patients", "relation": "experienced", "tail": "recurrence of psoriasis during post-transplantation follow-up"}
{"head": "Earliest recurrence of skin lesions", "relation": "occurred at", "tail": "1.4 months after transplantation"}
{"head": "Skin lesions", "relation": "disappeared at", "tail": "3.5 months after transplantation"}
{"head": "Latest recurrence of psoriasis", "relation": "occurred at", "tail": "60 months post-transplant"}
{"head": "Patient flare-up of psoriatic arthritis", "relation": "occurred at", "tail": "156 months post-transplant"}
{"head": "Severity and duration of psoriasis and arthritis", "relation": "improved compared to", "tail": "pretransplant"}
{"head": "Nurse cancer survivors", "relation": "face", "tail": "significant challenges in adapting to returning to work"}
{"head": "Nurse cancer survivors", "relation": "require", "tail": "special attention and support"}
{"head": "This interpretive phenomenological study", "relation": "aimed to explore", "tail": "NCSs' feelings and experiences after RTW"}
{"head": "Semi-structured interviews", "relation": "were conducted with", "tail": "15 NCSs in China"}
{"head": "The transcripts", "relation": "were analyzed using", "tail": "interpretative phenomenological analysis"}
{"head": "Data", "relation": "was categorized into", "tail": "psychological odyssey"}
{"head": "Data", "relation": "was categorized into", "tail": "accessing social support"}
{"head": "Data", "relation": "was categorized into", "tail": "benefiting from professional background"}
{"head": "Data", "relation": "was categorized into", "tail": "realization of professional values"}
{"head": "Managers", "relation": "should pay attention to", "tail": "psychology of RTW"}
{"head": "Managers", "relation": "should enhance", "tail": "support"}
{"head": "Managers", "relation": "should encourage", "tail": "use of professional strengths"}
{"head": "Managers", "relation": "should value", "tail": "insights and professional development of NCSs"}
{"head": "infection", "relation": "is a cause of", "tail": "emergency department visits among oncology patients aged 65 and older"}
{"head": "pain", "relation": "is a cause of", "tail": "emergency department visits among oncology patients aged 65 and older"}
{"head": "nausea-vomiting", "relation": "is a cause of", "tail": "emergency department visits among oncology patients aged 65 and older"}
{"head": "dyspnea", "relation": "is a cause of", "tail": "emergency department visits among oncology patients aged 65 and older"}
{"head": "reason for the patient's emergency department visit", "relation": "is associated with", "tail": "patient's knowledge of when to seek medical help"}
{"head": "recurrent visits of cancer patients to emergency departments", "relation": "suggests", "tail": "inadequacy of comprehensive information available to patients and caregivers concerning pursuit of emergency medical intervention"}
{"head": "gastric venous congestion", "relation": "occurs following", "tail": "total pancreatectomy"}
{"head": "gastric venous drainage reconstruction", "relation": "prevents", "tail": "gastric venous congestion"}
{"head": "intraoperative gastric venous congestion", "relation": "necessitates", "tail": "portal vein-right gastroepiploic vein side-to-side anastomosis"}
{"head": "portal vein-right gastroepiploic vein side-to-side anastomosis", "relation": "resolves", "tail": "intraoperative gastric venous congestion"}
{"head": "portal vein-right gastroepiploic vein side-to-side anastomosis", "relation": "has no major complications in", "tail": "patients with intraoperative gastric venous congestion"}
{"head": "portal vein-right gastroepiploic vein side-to-side anastomosis", "relation": "prevents", "tail": "postoperative gastric venous congestion"}
{"head": "portal vein-right gastroepiploic vein side-to-side anastomosis", "relation": "is a useful option when", "tail": "preservation of gastric drainage veins is not feasible"}
{"head": "acidic urine", "relation": "has pH less than or equal to", "tail": "5.5"}
{"head": "acidic urine", "relation": "is associated with", "tail": "higher fasting plasma glucose levels"}
{"head": "acidic urine", "relation": "is associated with", "tail": "higher serum uric acid level"}
{"head": "acidic urine", "relation": "is associated with", "tail": "lower estimated glomerular filtration rates"}
{"head": "acidic urine", "relation": "is associated with", "tail": "higher rates of abnormal urinary cytology"}
{"head": "acidic urine group", "relation": "has lower", "tail": "recurrence-free survival rate compared to high urine pH group"}
{"head": "acidic urine", "relation": "is associated with", "tail": "disease recurrence after intravesical BCG induction for NMIBC"}
{"head": "urine pH status", "relation": "has no difference in", "tail": "disease progression"}
{"head": "oral potentially malignant disorders", "relation": "have visual quality problems", "tail": "image distortion"}
{"head": "image distortion", "relation": "leads to", "tail": "misdiagnosis"}
{"head": "image distortion", "relation": "leads to", "tail": "missed diagnosis"}
{"head": "multiscale retinex", "relation": "enhances", "tail": "original images"}
{"head": "adaptive histogram equalization", "relation": "processes", "tail": "original images"}
{"head": "adaptive contrast enhancement", "relation": "processes", "tail": "original images"}
{"head": "You Only Look Once version 8", "relation": "detects", "tail": "lesions"}
{"head": "model performance in the MSR-enhanced image set", "relation": "is superior to", "tail": "model performance in the original image set"}
{"head": "total accuracy", "relation": "increases for", "tail": "all three lesion types in MSR-enhanced image set"}
{"head": "sensitivity of complete correct recognition", "relation": "improves for", "tail": "complex multi-lesion images in MSR-enhanced image set"}
{"head": "models trained with AHE and ACE preprocessing", "relation": "show", "tail": "reduced diagnostic performance"}
{"head": "image enhancement algorithms", "relation": "enhance", "tail": "visual quality of OPMDs images"}
{"head": "MSR algorithm", "relation": "strengthens", "tail": "object detection ability in computer vision model"}
{"head": "MSR algorithm", "relation": "reduces", "tail": "misdiagnosis of OPMDs lesions"}
{"head": "MSR algorithm", "relation": "reduces", "tail": "missed diagnosis of OPMDs lesions"}
{"head": "Laparoscopic surgery", "relation": "has shorter operating time than", "tail": "Robotic surgery"}
{"head": "Robotic surgery", "relation": "has lower rate of pancreatic fistula formation than", "tail": "Laparoscopic surgery"}
{"head": "Laparoscopic surgery", "relation": "has higher blood loss than", "tail": "Robotic surgery"}
{"head": "Re-exploration rate", "relation": "is similar in", "tail": "Laparoscopic and robotic surgery"}
{"head": "Length of hospital stay", "relation": "is similar in", "tail": "Laparoscopic and robotic surgery"}
{"head": "R0 resection rate", "relation": "is similar in", "tail": "Laparoscopic and robotic surgery"}
{"head": "Rate of conversion", "relation": "is similar in", "tail": "Laparoscopic and robotic surgery"}
{"head": "Spleen preservation rate", "relation": "is similar in", "tail": "Laparoscopic and robotic surgery"}
{"head": "Chromodomain-Helicase-DNA-binding protein 1", "relation": "regulates", "tail": "chromatin dynamics"}
{"head": "Chromodomain-Helicase-DNA-binding protein 1", "relation": "influences", "tail": "gene expression"}
{"head": "Chromodomain-Helicase-DNA-binding protein 1", "relation": "influences", "tail": "DNA repair"}
{"head": "Chromodomain-Helicase-DNA-binding protein 1", "relation": "influences", "tail": "genomic stability"}
{"head": "CHD1", "relation": "acts as", "tail": "tumour suppressor in prostate cancer"}
{"head": "CHD1", "relation": "facilitates", "tail": "neuroendocrine differentiation in prostate cancer"}
{"head": "Loss of CHD1", "relation": "is linked to", "tail": "aggressive phenotypes in prostate cancer"}
{"head": "Loss of CHD1", "relation": "is linked to", "tail": "resistance to androgen receptor therapies in prostate cancer"}
{"head": "Loss of CHD1", "relation": "has synthetic lethality with", "tail": "PTEN loss in prostate cancer"}
{"head": "CHD1", "relation": "is implicated in", "tail": "breast cancer"}
{"head": "CHD1", "relation": "is implicated in", "tail": "ovarian cancer"}
{"head": "CHD1", "relation": "is implicated in", "tail": "hematological cancers"}
{"head": "CHD1", "relation": "modulates", "tail": "chromatin accessibility in breast, ovarian, and hematological cancers"}
{"head": "CHD1", "relation": "modulates", "tail": "transcription regulation in breast, ovarian, and hematological cancers"}
{"head": "CHD1", "relation": "modulates", "tail": "therapy resistance in breast, ovarian, and hematological cancers"}
{"head": "Immune effector cell-associated neurotoxicity syndrome", "relation": "is a complication of", "tail": "CD19-directed CAR T-cell therapy"}
{"head": "EEG", "relation": "is a predictive biomarker of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Refractory B-cell non-Hodgkin lymphoma patients", "relation": "undergo", "tail": "CAR T-cell therapy"}
{"head": "EEG abnormalities grade 1 and 2 pre-infusion", "relation": "are risk factors for", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Post-infusion qualitative EEG abnormalities grade 2", "relation": "are associated with higher risk of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Post-infusion qualitative EEG abnormalities grade 3", "relation": "are associated with higher risk of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Higher theta energy in post-infusion EEGs", "relation": "is associated with higher risk of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Higher delta + theta/alfa ratio in post-infusion EEGs", "relation": "is associated with higher risk of", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "Higher beta energy in post-infusion EEGs", "relation": "is protective against", "tail": "Immune effector cell-associated neurotoxicity syndrome"}
{"head": "EEG", "relation": "identifies patients at risk for", "tail": "Immune effector cell-associated neurotoxicity syndrome before CAR T-cell infusion"}
{"head": "Financial toxicity", "relation": "has prevalence of", "tail": "73.7% as per the COST-FACIT scale"}
{"head": "Financial toxicity", "relation": "has prevalence of", "tail": "66% as per the CFPB scale"}
{"head": "Higher financial toxicity on the COST-FACIT scale", "relation": "is associated with", "tail": "poor financial well-being on the CFPB scale"}
{"head": "Financial toxicity", "relation": "is associated with", "tail": "poor quality of life"}
{"head": "Financial toxicity", "relation": "is associated with", "tail": "higher distress"}
{"head": "History of tobacco chewing", "relation": "is associated with", "tail": "significantly greater financial toxicity"}
{"head": "Monthly family income less than \u20b950,000", "relation": "is associated with", "tail": "significantly greater financial toxicity"}
{"head": "Lack of health insurance", "relation": "is associated with", "tail": "significantly greater financial toxicity"}
{"head": "Illiteracy", "relation": "is associated with", "tail": "significantly greater financial toxicity"}
{"head": "Depression", "relation": "is associated with", "tail": "significantly greater financial toxicity"}
{"head": "Cognitive impairment", "relation": "is associated with", "tail": "significantly greater financial toxicity"}
{"head": "Therapy planned with palliative intent", "relation": "was in", "tail": "63.7% patients"}
{"head": "Testosterone", "relation": "influences", "tail": "development of benign prostatic hyperplasia"}
{"head": "Prostatic inflammation", "relation": "influences", "tail": "development of benign prostatic hyperplasia"}
{"head": "Testicular cancer survivors", "relation": "have incidence of", "tail": "benign prostatic hyperplasia"}
{"head": "Receipt of chemotherapy", "relation": "is not significantly associated with", "tail": "incidence of benign prostatic hyperplasia"}
{"head": "Diagnosis of hypogonadism prior to BPH", "relation": "is not significantly associated with", "tail": "incidence of benign prostatic hyperplasia"}
{"head": "Age at diagnosis", "relation": "is significantly associated with increased incidence of", "tail": "benign prostatic hyperplasia"}
{"head": "Inpatient rehabilitation", "relation": "is used for", "tail": "patients with brain metastases"}
{"head": "Patients with brain metastasis", "relation": "underwent", "tail": "inpatient rehabilitation"}
{"head": "Median length of inpatient rehabilitation", "relation": "is", "tail": "19.2 days"}
{"head": "Discharge destination after inpatient rehabilitation", "relation": "includes", "tail": "home"}
{"head": "Discharge destination after inpatient rehabilitation", "relation": "includes", "tail": "long-term care facility"}
{"head": "Discharge destination after inpatient rehabilitation", "relation": "includes", "tail": "acute care ward"}
{"head": "Discharge destination after inpatient rehabilitation", "relation": "includes", "tail": "palliative care"}
{"head": "Functional Independence Measure", "relation": "is used to assess", "tail": "function after inpatient rehabilitation"}
{"head": "Weighted average total FIM percent gain", "relation": "is", "tail": "14.9%"}
{"head": "Average FIM efficiency", "relation": "is", "tail": "0.61"}
{"head": "Weighted average motor gain", "relation": "is", "tail": "16.5%"}
{"head": "Weighted average cognitive gain", "relation": "is", "tail": "3.6%"}
{"head": "Weighted average motor gain", "relation": "is greater than", "tail": "weighted average cognitive gain"}
{"head": "Inpatient rehabilitation", "relation": "enhances", "tail": "functional status in patients with brain metastases"}
{"head": "Inpatient rehabilitation", "relation": "enhances", "tail": "independence in patients with brain metastases"}
{"head": "Resistance training", "relation": "does not significantly impact", "tail": "inflammatory markers in patients with colon cancer undergoing adjuvant chemotherapy"}
{"head": "High-sensitivity C-reactive protein (hsCRP) baseline levels", "relation": "are associated with", "tail": "relative dose intensity (RDI) >70%"}
{"head": "Changes in inflammatory markers", "relation": "are not associated with", "tail": "relative dose intensity (RDI)"}
{"head": "Highest tertiles of hsCRP, interleukin-6, and tumor necrosis factor-\u03b1 receptor-II", "relation": "are associated with", "tail": "higher baseline body mass index"}
{"head": "Highest tertiles of hsCRP, interleukin-6, and tumor necrosis factor-\u03b1 receptor-II", "relation": "are associated with", "tail": "higher total lean mass"}
{"head": "Highest tertiles of hsCRP, interleukin-6, and tumor necrosis factor-\u03b1 receptor-II", "relation": "are associated with", "tail": "higher total fat mass"}
{"head": "Ultrasound monochromatic Superb Microvascular Index", "relation": "predicts", "tail": "malignancy of solid focal lesions"}
{"head": "Vascular index", "relation": "correlates with", "tail": "bioptic histological results"}
{"head": "Monochromatic Superb Microvascular Index examination", "relation": "visualizes", "tail": "extremely low-velocity flows"}
{"head": "Vascular index", "relation": "is calculated by", "tail": "semi-automatic method"}
{"head": "Bioptic procedures", "relation": "are performed under", "tail": "ultrasound guidance"}
{"head": "Malignant lesions", "relation": "have higher vascular index than", "tail": "benign lesions"}
{"head": "Threshold vascular index value of 15.4%", "relation": "differentiates", "tail": "malignant lesions"}
{"head": "Vascular index with monochromatic Superb Microvascular Index", "relation": "has diagnostic accuracy of", "tail": "0.878"}
{"head": "Monochromatic Superb Microvascular Index analysis of solid focal lesions", "relation": "correlates with", "tail": "histological findings in terms of malignant/benign predictive value"}
{"head": "Malignant lesions", "relation": "reflect", "tail": "histological vascular changes"}
{"head": "ICRP 103 model", "relation": "estimates lower risk than", "tail": "US EPA model"}
{"head": "ICRP 103 model", "relation": "estimates lower risk than", "tail": "BEIR VII model"}
{"head": "BEIR VII model", "relation": "estimates all-cancer risk", "tail": "162.08 median"}
{"head": "BEIR VII model", "relation": "estimates leukemia risk", "tail": "24.66 median"}
{"head": "US EPA model", "relation": "estimates all-cancer risk", "tail": "139.68 median"}
{"head": "US EPA model", "relation": "estimates leukemia risk", "tail": "23.34 median"}
{"head": "ICRP 103 model", "relation": "estimates all-cancer risk", "tail": "69.05 median"}
{"head": "ICRP 103 model", "relation": "estimates leukemia risk", "tail": "8.22 median"}
{"head": "Different oncogenic risk models", "relation": "estimate different", "tail": "organ, leukemia, and all-cancer risk values"}
{"head": "Intraclass correlation coefficient", "relation": "shows agreement between", "tail": "different risk models"}
{"head": "Friedman test", "relation": "compares risk values between", "tail": "different models"}
{"head": "Ion channels", "relation": "play crucial roles in", "tail": "tumor progression"}
{"head": "Ion channels", "relation": "regulate", "tail": "proliferation"}
{"head": "Ion channels", "relation": "regulate", "tail": "apoptosis"}
{"head": "Ion channels", "relation": "regulate", "tail": "migration"}
{"head": "Ion channels", "relation": "regulate", "tail": "metastasis"}
{"head": "Voltage-gated potassium (Kv) channels", "relation": "are implicated in", "tail": "oncogenic signaling pathways"}
{"head": "Voltage-gated sodium (Nav) channels", "relation": "are implicated in", "tail": "oncogenic signaling pathways"}
{"head": "Scorpion venom peptides", "relation": "have", "tail": "selective ion-channel-blocking properties"}
{"head": "Scorpion venom peptides", "relation": "demonstrate", "tail": "antineoplastic activity"}
{"head": "Bioactive fractions derived from Chihuahuanus coahuilae", "relation": "have potential therapeutic applications in", "tail": "breast cancer cell lines"}
{"head": "Venom-derived peptides", "relation": "interfere with", "tail": "cancer cell homeostasis"}
{"head": "Venom-derived peptides", "relation": "alter", "tail": "ion fluxes"}
{"head": "Venom-derived peptides", "relation": "promote", "tail": "apoptosis"}
{"head": "Venom-derived peptides", "relation": "inhibit", "tail": "metastatic traits"}
{"head": "Ion-channel-targeting peptides", "relation": "have", "tail": "therapeutic potential as selective anticancer agents"}
{"head": "Vipera ammodytes venom", "relation": "contains", "tail": "Phospholipases A2"}
{"head": "Vipera ammodytes venom", "relation": "contains", "tail": "C-type lectins"}
{"head": "Vipera ammodytes venom", "relation": "contains", "tail": "metalloproteinases"}
{"head": "Phospholipases A2", "relation": "have", "tail": "cytotoxic properties"}
{"head": "C-type lectins", "relation": "have", "tail": "anti-proliferative properties"}
{"head": "metalloproteinases", "relation": "have", "tail": "tumor-inhibiting properties"}
{"head": "Vipera ammodytes venom", "relation": "is cytotoxic to", "tail": "melanoma cell lines M001, Me501, and A375"}
{"head": "Vipera ammodytes venom", "relation": "has IC50 value of", "tail": "approximately 1.1 \u00b5g/mL in melanoma cell lines"}
{"head": "Combined treatment with Vipera ammodytes venom and cisplatin", "relation": "increases", "tail": "cytotoxicity compared to single-agent treatments"}
{"head": "Vipera ammodytes venom", "relation": "enhances sensitivity of", "tail": "cisplatin in resistant melanoma cell lines M001 and Me501"}
{"head": "Vipera ammodytes venom and cisplatin combination", "relation": "increases", "tail": "cell mortality by up to 40% in resistant melanoma cell lines"}
{"head": "A375 cell line", "relation": "is inherently more sensitive to", "tail": "cisplatin"}
{"head": "Vipera ammodytes venom", "relation": "induces", "tail": "morphological changes in melanoma cells"}
{"head": "Vipera ammodytes venom components", "relation": "selectively target", "tail": "melanoma cells in muscle-associated metastases"}
{"head": "Cisplatin", "relation": "has established", "tail": "cytotoxicity"}
{"head": "MyPal project", "relation": "provides", "tail": "palliative care support for patients with cancer"}
{"head": "MyPal project", "relation": "uses", "tail": "electronic patient-reported outcomes eHealth platform"}
{"head": "MyPal for adults", "relation": "is", "tail": "co-designed palliative care mobile app"}
{"head": "MyPal for adults", "relation": "supports", "tail": "adults with cancer"}
{"head": "participants", "relation": "found", "tail": "intervention content useful"}
{"head": "participants", "relation": "reported", "tail": "satisfactory usability"}
{"head": "Post-Study System Usability Questionnaire score", "relation": "is", "tail": "2.458"}
{"head": "System Usability Scale score", "relation": "is", "tail": "68.9"}
{"head": "User Experience Questionnaire aspects", "relation": "surpassed", "tail": "usability quality benchmarks"}
{"head": "qualitative analysis", "relation": "identified", "tail": "43 usability issues"}
{"head": "usability issues", "relation": "related to", "tail": "effectiveness and efficiency as defined in ISO 9241-210"}
{"head": "MyPal for adults app", "relation": "is", "tail": "digital tool designed to enhance the palliative care experience"}
{"head": "study findings", "relation": "reveal", "tail": "user-friendly interface"}
{"head": "study findings", "relation": "reveal", "tail": "positive patient experiences"}
{"head": "Bronchial sleeve lobectomies", "relation": "are", "tail": "technically challenging procedures"}
{"head": "Robotic technique", "relation": "provides", "tail": "advantages for anastomosis"}
{"head": "Uniportal robotic sleeve lower lobectomy", "relation": "is performed for", "tail": "endobronchial tumour of the lower lobe"}
{"head": "Endobronchial tumour of the lower lobe", "relation": "extends to", "tail": "distal end of the intermediate bronchus"}
{"head": "4-cm skin incision", "relation": "is made at", "tail": "sixth intercostal space in the middle axillary line"}
{"head": "30-degree 10-mm camera", "relation": "is placed on", "tail": "posterior edge of the incision"}
{"head": "Right lower sleeve lobectomy", "relation": "is performed with", "tail": "end-to-end anastomosis between proximal intermediate bronchial stump and middle lobe bronchial stump"}
{"head": "Postoperative endobronchial examination", "relation": "shows", "tail": "well-done anastomosis"}
{"head": "Patient", "relation": "is discharged on", "tail": "postoperative day 5"}
{"head": "Histologic examination", "relation": "confirms diagnosis of", "tail": "2-cm atypical carcinoid without lymph node involvement"}
{"head": "Glioblastoma", "relation": "is a type of", "tail": "brain cancer"}
{"head": "Glioblastoma", "relation": "has characteristic", "tail": "low survival rate"}
{"head": "Glioblastoma", "relation": "has characteristic", "tail": "frequently invasive"}
{"head": "Epithelial-mesenchymal transition biomarkers", "relation": "are modulated in", "tail": "glioblastoma cells"}
{"head": "Epithelial-mesenchymal transition biomarkers", "relation": "are associated with", "tail": "tumor progression"}
{"head": "Epithelial-mesenchymal transition biomarkers", "relation": "are associated with", "tail": "chemoresistance"}
{"head": "Epithelial-mesenchymal transition biomarkers", "relation": "are associated with", "tail": "relapse after treatment"}
{"head": "Marine eukaryotic microalgae", "relation": "are source of", "tail": "anticancer drugs"}
{"head": "Dinoflagellates of species Amphidinium carterae", "relation": "produce", "tail": "neurotoxins"}
{"head": "Dinoflagellates of species Amphidinium carterae", "relation": "produce", "tail": "cytotoxic compounds"}
{"head": "Chemical extracts from Amphidinium carterae strains", "relation": "modulate", "tail": "EMT markers in T98G human GBM cells"}
{"head": "Chemical extracts from Amphidinium carterae strains", "relation": "modulate", "tail": "proliferation capability of GBM cells"}
{"head": "Chemical extracts from Amphidinium carterae strains", "relation": "modulate", "tail": "migration capability of GBM cells"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "inhibit", "tail": "cell viability in A549 and H460 cells"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "reduce", "tail": "cell viability to 38.6% in A549-Ctr cells at 40 \u00b5g/mL after 48 h"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "reduce", "tail": "cell viability to 37.2% in A549-CR cells at 40 \u00b5g/mL after 48 h"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "reduce", "tail": "cell viability to 28.4% in H460-Ctr cells at 40 \u00b5g/mL after 48 h"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "reduce", "tail": "cell viability to 30.4% in H460-CR cells at 40 \u00b5g/mL after 48 h"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "suppress", "tail": "colony formation by over 90% in 2D and soft agar assays"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "show no cytotoxicity", "tail": "normal human keratinocytes up to 80 \u00b5g/mL"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "induce", "tail": "G1 phase arrest in A549-Ctr and A549-CR cells"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "cyclin D1"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "CDK4"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "cyclin E"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "downregulate", "tail": "CDK2"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "decrease", "tail": "phosphorylated STAT3 expression"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "decrease", "tail": "c-Myc expression"}
{"head": "STAT3 knockdown", "relation": "phenocopy", "tail": "effects of Allium pseudojaponicum Makino extracts"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "target", "tail": "STAT3 signaling pathway"}
{"head": "lycorine", "relation": "is a major compound in", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "tazettine", "relation": "is a major compound in", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "tricetin", "relation": "is a major compound in", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "alkaloids", "relation": "constitute 71.65% of", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "flavonoids", "relation": "constitute 8.81% of", "tail": "Allium pseudojaponicum Makino extracts"}
{"head": "Allium pseudojaponicum Makino extracts", "relation": "overcome", "tail": "cisplatin resistance in non-small-cell lung cancer"}
{"head": "Xanthocillin X dimethyl ether", "relation": "is isolated from", "tail": "Scedosporium apiospermum"}
{"head": "Xanthocillin X dimethyl ether", "relation": "binds to", "tail": "hemin"}
{"head": "Xanthocillin X dimethyl ether", "relation": "depletes", "tail": "intracellular regulatory heme"}
{"head": "Xanthocillin X dimethyl ether", "relation": "translocates into", "tail": "mitochondria"}
{"head": "Xanthocillin X dimethyl ether", "relation": "interacts with", "tail": "mitochondrial cytochromes"}
{"head": "Xanthocillin X dimethyl ether", "relation": "disrupts", "tail": "electron transport chain"}
{"head": "Xanthocillin X dimethyl ether", "relation": "inhibits activity of", "tail": "mitochondrial complexes"}
{"head": "Xanthocillin X dimethyl ether", "relation": "inactivates", "tail": "mitochondrial respiration"}
{"head": "Xanthocillin X dimethyl ether", "relation": "exhibits anti-proliferative effect on", "tail": "triple-negative breast cancer"}
{"head": "Resistance to PARP inhibitors", "relation": "is a challenge in", "tail": "ovarian cancer treatment"}
{"head": "Gukulenin A", "relation": "is isolated from", "tail": "marine sponge Phorbas gukhulensis"}
{"head": "Gukulenin A", "relation": "enhances", "tail": "olaparib-induced cytotoxicity in human ovarian cancer cells"}
{"head": "Combination treatment of Gukulenin A and olaparib", "relation": "increases", "tail": "reactive oxygen species levels"}
{"head": "Combination treatment of Gukulenin A and olaparib", "relation": "increases", "tail": "lipid peroxidation"}
{"head": "Combination treatment of Gukulenin A and olaparib", "relation": "induces", "tail": "ferroptotic cell death"}
{"head": "Combination treatment of Gukulenin A and olaparib", "relation": "does not induce", "tail": "apoptotic cell death"}
{"head": "Oxidative stress-related pathways", "relation": "mediate", "tail": "effect of combination treatment"}
{"head": "Inhibition of NADPH oxidase", "relation": "reverses", "tail": "combination-induced cell death"}
{"head": "Ferrostatin-1", "relation": "reduces", "tail": "lipid peroxidation and cytotoxicity induced by combination treatment"}
{"head": "Gukulenin A and olaparib treatment", "relation": "suppresses", "tail": "ERK1/2 activation"}
{"head": "ERK overexpression", "relation": "attenuates", "tail": "combination-induced cell death"}
{"head": "Marine-derived Gukulenin A", "relation": "enhances", "tail": "PARP inhibitor efficacy in ovarian cancer cells"}
{"head": "Marine-derived Gukulenin A", "relation": "induces", "tail": "ferroptosis through oxidative stress and ERK pathway modulation"}
{"head": "Colorectal cancer", "relation": "is", "tail": "third most common malignancy"}
{"head": "Marine-derived quinolone alkaloids", "relation": "exhibit", "tail": "antitumor properties"}
{"head": "Compounds 1-13", "relation": "were semi-synthesized based on", "tail": "4'-desmethoxyyaequinolone J1"}
{"head": "4'-desmethoxyyaequinolone J1", "relation": "is", "tail": "4-phenyl derivative of yaequinolone J1"}
{"head": "Yaequinolone J1", "relation": "was isolated from", "tail": "Penicillium sp. FKI-2140"}
{"head": "CHNQD-02792 (13)", "relation": "has most sensitivity to", "tail": "HT-29 cells"}
{"head": "CHNQD-02792 (13)", "relation": "has IC50", "tail": "4.5 \u03bcM in HT-29 cells"}
{"head": "5-fluorouracil", "relation": "has IC50", "tail": "15.58 \u03bcM in HT-29 cells"}
{"head": "CHNQD-02792", "relation": "completely inhibited growth of", "tail": "HT-29 cells at 9 \u03bcM"}
{"head": "CHNQD-02792 (4.5 \u03bcM)", "relation": "inhibited expression of", "tail": "CDK1 in HT-29 cells"}
{"head": "CHNQD-02792 (4.5 \u03bcM)", "relation": "triggered", "tail": "G2/M phase arrest in HT-29 cells"}
{"head": "CHNQD-02792", "relation": "induced apoptosis by suppressing", "tail": "Bcl-2"}
{"head": "CHNQD-02792", "relation": "induced apoptosis by upregulating", "tail": "Caspase-3"}
{"head": "CHNQD-02792", "relation": "induced apoptosis by upregulating", "tail": "Bax"}
{"head": "CHNQD-02792", "relation": "inhibited phosphorylation of", "tail": "ERK"}
{"head": "CHNQD-02792", "relation": "inhibited phosphorylation of", "tail": "JNK"}
{"head": "CHNQD-02792", "relation": "regulates", "tail": "MAPK signaling"}
{"head": "CHNQD-02792", "relation": "exerts cytotoxic effects on", "tail": "HT-29 cells"}
{"head": "CHNQD-02792", "relation": "induces", "tail": "G2/M arrest in HT-29 cells"}
{"head": "CHNQD-02792", "relation": "induces", "tail": "apoptosis in HT-29 cells"}
{"head": "CHNQD-02792", "relation": "regulates MAPK signaling through", "tail": "ERK/JNK dephosphorylation"}
{"head": "CD4+ T cells", "relation": "activate cytotoxicity of", "tail": "CD8+ T cells"}
{"head": "CD8+ T cells", "relation": "interact with", "tail": "CD4+ T cells after cryo-thermal therapy"}
{"head": "Activated CD4+ and CD8+ T cells", "relation": "are critical for", "tail": "CTT-induced antitumor immunity"}
{"head": "Interaction between activated T cells", "relation": "is enhanced", "tail": ""}
{"head": "Activated CD8+ and CD4+ T cells", "relation": "reciprocally regulate each other through", "tail": "LFA-1/ICAM-1 interactions"}
{"head": "CD8+ T cells", "relation": "facilitate Notch1-dependent differentiation of", "tail": "CD4+ Th1-dominant cells"}
{"head": "CD8+ T cells", "relation": "promote IL-2 secretion of", "tail": "CD4+ T cells"}
{"head": "IL-2 derived from CD4+ T cells", "relation": "enhances cytotoxicity of", "tail": "CD8+ T cells"}
{"head": "IL-2 derived from CD4+ T cells", "relation": "increases expression of", "tail": "LFA-1 and ICAM-1 on T cells"}
{"head": "LFA-1/ICAM interactions between CD4+ and CD8+ T cells", "relation": "are correlated with", "tail": "clinical outcomes"}
{"head": "LFA-1/ICAM-1 adhesion pathway", "relation": "functions in interaction of", "tail": "CD4+ and CD8+ T cells"}
{"head": "miR-146a", "relation": "plays a role in", "tail": "breast cancer"}
{"head": "SNP rs2910164:G>C", "relation": "is linked to", "tail": "breast cancer risk"}
{"head": "rs2910164:G>C", "relation": "is associated with", "tail": "increased breast cancer risk in early-onset sporadic breast cancer patients"}
{"head": "rs2910164:G>C", "relation": "upregulates expression of", "tail": "mature miR-146a sequences 3p and 5p"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "proliferation in luminal A and triple-negative breast cancer cells"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "migration in luminal A and triple-negative breast cancer cells"}
{"head": "pre-miR-146a-C", "relation": "enhances", "tail": "invasion in luminal A and triple-negative breast cancer cells"}
{"head": "pre-miR-146a-C", "relation": "decreases", "tail": "cisplatin-induced apoptosis in luminal A and triple-negative breast cancer cells"}
{"head": "pre-miR-146a C allele", "relation": "decreases", "tail": "cisplatin resistance in MCF-7 cells"}
{"head": "pre-miR-146a C allele", "relation": "increases", "tail": "cisplatin resistance in MDA-MB-231 cells"}
{"head": "rs2910164 C allele", "relation": "promotes", "tail": "miR-146a overexpression"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "proliferation"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "migration"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "invasion"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "apoptosis suppression"}
{"head": "miR-146a overexpression", "relation": "is involved in", "tail": "cisplatin resistance"}
{"head": "Paclitaxel", "relation": "improves", "tail": "overall survival of non-small cell lung cancer patients"}
{"head": "AdipoRon", "relation": "is", "tail": "adiponectin receptor agonist"}
{"head": "AdipoRon", "relation": "is", "tail": "anticancer compound in non-small cell lung cancer"}
{"head": "combination of AdipoRon and Paclitaxel", "relation": "inhibits", "tail": "cell growth in non-small cell lung cancer cells"}
{"head": "combination of AdipoRon and Paclitaxel", "relation": "inhibits", "tail": "clonogenic potential in non-small cell lung cancer cells"}
{"head": "combination of AdipoRon and Paclitaxel", "relation": "induces", "tail": "cell death in non-small cell lung cancer cells"}
{"head": "combination of AdipoRon and Paclitaxel", "relation": "causes cleavage of", "tail": "poly-ADP ribose polymerase"}
{"head": "combination of AdipoRon and Paclitaxel", "relation": "causes cleavage of", "tail": "caspase-3 apoptotic markers"}
{"head": "AMP-activated protein kinase", "relation": "is critical sensor in", "tail": "combination of AdipoRon and Paclitaxel efficacy"}
{"head": "inhibition of AMP-activated protein kinase by Compound-C", "relation": "rescues", "tail": "cell growth in non-small cell lung cancer cells treated with combination of AdipoRon and Paclitaxel"}
{"head": "combination of AdipoRon and Paclitaxel", "relation": "causes downregulation of", "tail": "extracellular signal-regulated kinase 1/2"}
{"head": "hindrance of extracellular signal-regulated kinase 1/2 cascade by PD98059", "relation": "counteracts", "tail": "effects of combination of AdipoRon and Paclitaxel"}
{"head": "Hepatocyte nuclear factor 4\u03b1", "relation": "is a member of", "tail": "nuclear receptor superfamily of transcription factors"}
{"head": "Hepatocyte nuclear factor 4\u03b1", "relation": "is a therapeutic candidate for", "tail": "colorectal adenocarcinoma"}
{"head": "HNF4\u03b1", "relation": "exhibits upregulation during", "tail": "carcinogenesis"}
{"head": "HNF4\u03b1 overexpression", "relation": "promotes or suppresses", "tail": "CRAC cell migration and invasion"}
{"head": "HNF4\u03b1 inhibition", "relation": "promotes or suppresses", "tail": "CRAC cell migration and invasion"}
{"head": "HNF4\u03b1 levels", "relation": "are diminished in", "tail": "metastatic and poorly differentiated CRAC"}
{"head": "HNF4\u03b1 levels", "relation": "are higher in", "tail": "primary CRAC samples"}
{"head": "Reduced HNF4\u03b1 levels", "relation": "are associated with", "tail": "unfavorable prognostic factors"}
{"head": "HNF4\u03b1 inhibition", "relation": "induces decrease in", "tail": "NF-\u03bab protein levels"}
{"head": "HNF4\u03b1 inhibition", "relation": "induces increase in", "tail": "YAP"}
{"head": "HNF4\u03b1 overexpression", "relation": "is linked to", "tail": "early carcinogenesis"}
{"head": "Reduced HNF4\u03b1 expression", "relation": "is associated with", "tail": "progression and metastasis of CRAC"}
{"head": "Tumor metabolism", "relation": "is a target in", "tail": "cancer therapy"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "affects", "tail": "cellular and molecular processes"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "plays a role in", "tail": "cancer cell metabolism"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "regulates", "tail": "balance between glycolysis and antioxidant defense mechanisms"}
{"head": "Cancer cells", "relation": "exhibit", "tail": "shift towards aerobic glycolysis"}
{"head": "Aerobic glycolysis", "relation": "allows", "tail": "rapid energy production"}
{"head": "Aerobic glycolysis", "relation": "gives rise to", "tail": "biosynthetic intermediates for proliferation"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "inhibits", "tail": "glycolysis"}
{"head": "Inhibition of glycolysis by TP53 inducible glycolysis and apoptosis regulator", "relation": "reduces", "tail": "proliferation rate of cancer cells"}
{"head": "Metabolic shift caused by TP53 inducible glycolysis and apoptosis regulator", "relation": "exerts", "tail": "tumor-suppressive effect"}
{"head": "Metabolic shift caused by TP53 inducible glycolysis and apoptosis regulator", "relation": "leads to", "tail": "increased levels of reactive oxygen species"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "promotes", "tail": "pentose phosphate pathway"}
{"head": "Pentose phosphate pathway", "relation": "generates", "tail": "NADPH"}
{"head": "NADPH", "relation": "is involved in", "tail": "antioxidant defense"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "decreases", "tail": "glycolytic flux"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "increases", "tail": "diversion of glucose-6-phosphate into pentose phosphate pathway"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "reduces", "tail": "reactive oxygen species levels"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "supports", "tail": "biosynthesis and cell survival"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "maintains", "tail": "balance of nucleotides and lipids"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "is a prognostic target in", "tail": "different types of cancers"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "is a potential therapeutic target in", "tail": "different types of cancers"}
{"head": "TP53 inducible glycolysis and apoptosis regulator", "relation": "is a diagnostic marker in", "tail": "different types of cancers"}
{"head": "Endometrial cancer", "relation": "is a common malignancy in", "tail": "women in developed countries"}
{"head": "Patients in early stages of endometrial cancer", "relation": "show better responses to", "tail": "surgery"}
{"head": "Patients in early stages of endometrial cancer", "relation": "show better responses to", "tail": "adjuvant hormonal therapy"}
{"head": "Patients in early stages of endometrial cancer", "relation": "show better responses to", "tail": "chemotherapy"}
{"head": "Patients with recurrence of endometrial cancer", "relation": "show", "tail": "treatment resistance"}
{"head": "Cancer stem cells", "relation": "are focused on in treatment of", "tail": "gynecologic cancer"}
{"head": "Cancer stem cells", "relation": "are focused on in treatment of", "tail": "endometrial cancer"}
{"head": "Cancer stem cells", "relation": "have resistance to", "tail": "conventional therapies"}
{"head": "Conventional therapies", "relation": "include", "tail": "chemotherapy"}
{"head": "Conventional therapies", "relation": "include", "tail": "radiotherapy"}
{"head": "Cancer stem cells", "relation": "induce", "tail": "progression of malignancy"}
{"head": "Cancer stem cells", "relation": "induce", "tail": "recurrence of malignancy"}
{"head": "Activation of WNT pathway", "relation": "could be basis of abilities of", "tail": "cancer stem cells"}
{"head": "Activation of PI3K pathway", "relation": "could be basis of abilities of", "tail": "cancer stem cells"}
{"head": "Activation of NF-kB pathway", "relation": "could be basis of abilities of", "tail": "cancer stem cells"}
{"head": "Activation of NOTCH pathway", "relation": "could be basis of abilities of", "tail": "cancer stem cells"}
{"head": "Specific markers and signaling pathways of cancer stem cells", "relation": "could be", "tail": "treatment targets for cancer stem cells"}
{"head": "Glioma stem cells", "relation": "express", "tail": "immunosuppressive effectors mimicking regulatory T cells"}
{"head": "Immunosuppressive Treg-like GSC state", "relation": "is specific to", "tail": "mesenchymal GSC subset"}
{"head": "Immunosuppressive Treg-like GSC state", "relation": "is driven by", "tail": "TGF\u03b2 type II receptor (TGFBR2)"}
{"head": "Immunosuppressive Treg-like GSC state", "relation": "is not driven by", "tail": "TGFBR1"}
{"head": "Transgenic TGFBR2 expression in patient-derived GBM neurospheres", "relation": "promotes", "tail": "mesenchymal transition"}
{"head": "Transgenic TGFBR2 expression in patient-derived GBM neurospheres", "relation": "induces", "tail": "six-gene ITL signature"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "CD274 (PD-L1)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "NT5E (CD73)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "ENTPD1 (CD39)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "LGALS1 (galectin-1)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "PDCD1LG2 (PD-L2)"}
{"head": "Six-gene ITL signature", "relation": "consists of", "tail": "TGFB1"}
{"head": "TGFBR2-driven ITL signature", "relation": "is identified in", "tail": "clinical GBM specimens"}
{"head": "TGFBR2-driven ITL signature", "relation": "is identified in", "tail": "patient-derived GSCs"}
{"head": "TGFBR2-driven ITL signature", "relation": "is identified in", "tail": "systemic mesenchymal malignancies"}
{"head": "TGFBR2high GSCs", "relation": "inhibit", "tail": "CD4+ T cell viability"}
{"head": "TGFBR2high GSCs", "relation": "inhibit", "tail": "CD8+ T cell viability"}
{"head": "TGFBR2high GSCs", "relation": "inhibit", "tail": "CD4+ and CD8+ T cell capacity to kill GBM cells"}
{"head": "Pharmacologic and shRNA-based TGFBR2 inhibition", "relation": "reverses", "tail": "inhibition of CD4+ and CD8+ T cell viability and function by TGFBR2high GSCs"}
{"head": "Immunosuppressive GSC state", "relation": "is TGFBR2-dependent", "tail": "true"}
{"head": "Immunosuppressive GSC state", "relation": "is susceptible to", "tail": "TGFBR2-targeted therapeutics"}
{"head": "HMGB1", "relation": "is overexpressed in", "tail": "various cancers"}
{"head": "HMGB1", "relation": "is linked to", "tail": "tumor progression"}
{"head": "HMGB1", "relation": "binds to", "tail": "RAGE"}
{"head": "HMGB1-RAGE signaling pathway", "relation": "promotes", "tail": "metastasis"}
{"head": "Metformin", "relation": "interacts with", "tail": "HMGB1"}
{"head": "Metformin", "relation": "inhibits", "tail": "HMGB1 pro-inflammatory functions"}
{"head": "Metformin", "relation": "reduces", "tail": "HMGB1-induced cell migration"}
{"head": "Metformin", "relation": "reduces", "tail": "cell proliferation"}
{"head": "Metformin", "relation": "decreases", "tail": "RAGE stabilization on the cell membrane"}
{"head": "Metformin", "relation": "disrupts", "tail": "NF-\u03baB signaling"}
{"head": "Metformin", "relation": "reverses", "tail": "epithelial-to-mesenchymal transition"}
{"head": "Metformin", "relation": "increases", "tail": "E-cadherin"}
{"head": "Metformin", "relation": "reduces", "tail": "vimentin"}
{"head": "Metformin", "relation": "stabilizes", "tail": "\u03b2-catenin at the cell membrane"}
{"head": "Metformin", "relation": "lowers", "tail": "HMGB1 protein levels"}
{"head": "Metformin", "relation": "lowers", "tail": "RAGE protein levels"}
{"head": "HMGB1/RAGE signaling pathway", "relation": "promotes", "tail": "cancer aggressiveness"}
{"head": "Metformin", "relation": "inhibits", "tail": "HMGB1/RAGE-driven metastasis"}
{"head": "Metformin", "relation": "is a therapeutic agent in", "tail": "triple-negative breast cancer"}
{"head": "Cancer cells", "relation": "need to be softer to migrate and invade tissues", "tail": "Cancer metastasis"}
{"head": "Softness of cancer cells", "relation": "serves as", "tail": "Universal physical marker for malignancy of cancer types"}
{"head": "Stiffer cancer cells", "relation": "are more migratory and invasive", "tail": "Cancer metastasis"}
{"head": "Stiffer cancer cells", "relation": "lead to", "tail": "More metastases"}
{"head": "Biophysical techniques", "relation": "affect", "tail": "Mechanical properties of cancer cells"}
{"head": "Culture and measurement conditions of cancer cells", "relation": "influence", "tail": "Mechanical measurements of cancer cells"}
{"head": "Microenvironment", "relation": "affects", "tail": "Mechanical characteristics of cancer cells"}
{"head": "ECM involvement, cell associations, biological multi-omics analyses, dynamic-mechanical analysis of cancer cells", "relation": "determine", "tail": "Malignant potential of tumors"}
{"head": "Malignant pleural mesothelioma", "relation": "is a", "tail": "aggressive cancer of the pleural lining"}
{"head": "Malignant pleural mesothelioma", "relation": "is associated with", "tail": "asbestos exposure"}
{"head": "Epithelial-mesenchymal transition", "relation": "drives", "tail": "Malignant pleural mesothelioma pathogenesis"}
{"head": "Epithelial-mesenchymal transition", "relation": "drives", "tail": "Malignant pleural mesothelioma metastasis"}
{"head": "Epithelial-mesenchymal transition", "relation": "drives", "tail": "Malignant pleural mesothelioma resistance to therapy"}
{"head": "TGF-\u03b2 signaling pathway", "relation": "is involved in", "tail": "epithelial-mesenchymal transition in Malignant pleural mesothelioma"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "is involved in", "tail": "epithelial-mesenchymal transition in Malignant pleural mesothelioma"}
{"head": "PI3K/Akt signaling pathway", "relation": "is involved in", "tail": "epithelial-mesenchymal transition in Malignant pleural mesothelioma"}
{"head": "EMT-related biomarkers", "relation": "have", "tail": "diagnostic and prognostic significance in Malignant pleural mesothelioma"}
{"head": "Targeted therapies", "relation": "aim at", "tail": "reversing epithelial-mesenchymal transition"}
{"head": "Targeted therapies", "relation": "exploit", "tail": "epithelial-mesenchymal transition-induced vulnerabilities"}
{"head": "MARS 2 trial", "relation": "is a", "tail": "clinical trial for Malignant pleural mesothelioma treatment"}
{"head": "Bone morphogenetic proteins", "relation": "regulate", "tail": "developmental processes such as limb, kidney and lung formation, cell fate determination, cell proliferation, and apoptosis"}
{"head": "Cancer stem cells", "relation": "are", "tail": "a subpopulation of self-renewing cells within tumors that possess stemness properties and a tumor cell-forming capability"}
{"head": "Cancer stem cells", "relation": "are linked to", "tail": "growth, metastasis, treatment resistance and cancer recurrence"}
{"head": "Tumor microenvironment", "relation": "plays role in", "tail": "onset, progression and treatment resistance in many cancers"}
{"head": "Bone morphogenetic proteins and growth differentiation factors", "relation": "counterbalance", "tail": "transforming growth factor-beta in maintenance of CSC pluripotency and cancer cell differentiation"}
{"head": "BMP signaling", "relation": "functions as", "tail": "tumor suppressor in various cancers"}
{"head": "BMP signaling", "relation": "induces", "tail": "CSC differentiation"}
{"head": "BMP signaling", "relation": "suppresses", "tail": "stemness characteristics"}
{"head": "CSC differentiation", "relation": "curtails", "tail": "self-renewal capacity of CSCs"}
{"head": "GREMLIN1", "relation": "is", "tail": "a secreted antagonist of BMPs"}
{"head": "GREMLIN1", "relation": "is overexpressed in", "tail": "human cancers such as gastric, colorectal, glioblastoma, and breast cancer"}
{"head": "GREMLIN1 overexpression", "relation": "inhibits", "tail": "BMP signaling"}
{"head": "GREMLIN1 overexpression", "relation": "facilitates", "tail": "maintenance of pluripotency in CSCs"}
{"head": "GREMLIN1 overexpression", "relation": "promotes", "tail": "tumorigenesis"}
{"head": "GREMLIN1 overexpression", "relation": "contributes to", "tail": "CSC immune evasion"}
{"head": "GREMLIN1", "relation": "is target of", "tail": "fibroblast growth factor to Sonic hedgehog signaling"}
{"head": "GREMLIN1", "relation": "is target of", "tail": "Wnt/Frizzled pathway"}
{"head": "Fibroblast growth factor to Sonic hedgehog signaling and Wnt/Frizzled pathway", "relation": "contribute to", "tail": "maintenance of CSC stemness"}
{"head": "Inhibiting GREMLIN1", "relation": "may hold promise for", "tail": "novel therapeutic strategies aimed at reducing CSC burden in cancers and improving patient outcomes"}
{"head": "Colorectal cancer", "relation": "is", "tail": "malignant pathology"}
{"head": "Drug resistance", "relation": "contributes to", "tail": "poor prognosis of neoplastic diseases"}
{"head": "Drug resistance", "relation": "reduces", "tail": "utility of therapeutic protocols"}
{"head": "Autophagy", "relation": "maintains", "tail": "nutrient recycling"}
{"head": "Autophagy", "relation": "maintains", "tail": "metabolic adaptation"}
{"head": "Autophagy", "relation": "is related to", "tail": "carcinogenesis"}
{"head": "Autophagy inhibition", "relation": "limits", "tail": "tumor growth"}
{"head": "Autophagy inhibition", "relation": "improves", "tail": "response to cancer therapeutics"}
{"head": "Lysosomes", "relation": "are key players in", "tail": "autophagy"}
{"head": "Lysosomes", "relation": "are targets for", "tail": "anticancer treatment"}
{"head": "Lysosome-associated membrane glycoproteins (LAMPs)", "relation": "are related to", "tail": "autophagy"}
{"head": "Lysosome-associated membrane glycoproteins (LAMPs)", "relation": "are involved in", "tail": "autophagy"}
{"head": "Lysosome-associated membrane glycoproteins (LAMPs)", "relation": "are involved in", "tail": "cancer development"}
{"head": "LAMPs", "relation": "drive", "tail": "drug resistance in colorectal cancer"}
{"head": "Allogeneic hematopoietic stem cell transplantation", "relation": "treats", "tail": "acute myeloid leukemia"}
{"head": "Risk stratification", "relation": "includes", "tail": "molecular profiling"}
{"head": "Risk stratification", "relation": "includes", "tail": "measurable residual disease assessment"}
{"head": "Post-transplant cyclophosphamide", "relation": "prevents", "tail": "graft-versus-host disease"}
{"head": "Advances in risk stratification", "relation": "improve", "tail": "outcomes"}
{"head": "Advances in conditioning regimens", "relation": "improve", "tail": "outcomes"}
{"head": "Advances in graft-versus-host disease prophylaxis", "relation": "improve", "tail": "outcomes"}
{"head": "Advances in risk stratification", "relation": "expand", "tail": "donor selection"}
{"head": "Advances in conditioning regimens", "relation": "expand", "tail": "donor selection"}
{"head": "Advances in graft-versus-host disease prophylaxis", "relation": "expand", "tail": "donor selection"}
{"head": "Advances in risk stratification", "relation": "expand", "tail": "transplant eligibility"}
{"head": "Advances in conditioning regimens", "relation": "expand", "tail": "transplant eligibility"}
{"head": "Advances in graft-versus-host disease prophylaxis", "relation": "expand", "tail": "transplant eligibility"}
{"head": "Chemotherapy", "relation": "is a component of", "tail": "leukemia treatment"}
{"head": "Targeted therapy", "relation": "is a component of", "tail": "leukemia treatment"}
{"head": "Post-transplant maintenance therapy", "relation": "is a component of", "tail": "leukemia treatment"}
{"head": "Artesunate", "relation": "inhibits", "tail": "metastatic potential in cisplatin-resistant bladder cancer cells"}
{"head": "Artesunate", "relation": "inhibits", "tail": "growth in cisplatin-sensitive bladder cancer cells"}
{"head": "Artesunate", "relation": "inhibits", "tail": "growth in cisplatin-resistant bladder cancer cells"}
{"head": "Artesunate", "relation": "reduces", "tail": "tumor cell adhesion to vascular endothelium in parental bladder cancer cells"}
{"head": "Artesunate", "relation": "reduces", "tail": "tumor cell adhesion to vascular endothelium in cisplatin-resistant bladder cancer cells"}
{"head": "Artesunate", "relation": "reduces", "tail": "tumor cell adhesion to immobilized collagen in parental bladder cancer cells"}
{"head": "Artesunate", "relation": "reduces", "tail": "tumor cell adhesion to immobilized collagen in cisplatin-resistant bladder cancer cells"}
{"head": "Artesunate", "relation": "suppresses", "tail": "tumor cell motility depending on cell type"}
{"head": "Artesunate", "relation": "diminishes", "tail": "integrin expression on bladder cancer cells"}
{"head": "Functional blocking of integrins altered by Artesunate", "relation": "reduces", "tail": "cell adhesion of bladder cancer cells"}
{"head": "Functional blocking of integrins altered by Artesunate", "relation": "reduces", "tail": "invasion of bladder cancer cells"}
{"head": "Artesunate", "relation": "inhibits", "tail": "metastatic potential of parental bladder cancer cells"}
{"head": "Artesunate", "relation": "inhibits", "tail": "metastatic potential of cisplatin-resistant bladder cancer cells"}
{"head": "Systemic lupus erythematosus", "relation": "increases", "tail": "radiosensitivity"}
{"head": "SLE patients", "relation": "have higher background rates of", "tail": "chromosomal aberrations than healthy individuals"}
{"head": "SLE patients", "relation": "have lower rates of", "tail": "chromosomal aberrations than cancer patients"}
{"head": "Non-oncologic SLE patients", "relation": "show similar rates of", "tail": "chromosomal aberrations as healthy individuals"}
{"head": "Patients with SLE and cancer", "relation": "have higher chromosome aberration rates compared to", "tail": "healthy individuals"}
{"head": "Patients with SLE and cancer", "relation": "have higher chromosome aberration rates compared to", "tail": "patients with isolated cancer"}
{"head": "Patients with SLE and cancer", "relation": "have higher chromosome aberration rates compared to", "tail": "patients with isolated SLE"}
{"head": "45% of patients with oncologic SLE", "relation": "show", "tail": "increased radiosensitivity"}
{"head": "Anti-Ro-52 autoantibodies", "relation": "have a weak association with", "tail": "radiosensitivity"}
{"head": "Radiation dose reduction", "relation": "was recommended in", "tail": "11 oncological SLE patients"}
{"head": "Radiation dose reduction", "relation": "was successfully achieved in", "tail": "5 oncological SLE patients"}
{"head": "Radiation dose reduction", "relation": "was up to", "tail": "21% of the dose per fraction in 5 oncological SLE patients"}
{"head": "Inflammatory bowel disease", "relation": "comprises", "tail": "ulcerative colitis"}
{"head": "Inflammatory bowel disease", "relation": "comprises", "tail": "Crohn's disease"}
{"head": "Inflammatory bowel disease", "relation": "is marked by", "tail": "persistent intestinal inflammation"}
{"head": "Disease onset", "relation": "involves", "tail": "genetic predisposition"}
{"head": "Disease onset", "relation": "involves", "tail": "environmental factors"}
{"head": "Genetic predisposition and environmental factors", "relation": "disrupt", "tail": "intestinal immune homeostasis"}
{"head": "Intestinal microbiome and immune response", "relation": "play roles in", "tail": "disease progression"}
{"head": "Advances in molecular therapies and early interventions", "relation": "reduce", "tail": "surgery rates"}
{"head": "Colorectal cancer", "relation": "is driven by", "tail": "chronic inflammation"}
{"head": "Risk of UC-associated neoplasia", "relation": "increases with", "tail": "disease duration"}
{"head": "Crohn's disease patients", "relation": "face elevated risks of", "tail": "small intestine cancer"}
{"head": "Crohn's disease patients", "relation": "face elevated risks of", "tail": "anal fistula cancer"}
{"head": "Crohn's disease patients", "relation": "face elevated risks of", "tail": "anal canal cancer"}
{"head": "Endoscopic surveillance", "relation": "is advised for", "tail": "UC-associated neoplasia"}
{"head": "UC-associated neoplasia morphology", "relation": "complicates", "tail": "detection"}
{"head": "UC-associated neoplasia morphology", "relation": "differs pathologically from", "tail": "sporadic colorectal cancer"}
{"head": "UC-associated neoplasia", "relation": "is frequently surrounded by", "tail": "dysplasia"}
{"head": "p53 mutations", "relation": "are evident at", "tail": "dysplasia stage"}
{"head": "IBD-associated gastrointestinal cancers", "relation": "exemplify", "tail": "inflammation-driven carcinogenesis"}
{"head": "IBD-associated gastrointestinal cancers", "relation": "have distinct molecular mechanisms from", "tail": "adenoma-carcinoma sequence"}
{"head": "chemotherapies", "relation": "cause", "tail": "cardiac defects"}
{"head": "chemotherapies", "relation": "cause", "tail": "microvascular defects"}
{"head": "cardiac and microvascular defects", "relation": "pose", "tail": "greatest health risk"}
{"head": "cardiac and microvascular defects", "relation": "are leading cause of death", "tail": "cancer survivors who do not succumb to relapse"}
{"head": "polyphenols", "relation": "are", "tail": "naturally occurring metabolites"}
{"head": "polyphenols", "relation": "have", "tail": "vasoprotective effects"}
{"head": "polyphenols", "relation": "possess", "tail": "antioxidant activities"}
{"head": "polyphenols", "relation": "possess", "tail": "anti-inflammatory activities"}
{"head": "polyphenols", "relation": "modulate", "tail": "vascular signalling pathways"}
{"head": "polyphenols", "relation": "modulate", "tail": "gene expression"}
{"head": "polyphenols", "relation": "counteract", "tail": "vascular toxicity induced by chemotherapy"}
{"head": "Cancer risk", "relation": "increases in", "tail": "dysmetabolic obese or overweight people with overt type 2 diabetes"}
{"head": "Cancer risk", "relation": "increases in", "tail": "individuals with intermediate hyperglycemia (pre-diabetes)"}
{"head": "Cancer risk", "relation": "is especially pronounced for", "tail": "pancreatic cancer"}
{"head": "Cancer risk", "relation": "is especially pronounced for", "tail": "hepatocellular cancer"}
{"head": "Cancer risk", "relation": "is especially pronounced for", "tail": "obesity-related cancers"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "colorectal cancer"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "kidney cancer"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "bladder cancer in men"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "endometrial cancer in women"}
{"head": "Obesity-related cancers", "relation": "include", "tail": "breast cancer in women"}
{"head": "Cancer", "relation": "may be present before or upon diagnosis of", "tail": "diabetes"}
{"head": "Insulin resistance", "relation": "is a common pathogenetic background for developing", "tail": "diabetes"}
{"head": "Insulin resistance", "relation": "is a common pathogenetic background for developing", "tail": "cardiorenal disease"}
{"head": "Insulin resistance", "relation": "is a common pathogenetic background for developing", "tail": "cancer"}
{"head": "Hyperinsulinemia", "relation": "is a potential carcinogenic priming event for", "tail": "cancer"}
{"head": "Ectopic visceral, hepatic, pancreatic, or renal fat accumulation", "relation": "fuels", "tail": "inflammation and lipo-oncogenic signals"}
{"head": "Inflammation and lipo-oncogenic signals", "relation": "cause", "tail": "mitochondrial oxidative stress and deregulation"}
{"head": "Hyperinsulinemia", "relation": "may foster", "tail": "mitogenic MAP kinase-related signaling"}
{"head": "Mitogenic MAP kinase-related signaling", "relation": "can occur via", "tail": "IGF1 receptors"}
{"head": "Increased free IGF1 levels in obesity", "relation": "cause", "tail": "mitogenic MAP kinase-related signaling"}
{"head": "Weight reduction of 10% or more in obese people with diabetes or pre-diabetes", "relation": "is associated with", "tail": "significantly lower incidence of diabesity-associated cancers"}
{"head": "Intensive lifestyle intervention", "relation": "causes", "tail": "weight reduction of 10% or more in obese people with diabetes or pre-diabetes"}
{"head": "Bariatric (metabolic) surgery", "relation": "causes", "tail": "weight reduction of 10% or more in obese people with diabetes or pre-diabetes"}
{"head": "Treatment with GLP-1 receptor agonists", "relation": "causes", "tail": "weight reduction of 10% or more in obese people with diabetes or pre-diabetes"}
{"head": "Treatment with metformin", "relation": "causes", "tail": "weight reduction of 10% or more in obese people with diabetes or pre-diabetes"}
{"head": "Cardio-Renal-Metabolic-Cancer Syndrome approach", "relation": "includes", "tail": "looking for cancer at the time of diabetes diagnosis"}
{"head": "Cardio-Renal-Metabolic-Cancer Syndrome approach", "relation": "includes", "tail": "proactively screening for undiagnosed dysglycemia"}
{"head": "Glioblastoma", "relation": "is", "tail": "primary brain tumor"}
{"head": "Glioblastoma", "relation": "has characteristic", "tail": "rapid growth"}
{"head": "Glioblastoma", "relation": "has characteristic", "tail": "extensive infiltration"}
{"head": "Glioblastoma", "relation": "has characteristic", "tail": "resistance to standard therapies"}
{"head": "Glioblastoma stem cells", "relation": "drive", "tail": "glioblastoma malignancies"}
{"head": "Glioblastoma stem cells", "relation": "possess", "tail": "self-renewal capacity"}
{"head": "Glioblastoma stem cells", "relation": "possess", "tail": "multipotency"}
{"head": "Glioblastoma stem cells", "relation": "possess", "tail": "ability to regenerate tumor heterogeneity"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "relentless progression of glioblastoma"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "resistance to chemotherapy"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "resistance to radiotherapy"}
{"head": "Glioblastoma stem cells", "relation": "contribute to", "tail": "inevitable recurrence of glioblastoma"}
{"head": "Glioblastoma stem cells", "relation": "exhibit", "tail": "distinct molecular signatures"}
{"head": "Glioblastoma stem cells", "relation": "exhibit", "tail": "enhanced DNA repair"}
{"head": "Glioblastoma stem cells", "relation": "exhibit", "tail": "metabolic adaptations"}
{"head": "Glioblastoma stem cells", "relation": "reside within", "tail": "perivascular microenvironments"}
{"head": "Glioblastoma stem cells", "relation": "reside within", "tail": "hypoxic microenvironments"}
{"head": "Perivascular microenvironments", "relation": "sustain", "tail": "stemness of glioblastoma stem cells"}
{"head": "Hypoxic microenvironments", "relation": "sustain", "tail": "stemness of glioblastoma stem cells"}
{"head": "Perivascular microenvironments", "relation": "promote", "tail": "immunosuppression"}
{"head": "Hypoxic microenvironments", "relation": "promote", "tail": "immunosuppression"}
{"head": "Perivascular microenvironments", "relation": "facilitate", "tail": "angiogenesis"}
{"head": "Hypoxic microenvironments", "relation": "facilitate", "tail": "angiogenesis"}
{"head": "Notch signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "Hedgehog signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "STAT3-PARN signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "TFPI2", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "HML-2", "relation": "regulates", "tail": "glioblastoma stem cell maintenance"}
{"head": "Notch signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "Hedgehog signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "STAT3-PARN signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "TFPI2", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "HML-2", "relation": "regulates", "tail": "glioblastoma stem cell plasticity"}
{"head": "Notch signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "Wnt/\u03b2-catenin signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "Hedgehog signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "STAT3-PARN signaling pathway", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "TFPI2", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "HML-2", "relation": "regulates", "tail": "glioblastoma stem cell immune evasion"}
{"head": "Emerging therapeutic strategies", "relation": "target", "tail": "glioblastoma stem cells"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "surface markers"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "immunotherapeutics"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "metabolic vulnerabilities"}
{"head": "Emerging therapeutic strategies", "relation": "include", "tail": "combination regimens"}
{"head": "Immunotherapeutics", "relation": "include", "tail": "CAR T cells"}
{"head": "Patient-derived organoids", "relation": "enable", "tail": "accurate representation of tumor ecosystem"}
{"head": "Single-cell omics", "relation": "enable", "tail": "accurate representation of tumor ecosystem"}
{"head": "3D co-culture models", "relation": "enable", "tail": "accurate representation of tumor ecosystem"}
{"head": "Improved understanding of glioblastoma stem cell-specific targets and tumor microenvironment", "relation": "promises", "tail": "more effective interventions"}
{"head": "More effective interventions", "relation": "lead to", "tail": "better clinical outcomes for glioblastoma patients"}
{"head": "Glioblastoma in patients affected by NF1 germline mutation", "relation": "represents", "tail": "unique heterogeneous clinical and pathological entity"}
{"head": "NF1-associated GBM", "relation": "has better response to", "tail": "standard therapy"}
{"head": "NF1-associated GBM", "relation": "has better overall survival than", "tail": "GBM in the non-NF1 population"}
{"head": "Case 1", "relation": "is", "tail": "38-year-old woman with cerebellar GBM"}
{"head": "Case 1", "relation": "underwent", "tail": "surgical asportation and the Stupp protocol many times"}
{"head": "Case 1", "relation": "has overall survival of", "tail": "117 months"}
{"head": "Case 2", "relation": "is", "tail": "47-year-old woman with GBM in the eloquent area of the right frontal lobe"}
{"head": "Case 2", "relation": "underwent", "tail": "surgical asportation and the Stupp protocol"}
{"head": "Case 2", "relation": "has overall survival of", "tail": "25 months"}
{"head": "NF1-associated GBM patients", "relation": "could be considered", "tail": "long-term survivors"}
{"head": "androgen receptor pathway inhibitors", "relation": "treat", "tail": "advanced prostate cancer"}
{"head": "Monte Carlo Markov model", "relation": "simulates", "tail": "management of advanced prostate cancer to end-of-life"}
{"head": "patients", "relation": "begin in", "tail": "metastatic castration-sensitive prostate cancer"}
{"head": "patients", "relation": "begin in", "tail": "nonmetastatic castration-sensitive prostate cancer"}
{"head": "metastatic castration-sensitive prostate cancer", "relation": "progresses to", "tail": "metastatic castration-resistant prostate cancer"}
{"head": "androgen receptor pathway inhibitors", "relation": "are most cost-effective when used early in", "tail": "advanced prostate cancer"}
{"head": "androgen receptor pathway inhibitors", "relation": "are most cost-effective at cost-effectiveness threshold of", "tail": "CAD 100K per QALY"}
{"head": "early androgen receptor pathway inhibitor use", "relation": "is most cost-effective in", "tail": "metastatic castration-sensitive prostate cancer-starting patients"}
{"head": "early androgen receptor pathway inhibitor use", "relation": "is not most cost-effective in", "tail": "nonmetastatic castration-sensitive prostate cancer-starting patients"}
{"head": "abiraterone", "relation": "is the most cost-effective androgen receptor pathway inhibitor at current Canadian prices", "tail": "advanced prostate cancer"}
{"head": "abiraterone", "relation": "has", "tail": "lower price level"}
{"head": "lung cancer", "relation": "has subtype", "tail": "non-small cell lung cancer"}
{"head": "targeted therapies", "relation": "treat", "tail": "advanced/metastatic non-small cell lung cancer"}
{"head": "early non-small cell lung cancer", "relation": "includes stages", "tail": "I-IIIA"}
{"head": "study population", "relation": "included patients with", "tail": "Stage IB-IIIA non-small cell lung cancer"}
{"head": "study population", "relation": "had mean age", "tail": "70.9 years"}
{"head": "69.9% of patients", "relation": "received", "tail": "definitive treatment"}
{"head": "definitive treatment", "relation": "includes", "tail": "surgery"}
{"head": "definitive treatment", "relation": "includes", "tail": "definitive radiation"}
{"head": "definitive treatment", "relation": "includes", "tail": "definitive chemoradiation"}
{"head": "30.1% of patients", "relation": "did not receive", "tail": "definitive treatment"}
{"head": "many definitive treatment patients", "relation": "received", "tail": "perioperative systemic therapy"}
{"head": "neoadjuvant use", "relation": "was limited in", "tail": "all treatment groups"}
{"head": "54.6% of patients receiving adjuvant therapy", "relation": "used", "tail": "immune checkpoint inhibitors"}
{"head": "immune checkpoint inhibitors", "relation": "were most common for", "tail": "definitive radiation patients"}
{"head": "immune checkpoint inhibitors", "relation": "were most common for", "tail": "definitive chemoradiation patients"}
{"head": "surgical patients", "relation": "predominantly received", "tail": "platinum-doublet therapy"}
{"head": "surgical patient outcomes", "relation": "were similar across", "tail": "all groups"}
{"head": "definitive chemoradiation or radiation patients without systemic therapy", "relation": "had", "tail": "lower survival rates"}
{"head": "Bispecific T-cell engager (TCE)", "relation": "treats", "tail": "relapsed or refractory multiple myeloma"}
{"head": "T-cell engagers", "relation": "associated with", "tail": "sustained efficacy in patients with heavily treated myeloma"}
{"head": "T-cell engagers", "relation": "associated with", "tail": "progression-free survival benefits in patients with heavily treated myeloma"}
{"head": "Bispecific T-cell engager (TCE) therapy", "relation": "complicated by", "tail": "cytokine release syndrome (CRS)"}
{"head": "Bispecific T-cell engager (TCE) therapy", "relation": "complicated by", "tail": "immune effector cell-associated neurotoxicity syndrome (ICANS)"}
{"head": "Bispecific T-cell engager (TCE) therapy", "relation": "complicated by", "tail": "infections"}
{"head": "Annual per-beneficiary spending", "relation": "increased by", "tail": "32.8% from CAD 4422 in 2017/18 to CAD 6579 in 2020/21"}
{"head": "Small-molecule targeted therapy and immunotherapy drug classes", "relation": "accounted for", "tail": "three-quarters of total public payer spending on take-home cancer medications in 2020/21"}
{"head": "Small-molecule targeted therapy and immunotherapy drug classes", "relation": "were dispensed to", "tail": "less than 8% of beneficiaries"}
{"head": "Declaration of emergency for SARS-CoV-2", "relation": "caused", "tail": "short-term decline in per-beneficiary spending between March and June 2020"}
{"head": "Number of beneficiaries receiving low-cost take-home cancer medications within cytotoxic chemotherapy and hormonal therapy drug class", "relation": "increased by", "tail": "5582 per month between March and June 2020"}
{"head": "Increase in number of beneficiaries receiving low-cost take-home cancer medications within cytotoxic chemotherapy and hormonal therapy drug class", "relation": "occurred without", "tail": "corresponding rise in public payer spending"}
{"head": "Crizotinib", "relation": "inhibits", "tail": "viability of bladder cancer cells"}
{"head": "Crizotinib", "relation": "inhibits", "tail": "migration of bladder cancer cells"}
{"head": "Crizotinib", "relation": "inhibits", "tail": "invasion of bladder cancer cells"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "c-Met/PI3K/Akt pathway"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "cell proliferation in T24 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "cell proliferation in T24R2 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "migration in T24 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "migration in T24R2 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "invasion in T24 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "suppresses", "tail": "invasion in T24R2 bladder cancer cell line"}
{"head": "Crizotinib", "relation": "reduces expression of", "tail": "E-cadherin"}
{"head": "Crizotinib", "relation": "enhances expression of", "tail": "vimentin"}
{"head": "Crizotinib", "relation": "increases expression of", "tail": "apoptosis-related genes"}
{"head": "Crizotinib", "relation": "decreases expression of", "tail": "phosphorylated c-Met"}
{"head": "Crizotinib", "relation": "decreases expression of", "tail": "phosphorylated Akt"}
{"head": "Crizotinib", "relation": "has antitumor effect on", "tail": "cisplatin-na\u00efve human bladder cancer cells"}
{"head": "Crizotinib", "relation": "has antitumor effect on", "tail": "cisplatin-resistant human bladder cancer cells"}
{"head": "Antitumor effect of crizotinib", "relation": "is associated with inhibition of", "tail": "phosphorylated activation of c-Met/PI3K/Akt pathway"}
{"head": "c-Met", "relation": "induces", "tail": "PI3K/Akt pathway"}
{"head": "Cancer diagnosis and its treatment", "relation": "disrupts", "tail": "Child's and adolescent's normal level of physical activity"}
{"head": "Physical activity interventions", "relation": "are safe and feasible", "tail": "When tailored to patient's age, treatment phase, and clinical condition"}
{"head": "Physical activity interventions", "relation": "improve", "tail": "Physical fitness"}
{"head": "Physical activity interventions", "relation": "improve", "tail": "Strength"}
{"head": "Physical activity interventions", "relation": "improve", "tail": "Quality of life"}
{"head": "Physical activity interventions", "relation": "reduce", "tail": "Fatigue"}
{"head": "Physical activity", "relation": "is a feasible and safe adjunct to", "tail": "Cancer treatment in children and adolescents"}
{"head": "Fiberoptic Endoscopic Evaluation of Swallowing (FEES)", "relation": "is preferred diagnostic approach for", "tail": "oropharyngeal dysphagia assessment in head and neck cancer population"}
{"head": "Late radiation-associated dysphagia (late-RAD)", "relation": "occurs in", "tail": "head and neck cancer (HNC) patients"}
{"head": "This study", "relation": "used", "tail": "FEES-based assessment to characterize swallowing safety and efficacy profiles"}
{"head": "This study", "relation": "used", "tail": "FEES-based assessment to identify distinct phenotypes in HNC patients with late-RAD"}
{"head": "This study", "relation": "used", "tail": "FEES-based assessment to examine correlations between safety and efficacy parameters"}
{"head": "Twenty-four post-radiotherapy HNC patients", "relation": "were evaluated using", "tail": "standardized FEES protocols across three bolus consistencies (liquid, semisolid, solid)"}
{"head": "Swallowing safety", "relation": "was quantified using", "tail": "Penetration-Aspiration Scale (PAS)"}
{"head": "Swallowing efficacy", "relation": "was measured via", "tail": "Yale Pharyngeal Residue Severity Rating Scale (YPRSRS)"}
{"head": "Six distinct dysphagia phenotypes", "relation": "were characterized in", "tail": "the cohort of HNC patients with late-RAD"}
{"head": "Propulsion deficit", "relation": "was predominant phenotype in", "tail": "HNC patients with late-RAD (92%)"}
{"head": "Delayed pharyngeal phase", "relation": "was phenotype in", "tail": "HNC patients with late-RAD (37.5%)"}
{"head": "Protective deficit", "relation": "was phenotype in", "tail": "HNC patients with late-RAD (25%)"}
{"head": "Forty-six percent of patients", "relation": "exhibited", "tail": "multiple dysphagia phenotypes"}
{"head": "Unsafe swallowing", "relation": "occurred most frequently with", "tail": "liquid consistency (62.5%)"}
{"head": "Residue", "relation": "was most prevalent with", "tail": "semisolid consistency (82.6% valleculae, 52.2% pyriform sinuses)"}
{"head": "Residue", "relation": "was most prevalent with", "tail": "solid consistency (92.3% valleculae, 53.8% pyriform sinuses)"}
{"head": "Penetration-aspiration scores", "relation": "correlated significantly with", "tail": "pharyngeal residue scores across consistencies"}
{"head": "Salivary gland carcinomas", "relation": "account for", "tail": "3-6% of all head and neck cancers"}
{"head": "Surgical resection", "relation": "is standard for", "tail": "locoregional control of salivary gland carcinomas"}
{"head": "Radiotherapy", "relation": "is standard for", "tail": "locoregional control of salivary gland carcinomas"}
{"head": "Systemic treatment", "relation": "is indicated for", "tail": "recurrent or metastatic salivary gland carcinomas"}
{"head": "Molecular profiling", "relation": "has identified", "tail": "NTRK gene fusions"}
{"head": "Molecular profiling", "relation": "has identified", "tail": "HER2"}
{"head": "Molecular profiling", "relation": "has identified", "tail": "immune checkpoint regulators"}
{"head": "Molecular profiling", "relation": "has identified", "tail": "androgen receptors"}
{"head": "Molecular profiling", "relation": "has identified", "tail": "RET receptors"}
{"head": "Targeted therapies", "relation": "include", "tail": "TRK inhibitors"}
{"head": "Targeted therapies", "relation": "include", "tail": "HER2-directed agents"}
{"head": "Targeted therapies", "relation": "include", "tail": "androgen receptor modulators"}
{"head": "Immunotherapy and chemotherapy", "relation": "are combined in", "tail": "emerging treatment combinations for salivary gland carcinomas"}
{"head": "Resistance mechanisms", "relation": "cause", "tail": "challenges in treatment of salivary gland carcinomas"}
{"head": "Limited therapeutic efficacy", "relation": "causes", "tail": "challenges in treatment of salivary gland carcinomas"}
{"head": "Overall response rates", "relation": "are low across", "tail": "most systemic therapies for salivary gland carcinomas"}
{"head": "Combination of immunotherapy and radiotherapy", "relation": "has", "tail": "synergistic potential"}
{"head": "Immune checkpoint inhibitors", "relation": "are administered in combination with", "tail": "radiotherapy"}
{"head": "CTLA-4 inhibitors", "relation": "have been assessed in", "tail": "clinical and preclinical studies"}
{"head": "PD-L1 inhibitors", "relation": "have been assessed in", "tail": "clinical and preclinical studies"}
{"head": "PD-1 inhibitors", "relation": "have been assessed in", "tail": "clinical and preclinical studies"}
{"head": "Radiotherapy", "relation": "activates", "tail": "immunomodulatory mechanisms"}
{"head": "Immunomodulatory mechanisms", "relation": "produce", "tail": "in situ vaccination effect"}
{"head": "Immunomodulatory mechanisms", "relation": "produce", "tail": "abscopal distant response of lesions outside irradiation field"}
{"head": "TIGIT", "relation": "is a", "tail": "new therapeutic target"}
{"head": "LAG-3", "relation": "is a", "tail": "new therapeutic target"}
{"head": "TIM-3", "relation": "is a", "tail": "new therapeutic target"}
{"head": "New therapeutic targets TIGIT, LAG-3, TIM-3", "relation": "are associated with", "tail": "traditional ICIs and radiotherapy"}
{"head": "Dynamic evaluation of T lymphocyte expression", "relation": "could have", "tail": "biomarker value in assessing response to combination therapy"}
{"head": "Combination therapy with traditional and new ICIs and irradiation", "relation": "is being explored in", "tail": "clinical trials in various tumor pathologies"}
{"head": "KEYNOTE-024", "relation": "results in", "tail": "pembrolizumab approval in first-line setting for metastatic NSCLC with PD-L1 \u2265 50%"}
{"head": "pembrolizumab", "relation": "approved for", "tail": "patients with metastatic NSCLC and PD-L1 \u2265 50%"}
{"head": "patients with metastatic non-small-cell lung cancer", "relation": "had 5-year overall survival rate of", "tail": "up to 10%"}
{"head": "first-line pembrolizumab", "relation": "efficacy investigated in", "tail": "patients with locally advanced and metastatic NSCLC with high PD-L1 expression"}
{"head": "patients with locally advanced and metastatic NSCLC", "relation": "had PD-L1 expression of", "tail": "\u2265 50%"}
{"head": "progression-free survival", "relation": "was", "tail": "9 months"}
{"head": "overall survival", "relation": "was", "tail": "14 months"}
{"head": "five-year overall survival rate", "relation": "was", "tail": "20%"}
{"head": "six-year overall survival rate", "relation": "was", "tail": "17.2%"}
{"head": "immunotherapy", "relation": "is revolution in treatment of", "tail": "NSCLC"}
{"head": "Medical care structures", "relation": "differ between", "tail": "urban and rural areas"}
{"head": "Brandenburg-Berlin Clinical-Epidemiological Cancer Registry", "relation": "documents", "tail": "5805 cases of gastric carcinoma"}
{"head": "Survival data", "relation": "show", "tail": "no significant differences between Berlin and Brandenburg"}
{"head": "Preoperative therapy for cT3/cT4N0 tumors", "relation": "is more common in", "tail": "Berlin than in Brandenburg"}
{"head": "Preoperative therapy for cT3/cT4N0 tumors", "relation": "is 72% in", "tail": "Berlin"}
{"head": "Preoperative therapy for cT3/cT4N0 tumors", "relation": "is 68% in", "tail": "Brandenburg"}
{"head": "Perioperative therapy", "relation": "is associated with survival benefit for", "tail": "stages T3-/T4N+"}
{"head": "Perioperative therapy", "relation": "is not associated with survival benefit for", "tail": "stages T1N+ or T2"}
{"head": "Lower proportion of pre-treated T3/T4N+ patients in rural Brandenburg", "relation": "does not result in", "tail": "significant survival difference"}
{"head": "Gastric cancer treatment outcomes", "relation": "are comparable between", "tail": "rural Brandenburg and urban Berlin"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "white blood cell count"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "neutrophil count"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "platelet count"}
{"head": "Upper rectal cancer", "relation": "has higher", "tail": "C-reactive protein levels"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "preoperative carcinoembryonic antigen levels"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "lymphovascular invasion"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "perineural invasion"}
{"head": "Mid-lower rectal cancer", "relation": "has higher", "tail": "tumor budding"}
{"head": "Age", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "ASA score", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "C-reactive protein", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Preoperative carcinoembryonic antigen", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Preoperative carbohydrate antigen 19-9", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Lymphovascular invasion", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Perineural invasion", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Tumor budding", "relation": "is independent prognostic factor for", "tail": "overall survival"}
{"head": "Age", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "ASA score", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "C-reactive protein", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Preoperative carcinoembryonic antigen", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Preoperative carbohydrate antigen 19-9", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Lymphovascular invasion", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Perineural invasion", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Tumor budding", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "T stage", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Tumor size", "relation": "is independent prognostic factor for", "tail": "disease-free survival"}
{"head": "Pancreatic cancer", "relation": "is", "tail": "one of the deadliest types of cancer globally"}
{"head": "Screening", "relation": "is recommended for", "tail": "individuals at high risk of pancreatic cancer"}
{"head": "High risk individuals", "relation": "include", "tail": "those with familial and/or genetic predispositions"}
{"head": "One-time screening for pancreatic cancer", "relation": "is cost-effective compared with", "tail": "no screening among high-risk individuals"}
{"head": "Annual screening for pancreatic cancer", "relation": "is cost-effective", "tail": "among high-risk individuals"}
{"head": "High risk", "relation": "is defined as", "tail": ">5% lifetime risk of pancreatic cancer"}
{"head": "High risk individuals", "relation": "include", "tail": "individuals with familial pancreatic cancer"}
{"head": "High risk individuals", "relation": "include", "tail": "individuals with genetic susceptibility syndromes"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "Peutz-Jeghers Syndrome"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "hereditary pancreatitis"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "hereditary non-polypoid colorectal cancer syndrome"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "familial adenomatous polyposis"}
{"head": "Genetic susceptibility syndromes", "relation": "include", "tail": "BRCA2 mutations"}
{"head": "Individuals with new-onset diabetes", "relation": "are considered", "tail": "high-risk for pancreatic cancer"}
{"head": "Screening using endoscopic ultrasound", "relation": "is cost-effective among", "tail": "familial pancreatic cancer individuals"}
{"head": "Screening using endoscopic ultrasound", "relation": "is cost-effective among", "tail": "individuals with genetic syndromes"}
{"head": "Risk-based screening", "relation": "is cost-effective among", "tail": "patients with new-onset diabetes"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "epidemiological factors"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "cost"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "diagnostic performance of screening tools"}
{"head": "Cost-effectiveness of pancreatic cancer screening", "relation": "depends on", "tail": "overall design of studies"}
{"head": "Bone metastases", "relation": "contribute to", "tail": "morbidity and mortality"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "breast cancer"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "prostate cancer"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "lung cancer"}
{"head": "Metastatic lesions", "relation": "arise from", "tail": "kidney cancer"}
{"head": "Metastatic lesions", "relation": "affect", "tail": "approximately 25% of cancer patients"}
{"head": "Metastatic lesions", "relation": "lead to", "tail": "pain"}
{"head": "Metastatic lesions", "relation": "lead to", "tail": "fractures"}
{"head": "Metastatic lesions", "relation": "lead to", "tail": "neurological deficits"}
{"head": "Oligometastases", "relation": "defined by", "tail": "limited metastatic spread (1-5 lesions)"}
{"head": "Oligometastases", "relation": "offer", "tail": "potential window for curative treatment"}
{"head": "Curative treatment", "relation": "includes", "tail": "stereotactic ablative radiotherapy"}
{"head": "Curative treatment", "relation": "includes", "tail": "resection surgery"}
{"head": "Tumor boards", "relation": "integrate", "tail": "systemic therapies with local interventions"}
{"head": "Tumor boards", "relation": "are crucial to optimize", "tail": "treatment"}
{"head": "Folliculin (FLCN)", "relation": "is a tumor suppressor gene in", "tail": "thyroid tumors"}
{"head": "Folliculin (FLCN)", "relation": "has pathogenic alterations in", "tail": "thyroid tumors"}
{"head": "Patient 1", "relation": "has germline FLCN mutation and history of", "tail": "Birt-Hogg-Dub\u00e9 (BHD) syndrome"}
{"head": "Patient 1", "relation": "presented with", "tail": "oncocytic adenoma"}
{"head": "Patient 1", "relation": "has biallelic FLCN inactivation confirmed by", "tail": "molecular testing"}
{"head": "Patient 2", "relation": "harbored somatic FLCN mutation in", "tail": "oncocytic poorly differentiated thyroid carcinoma"}
{"head": "Oncocytic poorly differentiated thyroid carcinoma", "relation": "exhibited", "tail": "extensive angioinvasion"}
{"head": "Oncocytic poorly differentiated thyroid carcinoma", "relation": "exhibited", "tail": "high proliferative activity"}
{"head": "Oncocytic poorly differentiated thyroid carcinoma", "relation": "harbored concurrent mutations in", "tail": "TP53 and RB1"}
{"head": "Thyroid carcinomas", "relation": "revealed FLCN alterations in", "tail": "1.1% of cases"}
{"head": "Pathogenic FLCN mutations", "relation": "are associated with", "tail": "oncocytic morphology"}
{"head": "Homozygous FLCN deletions", "relation": "occur more frequently in", "tail": "genomically unstable tumors including anaplastic thyroid carcinoma"}
{"head": "FLCN mutations", "relation": "may act as early oncogenic drivers in", "tail": "oncocytic thyroid neoplasms"}
{"head": "FLCN deletions", "relation": "represent secondary events in", "tail": "aggressive tumor evolution"}
{"head": "Including FLCN in genetic testing", "relation": "could improve", "tail": "tumor detection and characterization"}
{"head": "BHD patients", "relation": "may benefit from", "tail": "routine thyroid screening"}
{"head": "Computed tomography-based radiomic nomogram", "relation": "predicts", "tail": "occult pleural metastasis in lung cancer"}
{"head": "carcinoembryonic antigen", "relation": "is a predictor of", "tail": "occult pleural metastasis in lung cancer"}
{"head": "neutrophil-to-lymphocyte ratio", "relation": "is a predictor of", "tail": "occult pleural metastasis in lung cancer"}
{"head": "clinical T stage", "relation": "is a predictor of", "tail": "occult pleural metastasis in lung cancer"}
{"head": "tumor-pleural relationship", "relation": "is a predictor of", "tail": "occult pleural metastasis in lung cancer"}
{"head": "clinical model", "relation": "achieves", "tail": "area under the curve of 0.761 for predicting occult pleural metastasis"}
{"head": "integrated model combining radiomic scores, carcinoembryonic antigen, and neutrophil-to-lymphocyte ratio", "relation": "achieves", "tail": "area under the curve of 0.890 in training cohort for predicting occult pleural metastasis"}
{"head": "integrated model combining radiomic scores, carcinoembryonic antigen, and neutrophil-to-lymphocyte ratio", "relation": "achieves", "tail": "area under the curve of 0.855 in validation cohort for predicting occult pleural metastasis"}
{"head": "radiomic features derived from CT scans", "relation": "identify", "tail": "patients with lung cancer at risk of occult pleural metastasis"}
{"head": "nomogram integrating carcinoembryonic antigen, neutrophil-to-lymphocyte ratio, and radiomic tumor area scores", "relation": "enhances", "tail": "precision of preoperative occult pleural metastasis prediction"}
{"head": "Childhood Cancer Registry of Campania", "relation": "is", "tail": "Italian largest population-based registry specializing in children 0-19 years old"}
{"head": "Childhood Cancer Registry of Campania", "relation": "has target population", "tail": "approximately 1.1 million inhabitants"}
{"head": "study cohort", "relation": "included", "tail": "219 adolescents with newly diagnosed central nervous system tumors"}
{"head": "annual average incidence rate", "relation": "is", "tail": "48.9 cases per million per year"}
{"head": "5-year observed survival rate after diagnosis of CNS tumor", "relation": "is", "tail": "84.8%"}
{"head": "most common tumor site", "relation": "is", "tail": "pituitary gland and craniopharyngeal duct"}
{"head": "pituitary gland and craniopharyngeal duct", "relation": "represent", "tail": "22.4% of all tumors"}
{"head": "most frequently occurring malignant primary CNS tumor", "relation": "is", "tail": "germinoma"}
{"head": "most common non-malignant tumor", "relation": "is", "tail": "pituitary adenoma"}
{"head": "most patients", "relation": "were referred to", "tail": "adult services"}
{"head": "nearly half of patients", "relation": "migrated outside the region to receive", "tail": "cancer care"}
{"head": "care of adolescents with CNS tumors", "relation": "is", "tail": "fragmented across institutions"}
{"head": "significant variations in practice", "relation": "exist between", "tail": "adult and pediatric practitioners"}
{"head": "Head-and-neck cancer patients with dysphagia", "relation": "have", "tail": "lower health-related quality of life"}
{"head": "Head-and-neck cancer patients with dysphagia", "relation": "have", "tail": "lower physical functioning"}
{"head": "Head-and-neck cancer patients with dysphagia", "relation": "have", "tail": "lower social functioning"}
{"head": "Head-and-neck cancer patients with dysphagia", "relation": "have", "tail": "lower emotional functioning"}
{"head": "Head-and-neck cancer patients with dysphagia", "relation": "report", "tail": "more severe general symptoms including fatigue, pain, sleep disturbances, nausea/vomiting, diarrhea, and financial worries"}
{"head": "Control-2 patients", "relation": "have", "tail": "worse emotional functioning than Control-1 patients"}
{"head": "Control-2 patients", "relation": "have", "tail": "worse social functioning than Control-1 patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "social functioning in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "emotional functioning in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "role functioning in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "fatigue in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "nausea/vomiting in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "insomnia in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "appetite loss in head-and-neck cancer patients"}
{"head": "Cancer rehabilitation", "relation": "improves", "tail": "health-related quality of life in dysphagia patients"}
{"head": "Psychooncological counseling", "relation": "reduces", "tail": "depression in dysphagia patients"}
{"head": "Psychooncological counseling", "relation": "reduces", "tail": "depression in Control-2 patients"}
{"head": "Depression levels in dysphagia and Control-2 patients after psychooncological counseling", "relation": "are", "tail": "similar to levels in the general population"}
{"head": "Pseudomyogenic haemangioendotheliomas", "relation": "occur mostly in", "tail": "soft tissue"}
{"head": "Malignant cases of pseudomyogenic haemangioendotheliomas", "relation": "are", "tail": "uncommon"}
{"head": "28-year-old male", "relation": "had", "tail": "primary pseudomyogenic hemangioendothelioma of the bone"}
{"head": "Primary pseudomyogenic hemangioendothelioma of the bone", "relation": "had metastases to", "tail": "other skeletal segments"}
{"head": "Molecular analysis through targeted RNA sequencing", "relation": "confirmed diagnosis of", "tail": "primary pseudomyogenic hemangioendothelioma of the bone"}
{"head": "Fusion transcript ACTB::FOSB", "relation": "was revealed by", "tail": "molecular analysis through targeted RNA sequencing"}
{"head": "Patient", "relation": "suffered from", "tail": "multiple pathological fractures"}
{"head": "Rapid skeletal progression and onset of distant metastases", "relation": "occurred in", "tail": "primary pseudomyogenic hemangioendothelioma of the bone case"}
{"head": "breast cancer", "relation": "is associated with", "tail": "non-Hodgkin lymphoma of the spleen"}
{"head": "39-year-old woman", "relation": "developed", "tail": "invasive lobular carcinoma in her right breast"}
{"head": "invasive lobular carcinoma in her right breast", "relation": "was treated with", "tail": "mastectomy"}
{"head": "invasive lobular carcinoma in her right breast", "relation": "was treated with", "tail": "hormonal therapy"}
{"head": "right axillary mass", "relation": "was confirmed by", "tail": "fine-needle aspiration biopsy"}
{"head": "patient", "relation": "received", "tail": "neoadjuvant chemotherapy"}
{"head": "patient", "relation": "underwent", "tail": "axillary lymph node dissection"}
{"head": "patient", "relation": "underwent", "tail": "bilateral adnexectomy"}
{"head": "CT and PET scans", "relation": "showed", "tail": "suspicious splenic lesions suggestive of metastases"}
{"head": "laparoscopic splenectomy", "relation": "was performed due to", "tail": "suspicious splenic lesions"}
{"head": "histological examination", "relation": "revealed", "tail": "follicular B-cell non-Hodgkin lymphoma"}
{"head": "patient", "relation": "is on", "tail": "biannual follow-up"}
{"head": "Lymph node status", "relation": "is", "tail": "the most critical prognostic factor in vulvar cancer"}
{"head": "Inguinofemoral lymphadenectomy", "relation": "is associated with", "tail": "significant morbidity"}
{"head": "Sentinel lymph node biopsy", "relation": "is", "tail": "a less invasive alternative to inguinofemoral lymphadenectomy"}
{"head": "Sentinel lymph node biopsy", "relation": "has", "tail": "favorable oncologic outcomes in selected cases"}
{"head": "Sentinel lymph node biopsy", "relation": "is recommended for", "tail": "unifocal vulvar tumors < 4 cm with stromal invasion > 1 mm and clinically negative nodes"}
{"head": "GROINSS-V-I and GOG-173 trials", "relation": "confirmed", "tail": "accuracy and lower morbidity of sentinel lymph node biopsy compared to lymphadenectomy"}
{"head": "Sentinel lymph node biopsy utilization", "relation": "has increased since", "tail": "its inclusion in guidelines"}
{"head": "Lymphadenectomy rates", "relation": "have declined due to", "tail": "increased sentinel lymph node biopsy utilization"}
{"head": "Combined detection techniques", "relation": "are", "tail": "mandatory for sentinel lymph node biopsy"}
{"head": "Indocyanine green", "relation": "is", "tail": "an emerging detection option for sentinel lymph node biopsy"}
{"head": "Sentinel lymph node biopsy", "relation": "is", "tail": "a validated, minimally invasive staging approach in early-stage vulvar cancer"}
{"head": "Soft tissue sarcoma", "relation": "has incidence in", "tail": "adolescent and young adult population"}
{"head": "Soft tissue sarcoma", "relation": "requires", "tail": "multimodal management"}
{"head": "Multimodal management", "relation": "includes", "tail": "surgery"}
{"head": "Multimodal management", "relation": "includes", "tail": "radiation"}
{"head": "Multimodal management", "relation": "includes", "tail": "chemotherapy"}
{"head": "Surgical and radiation-related morbidity", "relation": "is a lasting side effect of", "tail": "therapy for soft tissue sarcoma"}
{"head": "Chemotherapy toxicity", "relation": "is a lasting side effect of", "tail": "therapy for soft tissue sarcoma"}
{"head": "Secondary effects on cardiac and endocrine systems", "relation": "are lasting side effects of", "tail": "therapy for soft tissue sarcoma"}
{"head": "Development of secondary cancers", "relation": "is a lasting side effect of", "tail": "therapy for soft tissue sarcoma"}
{"head": "Sarcoma diagnosis", "relation": "impacts", "tail": "fertility"}
{"head": "Sarcoma diagnosis", "relation": "impacts", "tail": "mental health"}
{"head": "Sarcoma diagnosis", "relation": "impacts", "tail": "relationships"}
{"head": "Sarcoma diagnosis", "relation": "impacts", "tail": "education"}
{"head": "Sarcoma diagnosis", "relation": "impacts", "tail": "career"}
{"head": "Azacitidine and venetoclax", "relation": "are part of", "tail": "new standard of care for elderly patients with Acute Myeloid Leukemia"}
{"head": "patients with Acute Myeloid Leukemia", "relation": "were routinely admitted during initiation of", "tail": "Azacitidine and venetoclax"}
{"head": "patients with Acute Myeloid Leukemia", "relation": "were monitored for", "tail": "tumour lysis syndrome"}
{"head": "incidence of tumour lysis syndrome", "relation": "was", "tail": "25% using Cairo-Bishop diagnostic criteria"}
{"head": "tumour lysis syndrome incidence", "relation": "was", "tail": "2% using Howard diagnostic criteria"}
{"head": "patients who developed Cairo-Bishop tumour lysis syndrome", "relation": "had", "tail": "significantly higher baseline white blood count"}
{"head": "patients with white blood count less than 30 \u00d7 10^9/L", "relation": "completed", "tail": "outpatient initiation of Azacitidine and venetoclax"}
{"head": "patients with white blood count less than 30 \u00d7 10^9/L", "relation": "had", "tail": "low incidence of mild, transient tumour lysis syndrome by Cairo-Bishop criteria"}
{"head": "Intensity-modulated radiotherapy", "relation": "treats", "tail": "localized prostate cancer"}
{"head": "Intensity-modulated proton therapy", "relation": "treats", "tail": "localized prostate cancer"}
{"head": "Intensity-modulated radiotherapy", "relation": "causes", "tail": "clinically meaningful decline in bowel function mean score at 24 months post-radiotherapy"}
{"head": "Intensity-modulated proton therapy", "relation": "does not cause", "tail": "clinically meaningful decline in bowel function mean score at 24 months post-radiotherapy"}
{"head": "Intensity-modulated radiotherapy", "relation": "causes", "tail": "higher proportion of clinically relevant reduction in bowel function compared to intensity-modulated proton therapy"}
{"head": "Intensity-modulated radiotherapy", "relation": "does not cause", "tail": "statistically significant or clinically relevant changes in urinary irritative/obstructive symptoms"}
{"head": "Intensity-modulated proton therapy", "relation": "does not cause", "tail": "statistically significant or clinically relevant changes in urinary irritative/obstructive symptoms"}
{"head": "Intensity-modulated radiotherapy", "relation": "does not cause", "tail": "statistically significant or clinically relevant changes in urinary incontinence"}
{"head": "Intensity-modulated proton therapy", "relation": "does not cause", "tail": "statistically significant or clinically relevant changes in urinary incontinence"}
{"head": "Intensity-modulated proton therapy", "relation": "leads to", "tail": "smaller decrease in bowel function than intensity-modulated radiotherapy at 24 months post-radiotherapy"}
{"head": "Merkel cell carcinomas", "relation": "spread to", "tail": "lymph nodes"}
{"head": "Merkel cell carcinomas", "relation": "spread to", "tail": "distant metastases"}
{"head": "patients", "relation": "presented with", "tail": "lymph node metastases"}
{"head": "patients", "relation": "presented with", "tail": "distant metastases"}
{"head": "patients", "relation": "developed", "tail": "lifetime distant metastases"}
{"head": "patients with lifetime distant metastases", "relation": "also developed", "tail": "lymph node metastases"}
{"head": "patients", "relation": "developed first", "tail": "lymph node metastases before distant metastases"}
{"head": "time from initial diagnosis to lymph node metastases", "relation": "is shorter than", "tail": "time from initial diagnosis to distant metastases"}
{"head": "patients with primary tumors \u22641 cm", "relation": "developed", "tail": "lifetime distant metastases"}
{"head": "prior lymph node metastases", "relation": "gives rise to", "tail": "subsequent distant metastases"}
{"head": "patients with nodal metastases", "relation": "should be considered for", "tail": "adjuvant systemic therapy studies"}
{"head": "Fear of cancer recurrence", "relation": "affects", "tail": "family caregivers"}
{"head": "Fear of cancer recurrence in cancer patients", "relation": "has been", "tail": "well-documented"}
{"head": "Family caregivers", "relation": "participated in", "tail": "focus group"}
{"head": "Family caregivers", "relation": "participated in", "tail": "semi-structured interviews"}
{"head": "Family caregivers", "relation": "described experience of", "tail": "fear of cancer recurrence"}
{"head": "Fear of cancer recurrence in family caregivers", "relation": "is", "tail": "all-consuming"}
{"head": "Fear of cancer recurrence in family caregivers", "relation": "is", "tail": "constant"}
{"head": "Fear of cancer recurrence in family caregivers", "relation": "is marked by", "tail": "sense of helplessness"}
{"head": "Relational aspects of fear of cancer recurrence in family caregivers", "relation": "include", "tail": "patient-centric hypervigilance"}
{"head": "Relational aspects of fear of cancer recurrence in family caregivers", "relation": "include", "tail": "self-silencing"}
{"head": "Relational aspects of fear of cancer recurrence in family caregivers", "relation": "include", "tail": "fear of cancer recurrence as isolating"}
{"head": "Relational aspects of fear of cancer recurrence in family caregivers", "relation": "include", "tail": "finding support"}
{"head": "Relational factors", "relation": "shape", "tail": "how family caregivers experience and manage fear of cancer recurrence"}
{"head": "High-quality survivorship care", "relation": "should include", "tail": "fear of cancer recurrence interventions tailored to family caregivers"}
{"head": "Oral squamous cell carcinoma", "relation": "has high", "tail": "recurrence rates"}
{"head": "Tongue", "relation": "is most affected site in", "tail": "oral squamous cell carcinoma"}
{"head": "Tongue", "relation": "has highest", "tail": "recurrence rate"}
{"head": "Floor of the mouth", "relation": "has second highest", "tail": "recurrence rate"}
{"head": "24.3% of patients", "relation": "experienced", "tail": "recurrence"}
{"head": "Most recurrence cases", "relation": "occurred within", "tail": "first year"}
{"head": "T2 tumors", "relation": "have highest", "tail": "recurrence rates"}
{"head": "Patients with adjuvant therapy", "relation": "have comparable", "tail": "recurrence rates to patients without adjuvant therapy"}
{"head": "Positive surgical margins", "relation": "are more common in", "tail": "recurrence cases"}
{"head": "No significant correlation", "relation": "exists between", "tail": "margin status and recurrence in patients without adjuvant therapy"}
{"head": "Recurrence-free survival in oral squamous cell carcinoma", "relation": "does not solely depend on", "tail": "surgical technique"}
{"head": "Recurrence-free survival in oral squamous cell carcinoma", "relation": "does not solely depend on", "tail": "adjuvant therapy"}
{"head": "Tumors of the tongue and floor of the mouth", "relation": "exhibit high", "tail": "recurrence rates regardless of disease stage"}
{"head": "Ectopic adrenocorticotropic hormone syndrome", "relation": "occurs when", "tail": "a tumor develops neuroendocrine differentiation with the secretion of ACTH"}
{"head": "Secretion of ACTH", "relation": "results in", "tail": "hypercortisolism"}
{"head": "Secretion of ACTH", "relation": "results in", "tail": "Cushing's syndrome"}
{"head": "5-10% of Cushing's syndrome cases", "relation": "are attributed to", "tail": "Ectopic adrenocorticotropic hormone syndrome"}
{"head": "Breast tumors", "relation": "comprise", "tail": "less than 1% of Ectopic adrenocorticotropic hormone syndrome cases"}
{"head": "Breast neuroendocrine tumors", "relation": "include", "tail": "neuroendocrine-differentiated carcinoma"}
{"head": "Breast neuroendocrine tumors", "relation": "include", "tail": "ductal carcinoma with neuroendocrine features"}
{"head": "Biopsy", "relation": "demonstrated", "tail": "invasive poorly differentiated breast carcinoma with high-grade neuroendocrine features and necrosis"}
{"head": "Staging at diagnosis", "relation": "confirmed", "tail": "metastatic disease of the liver and bone"}
{"head": "First-line chemotherapy", "relation": "includes", "tail": "Cisplatin/Etoposide/Durvalumab"}
{"head": "First-line chemotherapy", "relation": "was initiated for", "tail": "patient with breast neuroendocrine carcinoma"}
{"head": "Disease progression", "relation": "occurred after", "tail": "four cycles of first-line chemotherapy"}
{"head": "Simple mastectomy", "relation": "was performed for", "tail": "local control and complete pathologic analysis"}
{"head": "Pathologic analysis", "relation": "demonstrated", "tail": "high-grade neuroendocrine carcinoma with large-cell features"}
{"head": "Second-line therapy", "relation": "includes", "tail": "Adriamycin/Cyclophosphamide"}
{"head": "Second-line therapy", "relation": "was initiated for", "tail": "patient with breast neuroendocrine carcinoma"}
{"head": "Patient", "relation": "required admission for", "tail": "severe and refractory hypokalemia"}
{"head": "Workup", "relation": "confirmed", "tail": "elevated ACTH consistent with paraneoplastic Ectopic adrenocorticotropic hormone syndrome"}
{"head": "Workup", "relation": "confirmed", "tail": "disease progression"}
{"head": "Third-line therapy", "relation": "includes", "tail": "Nab-Paclitaxel"}
{"head": "Third-line therapy", "relation": "was initiated for", "tail": "patient with breast neuroendocrine carcinoma"}
{"head": "Genetic testing", "relation": "confirmed", "tail": "PIK3 mutation"}
{"head": "PIK3 mutation", "relation": "is target for", "tail": "Alpelisib therapy"}
{"head": "Patient", "relation": "underwent", "tail": "urgent bilateral laparoscopic adrenalectomy"}
{"head": "Bilateral laparoscopic adrenalectomy", "relation": "is", "tail": "definitive treatment option for Ectopic adrenocorticotropic hormone syndrome resulting in Cushing's syndrome secondary to breast neuroendocrine carcinoma"}
{"head": "biological sex and gender factors", "relation": "influence", "tail": "pathogenesis in hematologic malignancies"}
{"head": "biological sex and gender factors", "relation": "influence", "tail": "progression in hematologic malignancies"}
{"head": "biological sex and gender factors", "relation": "influence", "tail": "treatment response in hematologic malignancies"}
{"head": "male patients", "relation": "have higher disease incidence", "tail": "multiple myeloma"}
{"head": "male patients", "relation": "have higher disease incidence", "tail": "acute myeloid leukemia hospitalizations for ages 18-39"}
{"head": "male patients", "relation": "have inferior outcomes", "tail": "hematologic malignancies"}
{"head": "female patients", "relation": "exhibit superior survival", "tail": "hematologic malignancies"}
{"head": "female patients", "relation": "experience greater treatment-related toxicities", "tail": "hematologic malignancies"}
{"head": "sex-specific patterns", "relation": "include", "tail": "distinct mutational profiles"}
{"head": "sex-specific patterns", "relation": "include", "tail": "differences in immune system function"}
{"head": "sex-specific patterns", "relation": "include", "tail": "sex-based pharmacokinetic variations"}
{"head": "females", "relation": "demonstrate", "tail": "favorable prognostic mutations in leukemias"}
{"head": "females", "relation": "have higher rates of", "tail": "chromosomal abnormalities in multiple myeloma"}
{"head": "Neuropilin-1", "relation": "regulates", "tail": "cancer biology"}
{"head": "Neuropilin-1", "relation": "influences", "tail": "tumor cell proliferation"}
{"head": "Neuropilin-1", "relation": "influences", "tail": "tumor cell migration"}
{"head": "Neuropilin-1", "relation": "influences", "tail": "tumor cell invasion"}
{"head": "Neuropilin-1", "relation": "influences", "tail": "tumor cell metastasis"}
{"head": "Neuropilin-1", "relation": "interacts with", "tail": "vascular endothelial growth factor"}
{"head": "Neuropilin-1", "relation": "interacts with", "tail": "semaphorins"}
{"head": "Neuropilin-1", "relation": "interacts with", "tail": "transforming growth factor-beta"}
{"head": "Neuropilin-1", "relation": "modulates", "tail": "tumor microenvironment"}
{"head": "Neuropilin-1", "relation": "promotes", "tail": "angiogenesis"}
{"head": "Neuropilin-1 expression", "relation": "correlates with", "tail": "poor prognosis in various malignancies"}
{"head": "targeting Neuropilin-1", "relation": "inhibits", "tail": "tumor growth"}
{"head": "targeting Neuropilin-1", "relation": "enhances", "tail": "efficacy of chemotherapy"}
{"head": "targeting Neuropilin-1", "relation": "enhances", "tail": "efficacy of radiotherapy"}
{"head": "NRP1-targeted therapies", "relation": "include", "tail": "monoclonal antibodies"}
{"head": "NRP1-targeted therapies", "relation": "include", "tail": "small molecule inhibitors"}
{"head": "NRP1-targeted therapies", "relation": "include", "tail": "gene silencing techniques"}
